EASTERN OYSTER LARVAL TRANSCRIPTOMES IN RESPONSE TO PROBIOTIC AND PATHOGENIC BACTERIA

Tejashree Modak
University of Rhode Island, tejashree@uri.edu

Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss

Recommended Citation
Modak, Tejashree, "EASTERN OYSTER LARVAL TRANSCRIPTOMES IN RESPONSE TO PROBIOTIC AND PATHOGENIC BACTERIA" (2018). Open Access Dissertations. Paper 805.
https://digitalcommons.uri.edu/oa_diss/805

This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
EASTERN OYSTER LARVAL TRANSCRIPTOMES IN RESPONSE TO PROBIOTIC AND PATHOGENIC BACTERIA

BY

TEJASHREE MODAK

A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN BIOLOGICAL AND ENVIRONMENTAL SCIENCES

UNIVERSITY OF RHODE ISLAND

2018
DOCTOR OF PHILOSOPHY DISSERTATION

OF

TEJASHREE MODAK

APPROVED:

Dissertation Committee:

Major Professor       Marta Gomez-Chiarri
David Nelson
Dina Proestou
Nasser H. Zawia
DEAN OF THE GRADUATE SCHOOL

UNIVERSITY OF RHODE ISLAND
2018
ABSTRACT

Oysters are described as keystone species serving an important ecological role. As filter-feeders they help in maintaining water quality. Oyster reefs provide refuge and support to different organisms. The eastern oyster, *Crassostrea virginica*, native to the East Coast of United States and Gulf of Mexico is a part of the rapidly growing aquaculture industry. Aquaculture production depends on a healthy and constant supply of oyster larvae that are provided by hatcheries. Several hatcheries on the east coast that provide *C. virginica* seed to oyster farms face significant losses owing to *Vibrio* infections causing massive larval mortalities. Use of antibiotics is avoided due to possibility of development of antibiotic resistance. The probiotic bacteria, *Phaeobacter inhibens* S4 and *Bacillus pumilus* RI06-95 have been shown to successfully protect *C. virginica* larvae from *V. coralliilyticus* RE22 infection. Use of these probiotics in hatcheries can reduce mortalities due to disease thereby avoiding significant economic losses. In order to design best practices for probiotic use it is crucial to understand their mechanisms of action. There has been great progress in understanding the components of oyster immune system, its functioning in response to various stimuli and its uniqueness as compared to other organisms. This is in part due to availability of sophisticated tools like high throughput sequencing and various –omics analyses such as proteomics, genomics and transcriptomics and partly due to interest in controlling diseases affecting aquaculture. As such most of our knowledge is based on studies that focus on oyster-pathogen or oyster-environmental stimuli interaction. Little is known about the effect of bacteria other than pathogens on the oysters. Moreover, very little about larval immunity of eastern oyster, *C. virginica*. This is the first study to investigate
the effect of both pathogen and probiotic bacteria on *C. virginica* larval immunity using transcriptomes. The aim of this study is to test the safety and efficacy of formulated probiotic *Bacillus pumilus* RI06-95 in a hatchery, understand the mechanisms of action of both probiotics and to characterize the effect of *V. coralliilyticus* RE22 infection on the larval immune system of eastern oysters.

Chapter 1 reviews the current knowledge of oyster immune system and the mechanisms of action of probiotics especially mechanisms related to immunomodulation of innate immunity. Previous studies have demonstrated successful protection of *C. virginica* larvae from *V. coralliilyticus* RE22 infection in a laboratory based setting as well as in a hatchery using laboratory grown cultures of probiotics. The ultimate use of the probiotics is in a hatchery setting, which would require easy to use and stable formulation of the probiotics instead of time consuming laboratory-grown probiotic cultures that are viable for only a short duration of time.

Chapter 2 discusses methods of formulation of probiotic *Bacillus pumilus* RI06-95, testing the formulation in a hatchery and its effect on larval survival at the hatchery and post *V. coralliilyticus* RE22 experimental challenge in the laboratory. A spray dried formulation of *Bacillus pumilus* RI06-95 was both shelf-stable and effective in protecting *C. virginica* larvae from *V. coralliilyticus* RE22 challenge. The formulation did not show any adverse effects on the larvae during the course of the trial.

Chapter 3 investigates the host–pathogen interaction between *C. virginica* larvae and *V. coralliilyticus* RE22 using transcriptomes produced after experimental challenge. Exposure of larvae to the pathogen for 6 hours provided information of the changes in the larval oysterimmune system brought about by the pathogen in the early stages of
disease. Overall, despite upregulation of several pattern recognition receptors, immune signaling pathways leading to the production of antimicrobial effectors, such as protease inhibitors and the pore forming protein perforin-2, were suppressed by *V. coralliilyticus* RE22. The transcriptomic evidence suggests that lack of an adequate immune response to thwart the infection of RE22, combined with a high metabolic load and decreased feeding, leads to large-scale mortalities of *C. virginica* larvae. This research allows for a better understanding of the disease process caused by *V. coralliilyticus* RE22 in larval eastern oysters.

Chapter 4 investigates the effect of exposure to non-pathogenic probiotic bacteria *P. inhibens* S4 and *B. pumilus* RI06-95 on the immune system of the host, *C. virginica* larvae. It presents evidence of immunomodulation of *C. virginica* larval immunity by both probiotic organisms. High upregulation of immune effectors such as serine protease inhibitors is seen in larval oysters after short exposures to the probiotic (6 and 24h) in the laboratory as well as after exposure for several days during a hatchery trial. Other important modulations that help larvae protect themselves from *V. coralliilyticus* RE22 infection include activation of pathogen receptors and signaling pathways, modulation of mucin genes, and upregulation of pore-forming protein perforin-2.

Chapter 5 summarizes and advocates the use of probiotics in the larviculture of *C. virginica* and suggests their potential role in limiting vibriosis.
ACKNOWLEDGEMENTS

I want to take this opportunity to sincerely thank my advisor Dr. Marta Gómez-Chiarri, who kept a sense of humor even when I sometimes lost mine. She is a role model for an excellent advisor, a female scientist and the kindest and warmest boss I have ever met. She welcomed me to join her lab in the middle of my program ensuring a very smooth transition. She encouraged free thought in my research, while occasionally giving me a nudge in the right direction. In her company, I always found myself working the hardest due to the confidence she entrusted in me. I am so thankful and lucky to have her as my mentor.

I also want to thank Dr. Bethany Jenkins who championed me during my transition and pivoted my research career by helping me pick the right lab. I want to express my sincere thanks to all the hatchery managers that I hounded every spring for sending me oyster larvae and who patiently shipped millions of these critters for free to be sacrificed in the name of science. Special mention to Mike Congrove, Lauren Shirley, Karen Rivara and Karen Tammi who I hounded the most. I want to thank Dr. Dina Proestou for letting me barge into her lab anytime to take over her RNA lab bench and her valuable advice while designing my experiment. I want to thank the rest of my committee members/collaborators Dr. David Rowley and Dr. David Nelson for lab meetings at Whalers and their advice on the project and manuscript. I also want to thank Janet Atoyan for her advice and help in qPCR and budgeting for RNA-seq.
I want to thank Saebom Sohn for training me in oyster handling and incessant counting during oyster survival experiments. I want to thank all my labmates Erin Roberts, Melissa Hoffman, Rebecca Stevick, Evelyn Takyi, Sam Hughes, and Ashley Hogan for their valued friendship, who made our lab such a fun and supportive place. I will miss you all dearly. Thanks to Proestou lab members Christopher O’Brien for passing on RNA extraction knowledge, Kate Markey-Lundgren and Tal Ben-Horin for sharing their office with me and their advice in technical issues.

Finally, I want to express my heartfelt gratitude to my family for their unconditional support and their belief in me. Thank you to my parents and in-laws who came to my help literally dropping everything whenever I needed them. Thanks to my sister for her overseas support and pep talks to keep me going. I want to thank my husband who often filled in my shoes to become Mr. Mom, who always supported and encouraged me immensely. Lastly of course, my personal little cheer leaders, my sons, who did not mind my late work hours and greeted me with the biggest hugs and kisses, I cannot thank you enough.
Dedication

I dedicate this dissertation to my parents Dr. Harshvardhan Modak and Shriya Modak, my husband Aniket Kulkarni and my sons Ishir and Akaash Kulkarni. Thank you mum and dad for exposing me to science in an early age and kindling that passion ever since. Thank you Aniket, without your constant support, patience, enthusiasm and encouragement, I could not have seen this day. Thank you, little bubs I owe this to you both. I hope I have sparked the same love for curiosity and science that my parents sparked in me.
PREFACE

This dissertation was written in accordance with the manuscript format guidelines established by the Graduate School of the University of Rhode Island. The dissertation includes an introduction and the following three manuscripts:

1. “Use of formulated probiotic _Bacillus pumilus_ RI06-95 for preventing vibriosis in larviculture of the eastern oyster _Crassostrea virginica._” prepared for submission to Journal of Shellfish Research.

2. “Characterizaton of _Crassostrea virginica_ larval response to _Vibrio coralliilyticus_ RE22” prepared for submission to Developmental and Comparative Immunology.

3. “Immunological response of _Crassostrea virginica_ larvae to probiotics _Bacillus pumilus_ RI06-95 and _Phaeobacter inhibens_ S4” prepared for submission to Developmental and Comparative Immunology.
TABLE OF CONTENTS

ABSTRACT .............................................................................................................. ii
ACKNOWLEDGMENTS ......................................................................................... v
PREFACE .............................................................................................................. viii
TABLE OF CONTENTS ......................................................................................... ix
LIST OF TABLES .................................................................................................. x
LIST OF FIGURES ............................................................................................... xii
CHAPTER 1 .......................................................................................................... 1
CHAPTER 2 .......................................................................................................... 22
CHAPTER 3 .......................................................................................................... 64
CHAPTER 4 .......................................................................................................... 100
CHAPTER 5 .......................................................................................................... 170
APPENDIX ........................................................................................................... 177
LIST OF TABLES

TABLE

Table 2-1. Treatments included in each hatchery trial and the total length of treatment in days ........................................................................................................................................57

Table 2-2. Laboratory challenged experiments results: Effect of pre-incubation of oyster larvae for 24 h with RI06-95 formulated products on survival (RPS, % ± SEM) after challenge with V. coralliilyticus RE22 ........................................................................58

Table 2-3. Effect of daily exposure to formulations of B. pumilus RI06-95 in the hatchery on larval oyster survival (%) 24 h after challenge with Vibrio coralliilyticus RE22 ........................................................................................................65

Table 3-1. Oyster larval transcriptomes in response to a 6hour challenge with Vibrio coralliilyticus RE22 challenge .................................................................................................................................100

Table 3-2. Gene Ontology (GO) terms of biological functions significantly (p<0.05) enriched in oyster larvae in response to pathogen challenge (RE22) .............................................100

Table 3-3. Mapping of differentially expressed transcripts to biological pathways in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database .............................................103

Table 3-4. Comparison of expression of selective differentially expressed genes (DEGs) as compared to control categorized by immune processes ............................104

Table 4-1. Effect of varying lengths of probiotic pretreatment on larval survival after experimental challenge with the pathogen V. coralliilyticus RE22 .........................142

Table 4-2. Oyster larval transcriptomes in response to probiotic treatment .............145

Table 4-3. Number of differentially expressed genes per comparison (p-adj ≤ 0.05)146

Figure 4-4. KEGG annotation of differentially expressed genes .............................151
Table 4-5. Patterns of differential gene expression of immune receptors in oyster larvae in response to probiotic treatment

Table 4-6. Patterns of differential gene expression of immune signaling pathways in oyster larvae in response to probiotic treatment

Table 4-7. Patterns of differential gene expression of immune effectors in oyster larvae in response to probiotic treatment

Table 4-8. Patterns of differential gene expression that are part of cytoskeletal reorganization in oyster larvae in response to probiotic treatment

Table 4-9. Patterns of differential gene expression that are part of apoptosis and autophagy in oyster larvae in response to probiotic treatment

Table 4-10. Patterns of differential gene expression that are part of phagosome, endosome, peroxisome, lysosome, antioxidant enzymes and acute phase proteins in oyster larvae in response to probiotic treatment

Table 4-11. Patterns of differential gene expression that are part of metabolism, biomineralization and other processes in oyster larvae in response to probiotic treatment
# LIST OF FIGURES

| FIGURE | PAGE |
|--------|------|
| Figure 1-1. Immune-related genes present in the eastern oyster, *Crassostrea virginica.* | 28 |
| Figure 1-2. Major mechanisms of action of probiotics. | 29 |
| Figure 1-3. Examples of modulation of innate immune response by probiotics | 30 |
| Figure 2-1. Impact of formulation processing (granulation or lyophilization) and temperature storage on the stability of *Bacillus pumilus* R106-95 | 57 |
| Figure 2-2. Laboratory challenged experiments results: Effect of pre-incubation of oyster larvae with *Bacillus pumilus* R106-95 formulated products for 24 h on survival (% ± SEM) after challenge with *V. coralliilyticus* RE22 | 58 |
| Figure 2-3. Effect of daily treatment with different formulations of *Bacillus pumilus* R106-95 of larval eastern oysters (*Crassostrea virginica*) in the hatchery on mean larval size (µm ± SEM) at selected time points | 61 |
| Figure 2-4. Effect of daily treatment with probiotics in the hatchery on interval survival (% ± SEM) of oyster larvae between selected time points | 62 |
| Figure 2-5. Effect of daily probiotic treatment in the hatchery on larval survival to a laboratory challenge with the pathogen *Vibrio coralliilyticus* RE22 | 63 |
| Figure 2-6. Effect of daily treatment with probiotics on total vibrio levels (Log$_{10}$(CFU/mL) ± SEM) in water (A, B, C, G) and tank surfaces (D, E, F) in a hatchery. (A and D) | 66 |
| Figure 2-7. Effect of daily treatment with probiotics on total vibrio levels |
(Log$_{10}$(CFU/mL) ± SEM) on oyster larvae in the hatchery

Figure 3-1a. Effect of *Vibrio coralliilyticus* RE22 on mortality of *C. virginica* larvae

Figure 3-1b. Effect of *Vibrio coralliilyticus* RE22 on mortality of *C. virginica* larvae

Figure 3-2. Sequencing saturation curves for control and challenged larval transcriptomes showing comparable depth of sequencing for all transcriptomes

Figure 3-3. Functional enrichment of differentially expressed transcripts using Gene Ontology terms in Biological Process

Figure 3-4. Functional enrichment of differentially expressed transcripts using Gene Ontology terms in Metabolic Function

Figure 4-1a. Sequencing saturation curves for RNA-seq samples for control, RI treated 6h, RI treated 24h, S4 treated 6h, S4 treated 24h larval transcriptomes

Figure 4-1b. Sequencing saturation curves for RNA-seq samples for control and *B. pumilis* RI06-95 treated oyster larval transcriptomes

Figure 4-2a. Venn Diagram of differentially expressed genes for each probiotic treatment (*B. pumilus* RI0-695 and *Phaeobacter inhibens* S4) at 6h and 24h

Figure 4-2b. Plot comparing number of differentially expressed genes in probiotic and control treatments at 5, 12 and 16 days

Figure 4-3a. Functional enrichment of differentially expressed transcripts in S4 (6h) using Gene Ontology terms in Biological Process

Figure 4-3b. Functional enrichment of differentially expressed transcripts in S4 (24h) using Gene Ontology terms in Biological Process

Figure 4-3c. Functional enrichment of differentially expressed transcripts in hatchery
RI transcriptomes using Gene Ontology terms in Biological Process

Figure 4-4. Overview of the immune responses induced in oyster larvae in response to treatment with probiotics S4 and RI0695, as measured through high-throughput analysis of differential gene expression

Figure 4-7. Hypothesized role of selected effectors of immunity whose expression was found to be upregulated in larval oysters in response to probiotic treatment on providing protection against challenge to *V. coralliilyticus* RE22

Figure 5-1. Hypothesized model showing in a series of steps (1-6) how effects of probiotic pretreatment on host immunity may play a role in providing protection from *V. coralliilyticus* RE22 challenge
CHAPTER 1

LITERATURE REVIEW: IMMUNITY IN OYSTERS AND GENERAL MECHANISMS OF ACTION OF PROBIOTICS
Abstract

Oysters are a unique model of immunology since they lack a classic adaptive immune system and only possess an innate immune system. Some research suggests presence of memory although a lot more remains to be elucidated. Oysters possess a wide variety of pattern recognition receptors. Most of the components of signaling pathways like TLR, NF-kB and MAPK are known while others like the complement system are not fully known yet. Immune effectors like antimicrobial peptides and enzymes like lysozyme are important in oysters especially in mucosal immunity. Exposure to probiotics leads to modulation of host immune genes that eventually provide protection from pathogens. Probiotics can modulate expression of receptors, signaling pathways and production of effectors in specific hosts. Immunomodulation as a mechanism of action of probiotics is seen in a variety of organisms including invertebrates and vertebrates alike and therefore may play an important role in the mechanism of probiotics in oysters.
**Immunity in oysters**

Oysters are sessile filter feeding animals that provide important ecological and economical services. As such immunological studies to understand disease resistance and improve aquaculture practices has given a boost in our understanding of the oyster immunology. Although some research suggests presence of immunological memory (Green et al., 2015) it is generally recognized that oysters lack adaptive immunity and only possess innate immunity. The circulating phagocytic hemocytes form the cellular branch of the innate immunity in oysters. The production of antimicrobial effectors via activated signaling pathways due to recognition of PAMPs (pathogen-associated molecular patterns) by PRRs (pattern recognition receptors) forms the humoral branch of innate immunity (Wang et al., 2018). Current research of the oyster immunity is reviewed below with emphasis on (i) Recognition (ii) Signaling pathways (iii) Effectors (iv) Apoptosis and autophagy and (v) Mucosal immunity. Immune-related genes in the eastern oyster *Crassostrea virginica* are illustrated in Fig 1.

**Recognition**

Recognition of non-self is achieved via PRRs that comprise of peptidoglycan recognition proteins (PGRPs), lectins, toll-like receptors (TLRs), Gram-negative binding proteins (GNBPs), scavenger receptors (SRs) and fibrinogen-related proteins (FREPs) (Gerdol et al., 2018, Wang et al., 2018). Lectins are further classified into major families including C-type, F-type, R-type, H-type, P-type, X-type, I-type lectins, pentraxins, galectins (formerly S-type lectins), ficolins, and others (Vasta et al. 2007).
Several of these PRRs are highly diversified in oysters (Zhang et al., 2014, Zhang et al., 2015). C-type lectins require a special mention since they are not only involved in pathogen recognition but also in activation of complement cascade.

**Signaling pathways**

Signals transmitted by receptors allow activation of several signaling pathways like TLR signaling pathway, NF-kB signaling pathway, mitogen-activated protein kinase (MAPK) signaling cascade, prophenol/phenol oxidase cascade and complement pathway in oysters. Sophisticated tools like whole genome sequencing and –omics analysis have led to tremendous progress in understanding molecules involved in these pathways that are common with other organisms as well unique to oysters. The TLR/NF-kB signaling pathway is a crucial pathway that upon recognition by TLR receptors activate transcription factors facilitating production of effectors like cytokines, interleukins, antimicrobial peptides (AMPs) and others (Gerdol et al., 2018). MyD88 serves as a critical cytosolic adaptor modulating TLR signaling pathway and Pacific oyster genome encodes an expanded set of 10 MyD88 genes (Zhang et al., 2015). MAPK pathway comprises of many protein kinases and its active involvement in oyster immunity is evidenced by their activation upon bacterial exposures (Qu et al., 2016). Although studies support existence of a complement pathway in bivalves (Gerdol et al., 2015, Li et al., 2015) the exact components and mechanisms of activation remain to be identified (Gerdol et al., 2018).

**Effectors**
Broad ranged effectors are produced upon induction of signaling pathways by PRR recognition and function in elimination of pathogens. These include antimicrobial peptides (AMPs), defensins, lysozymes, cytokines, protease inhibitors, antioxidant enzymes and acute phase proteins. Serine protease inhibitors have been identified for their role as important effectors in granting resistance to pathogens (La Peyre et al. 2010, Xue et al. 2006, McDowell et al., 2014). Enzymes, such as superoxide dismutase, catalase and glutathione peroxidase defend oysters by eliminating reactive oxygen species (ROS). They are important especially during increased oxidative stress caused by pathogen infection. Another important member of effectors are the heat shock proteins (HSPs) that help oysters modulate stress response and protect them from environmentally induced cellular damage caused by a variety of stressors (Wang et al., 2018).

*Apoptosis and autophagy*

Apoptosis, programmed cell death is an extremely important process in oysters involved in immune system homeostasis and function, defense against parasite and pathogens and self/non-self recognition. The baseline apoptosis rates observed in circulating and resident hemocytes in oysters is high (Sokolova, 2009). Apoptosis in oysters has two major pathways intrinsic and extrinsic. The main players consist of caspases and inhibitors of apoptosis (IAPs) that regulate the process. Apoptosis limits the spread of pathogen while preventing inflammatory damage of surrounding tissues (Sokolova, 2009). Although apoptosis has been studied for a long time the exact functional
relevance of its modulation by biotic and abiotic factors is still unknown in bivalves (Gerdol et al., 2018, Wang et al., 2018).

Autophagy plays a housekeeping role in organisms and is important in innate immunity. It is activated in oysters in response to bacterial, viral and environmental stimuli (Gerdol et al., 2018, Wang et al., 2018). Its role in protecting Pacific oysters from viral and bacterial challenge was demonstrated recently (Moreau et al., 2015) but a lot more remains to be investigated.

*Mucosal immunity*

Mucus forms an external barrier of defense and plays a key role in host-microbe interactions. Mucus consisting of crosslinked glycoproteins forms a physical barrier to microbes and contains a myriad of effectors that defend the host from infection (Allam and Espinosa, 2016). These include enzymes like lysozymes, hydrolases and proteases, AMPs, antioxidants and lectins to name a few (Espinosa et al., 2016). Mucus composition can affect pathogen adhesion and production of components is often regulated by them (Linden et al., 2008, Allam and Espinosa, 2016). This understudied topic is a crucial part of the innate immunity in oysters and needs further exploration.

Most of the knowledge of oyster immunity is based on a large body of research that is centered on bacterial and viral pathogens and environmental stressors but we know very little about the impact of friendly or beneficial bacteria on the immune system of oysters. Addressing this dearth of knowledge might reveal important novel insights in the oyster
immune system. The next section of this review discusses the effect of probiotics on different organisms focusing especially on their impact on immune system.

**General mechanisms of action of probiotics**

Probiotics, as defined by Food and Agricultural Organization and World Health Organization, are live microorganisms that when administered in adequate amounts confer a health benefit on the host (FAO and WHO 2006). Although probiotic uses for better growth, digestion, immunity and disease resistance of the host have been known their mechanisms have not been fully elucidated yet. Some of the known mechanisms of action are summarized in Fig 2 and discussed in detail below.

**Nutrient availability**

Probiotics improve the utilization of feed by the host by producing or stimulating production of exoenzymes that digest ingredients in feed such as carbohydrates, proteins and fat. This aid in increased digestibility of feed, boosts host growth. Probiotics *Bacillus subtilis, Lactococcus lactis* and *Saccharomyces cerevisiae* showed increased secretion of amylase, trypsin, protease and lipase in sea bass (*Labeo rohita*) (Tovar-Ramirez et al., 2002, Mohapatra et al., 2012). Application of probiotic strains of *Bacillus* in white shrimp (*Litopenaeus vannamei*) and *Fenneropenaeus indicus* feed, improved feed digestibility resulting in increased size of the shrimp (Heizhao et al., 2004). In fact, production of chitinases, proteases, cellulases, lipases and trypsin by the bacteria isolated from the digestive tract of various aquatic organisms have been shown contribute to fish nutrition (Vine et al., 2006, Ray et al. 2012). Increasing nutrient
availability and stimulation of growth through increased volatile fatty acids production by probiotics has been studied in poultry industry as well (Ajuwon., 2016).

**Production of inhibitory compounds**

Probiotics produce or stimulate production of several non-specific compounds that are effective in inhibiting pathogen growth including, antimicrobial compounds (hydrogen peroxide, nitric acid and bacteriocins), siderophores, proteases and lysozymes. A non-pathogenic strain *Vibrio mediterranei* 1 produces bacteriocin-like inhibitory substance against *Vibrio parahaemolyticus* spp (Carratuoro et al., 2006). In fact, bacteriocin production allows probiotics to compete within complex microbial communities and influence the health of the host (Dobson et al., 2012). Probiotics administered to tilapia (*Oreochromis niloticus*) increased lysozyme activity in host (Taoka et al., 2006). *Phaeobacter inhibens* S4 produces tropodiethic acid (TDA) that kill pathogenic *V. coralliilyticus* RE22, *Vibrio harveyi* BB120 and *Alioseovarius crassostreae* CV919-312\textsuperscript{T} in oysters (Karim et al., 2013, Zhao et al., 2016). *Enterococcus durans* strain LAB18s showed antimicrobial and antioxidant activity against several pathogenic bacteria (Pieniz et al., 2014).

**Competitive exclusion of pathogenic bacteria**

Probiotics often compete with pathogenic bacteria for space and nutrients that hinder their proliferation. Direct inhibition of pathogens by production of inhibitory compounds as discussed above is one way they competitively exclude pathogens. Other mechanisms include formation of biofilms, blocking adhesion sites and profuse
probiotic growth. An oyster probiotic, *P. inhibens* S4 produces biofilms that inhibit the growth of pathogens *V. coralliilyticus* and *V. anguillarum* (Zhao et al., 2016). *Lactobacilli* reduced the adhesion of rainbow trout pathogens (Balcazar et al., 2007). Exclusion of pathogenic bacteria by competition from probiotic bacteria was also shown in poultry. Native bacteria from adult chickens were used to protect chicks from infestation of *Salmonella infantis* (Rantala and Nurmi., 1973) as well as other enteropathogens (Schneitz, 2005). Porcine probiotics *Lactobacilli* and *Bifidobacteria* compete for attachment sites on epithelial cells and exclude pathogens in the intestine (Gross et al., 2008).

*Enhancement of the Epithelial Barrier*

Gut is in constant contact with a large number of bacteria and its integrity is often one of the most important barriers against invading pathogens. Increased expression of genes involved in tight junction signaling due to probiotic treatment reinforces this barrier (Anderson et al., 2010). *Escherichia coli* Nissle 1917 (EcN1917) has been shown to not only prevent disruption of the mucosal barrier by enteropathogenic *E. coli*, but also restore mucosal integrity (Anderson et al., 2010). Probiotics differentially modulate epithelial cell responses via activation or suppression of distinct signaling pathways in a strain-dependent manner (Llewellyn et al., 2017).

*Immunity*

*Effects on mucosal immunity*
Mucus is made up of polymerized mucins that protect hosts from pathogens, enzymes, toxins, dehydration and abrasion (Hardy et al., 2013). *Lactobacillus plantarum* 299v and *Lactobacillus rhamnosus* GG have been shown to up-regulate production of MUC2 and MUC3 intestinal mucins that weakens the adherence of pathogenic *Escherichia coli* O157:H7 (Mack et al., 1999). Probiotics mediate modulation of mucin expression as a strategy for intestinal colonization of beneficial microbes to the host (Caballero-Franco et al., 2007). Mucus contains lysozymes, antimicrobial substances, antibodies and enzymes that have added benefits in controlling pathogenic invasion. Production of these substances can be modulated by presence of probiotics. Probiotic treatment led to increase in lysozyme production in Japanese flounder (Ye et al., 2011). Probiotic strains such as *Lactobacillus* GG, *Bifidobacterium actis* Bb-12 (Rautava et al., 2006) and *Saccharomyces boulardii* (Rodrigues et al., 2000) have been demonstrated to enhance IgA production and secretion.

**Immunomodulation**

Probiotic research shows mounting evidence of probiotic-host communication through pattern recognition receptors resulting in modulation on key signaling pathways such as NF-kB and MAPK to enhance or suppress activation and influence downstream pathways (Bermudez-Brito et al., 2012, Hardy et al., 2013, De et al., 2014). Probiotics and pathogens share PAMPs/MAMPs that can induce innate inflammatory pathways. Secondary and chronic exposure to probiotics induce suppressive /tolerogenic response that modulate NF-kB and MAPK pathways (Llewellyn et al., 2017). Effect in humans for some example probiotics is illustrated in Fig 3. *L. casei* CRL 431 interacts with
epithelial cells through TLR2 and induces an increase in the number of CD-206 and TLR2 receptors in the cells involved in the innate immune response in humans (Vinderola et al., 2005). *Lactobacillus* stimulates TLR9 that induces cytoplasmic accumulation of ubiquitinated IkB and inhibition of NF-kB activation (Lee et al., 2006). *L. reuteri* and *L. casei* engage with C-type lectin, prime dendritic cells and that lead to increased production of IL-10 (Smits et al., 2005). In contrast, *L. reuteri* strains DSM 17938 and ATCC PTA 4659 downregulates expression of TNF-α, TLR4 and NF-kB and upregulates IL-10 expression in rats (Bermudez-Brito et al., 2012). Along with the influence on innate immunity probiotics also have impacts on adaptive immunity (Hardy et al., 2013).

In addition, increase in phagocytic activity in probiotic fed Nile tilapia (*Oreochromis niloticus*) (Vieira et al., 2010) and increase in total hemocyte count and serum agglutination activity in probiotic fed and challenged marine shrimp (Sayed et al., 2011) are also documented. Probiotics have also been shown to confer protection against many cellular stresses, which include oxidative stress-mediated apoptosis (Llewellyn et al., 2017).

Thus, probiotic bacterial strains can be generalized to exert immune-activation, -deviation or -regulation/suppression responses (Hardy et al., 2013). Selection of probiotic strains especially in combination along with prebiotics can have beneficial effects on hosts. However, it is crucial to gain full knowledge of their modulatory capabilities and formulate their use with careful consideration.

**Goals of this study**
There has been much progress in understanding immunity in mollusks especially in bivalves but we still lack knowledge of larval immunity in eastern oyster *C. virginica*. There is also a dearth of understanding in the effect of bacteria on larval immunity. Probiotics protect several organisms from *Vibrio spp* infection including crayfish (*Cherax tenuimanus*) (Ambas et al., 2013), brine shrimp (*Artemia franciscana*) (Giarma et al., 2017), oyster (*C. virginica*) (Karim et al., 2013), turbot (*Scophthalmus maximus*) (Villamil et al., 2002) as well as humans (Carraturo et al., 2006) using mechanisms like antibiotic production and indications of immunomodulation. However, we need a thorough investigation of the nature of their immunomodulatory ability.

The overall goal of this study was to understand the mechanism of action of probiotics *B. pumilis* RI06-95 and *P. inhibens* S4 against pathogen *V. coralliilyticus* RE22 and formulate them for use in the field.

Laboratory grown bacterial culture of *B. pumilis* RI06-95 was previously shown to protect *C. virginica* larvae from infection of *V. coralliilyticus* RE22 (Karim et al., 2013). The first aim was to formulate the probiotic such that it can be effectively used in hatcheries and to test their efficacy. A series of formulations were prepared and tested in lab as well as in hatcheries to establish their efficacy.

The second specific aim was to understand the immunological response of *C. virginica* larvae to both probiotics *B. pumilis* RI06-95 and *P. inhibens* S4 in order to understand if immunomodulation is one of the mechanisms of action of these probiotics. Next generation RNA sequencing technology was used to obtain the transcriptomic response of *C. virginica* larvae to probiotics in a lab controlled and a hatchery environment to thoroughly investigate their effect on several larval genes at a time.
The third specific aim was to understand the immunological response of *C. virginica* larvae to pathogen *V. corallilalyticus* RE22 in order to understand its pathogenesis. To investigate this, larval transcriptomes generated post challenge with *V. corallilalyticus* RE22 were compared to control transcriptomes.
Figure 1: Immune-related genes present in the eastern oyster, *Crassostrea virginica*. Adapted from Zhang et al., 2014.
Figure 2: Major mechanisms of action of probiotics. Illustration adapted from Bermudez-Brito et al., 2012.
Figure 3: Examples of modulation of innate immune response by probiotics. Adapted from Bermudez-Brito et al., 2012.
Bibliography

Ajuwon K. M., 2016 Toward a better understanding of mechanisms of probiotics and prebiotics action in poultry species. The Journal of Applied Poultry Research. 25, 2, 1, 277–283.

Allam, B., Espinosa, E., 2016. Bivalve immunity and response to infections: Are we looking at the right place? Fish & Shellfish Immunology 53, 4–12.

Ambas, I., Suriawan, A., Fotedar, R., 2013. Immunological responses of customized probiotics-fed marron, *Cherax tenuimanus*, (Smith 1912) when challenged with *Vibrio mimicus*. Fish & Shellfish Immunology 35, 262–270.

Anderson R.C, Cookson A.L, McNabb W.C, Park Z, McCann M.J, Kelly W.J, Roy N.C, 2010 *Lactobacillus plantarum* MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiology 10, 316.

Balcazar J.L., Vendrell D., de Blas I., Ruiz-Zarzuela I., Girones O., Muzquiz J.L., 2007. In vitro competitive adhesion and production of antagonistic compounds by lactic acid bacteria against fish pathogens. Vet Microbiol 122, 373–380.

Bermudez-Brito, M., Plaza-Díaz, J., Muñoz-Quezada, S., Gómez-Llorente, C., Gil, A., 2012. Probiotic Mechanisms of Action. Ann Nutr Metab 61, 160–174.

Carraturo, Raieta, Ottaviani, Russo, G.L., 2006. Inhibition of *Vibrio parahaemolyticus* by a bacteriocin-like inhibitory substance (BLIS) produced by *Vibrio mediterranei* 1. J Appl Microbiol 101, 234–241.

Caballero-Franco C, Keller K, De Simone C, Chadee, 2007 The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 292, 315-2.

De, B., Meena, Behera, Das, P., Mohapatra, D., Sharma, 2014. Probiotics in fish and shellfish culture: immunomodulatory and ecophysiological responses. Fish Physiology and Biochemistry 40, 921–71.

Dobson, A., Cotter, P., Ross, P., Hill, C., 2012. Bacteriocin Production: a Probiotic Trait? Appl Environ Microb 78, 1–6.

Espinosa, E., Koller, A., Allam, B., 2016. Proteomic characterization of mucosal secretions in the eastern oyster, *Crassostrea virginica*. Journal of Proteomics 132, 63–76.
FAO, WHO (Eds) (2006) Probiotics in food: health and nutritional properties and guidelines for evaluation. Food and Agriculture Organization of the United Nations: World Health Organization, Rome

Giarma, E., Amanetidou, E., Toufexi, A., Touraki, M., 2017. Defense systems in developing *Artemia franciscana nauplii* and their modulation by probiotic bacteria offer protection against a Vibrio anguillarum challenge. Fish & Shellfish Immunology 66, 163–172.

Gerdol, M., Venier, P., Pallavicini, A., 2015. The genome of the Pacific oyster *Crassostrea gigas* brings new insights on the massive expansion of the C1q gene family in Bivalvia. Dev. Comp. Immunol. 49, 59-71.

Gerdol M. et al., 2018 Immunity in Molluscs: Recognition and Effector Mechanisms, with a Focus on Bivalvia. In: Cooper E. (eds) Advances in Comparative Immunology. Springer, Cham

Green, T., Raftos, D., Speck, P., Montagnani, C., 2015. Antiviral immunity in marine molluscs. J Gen Virol 96, 2471–2482.

Gross G, van der Meulen J, Snel J, van der Meer R, Kleerebezem M, Niewold TA, Hulst MM, Smits MA, 2008 Mannose-specific interaction of *Lactobacillus plantarum* with porcine jejunal epithelium. FEMS Immunol Med Microbiol. 54,215-23.

Hardy, H., Harris, J., Lyon, E., Beal, J., Foey, A., 2013. Probiotics, Prebiotics and Immunomodulation of Gut Mucosal Defences: Homeostasis and Immunopathology. Nutrients 5, 1869–1912.

Heizhao Z., Zhixun G., Yingying Y., Wenhui Z., Zhuojia J.,2004 Effect of dietary probiotics on apparent digestibility coefficients of nutrients of white shrimp (*Litopenaeus vannamei*) Boone. Aquaculture Research 35,1441–1447.

Karim, M., Zhao, W., Rowley, D., Nelson, D., Gomez-Chiarri, M., 2013. Probiotic Strains for Shellfish Aquaculture: Protection of Eastern Oyster, *Crassostrea virginica*, Larvae and Juveniles Against Bacterial Challenge. Journal of Shellfish Research 33, 401–408.

La Peyre JF, Xue Q-G, Itoh N et al (2010) Serine protease inhibitor cvSI-1 potential role in the eastern oyster host defense against the protozoan parasite *Perkinsus marinus*. Dev Comp Immunol 34, 84–92.

Lee J, Mo JH, Katura K, Alkalay I, Rucker AN, Liu YT, Lee HK, Shen C, Cojocaru G, Shenouda S, et al. 2006 Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 8, 1327–1336.
Li, H., Zhang, H., Jiang, S., Wang, W., Xin, L., Wang, H., Wang, L., Song, L., 2015 A single-CRD C-type lectin from oyster *Crassostrea gigas* mediates immune recognition and pathogen elimination with a potential role in the activation of complement system. Fish Shellfish Immunol. 44, 566-575.

Linden S., et al., 2008 Mucins in the mucosal barrier to infection, Mucosal Immunol. 1,3,183-197.

Llewellyn, A., Foey, A., 2017. Probiotic Modulation of Innate Cell Pathogen Sensing and Signaling Events. Nutrients 9, 1156.

Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA, 1999 Probiotics inhibit enteropathogenic *E. coli* adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol. 276, 941-50.

McDowell, I.C., Nikapitiya, C., Aguiar, D., Lane, C.E., Istrail, S., Gomez-Chiarri, M., 2014. Transcriptome of American oysters, *Crassostrea virginica*, in response to bacterial challenge: insights into potential mechanisms of disease resistance. PLoS ONE 9, e105097.

Mohapatra S., Chakraborty T., Prusty A.K., Das P., Prasad P.K., Mohanta K.N., 2012 Use of different microbial probiotics in the diet of rohu (*Labeo rohita*) fingerlings: effect on growth, nutrient digestibility and retention, digestive enzyme activities and intestinal microflora. Aquac Nutr 18,1–11.

Moreau, P., Moreau, K., Segarra, A., Tourbiez, D., Travers, M.-A., Rubinsztein, D., Renault, T., 2015. Autophagy plays an important role in protecting Pacific oysters from OsHV-1 and *Vibrio aestuarianus* infections. Autophagy 11, 516–526.

Pieniz, S., Andreazza, R., Anghinoni, T., Camargo, F., & Brandelli, A. 2014. Probiotic potential, antimicrobial and antioxidant activities of *Enterococcus durans* strain LAB18s. *Food Control*, 37(1), 251–256.

Qu, F., Xiang, Z., Zhang, Y., Li, J., Xiao, S., Zhang, Y., Mao, F., Ma, H., Yu, Z., 2016. A novel p38 MAPK indentified from *Crassostrea hongkongensis* and its involvement in host response to immune challenges. Mol. Immunol. 79, 113-124.

Rantala M., Nurmi E.,1973 Prevention of the growth of *Salmonella infantis* in chickens by flora of the alimentary tract of chickens. Brit. Poult. Sci., 14,627-630.

Rautava S, Arvilommi H, Isolauri E, 2006 Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatric Research 60,221-4.

Rodrigues AC, Cara DC, Fretez SH, Cunha FQ, Vieira EC, Nicoli JR, Vieira LQ, 2000 *Saccharomyces boulardii* stimulates IgA production and the phagocytic system of gnotobiotic mice. Journal of Applied Microbiol. 89, 404-14.

19
Schneitz C., 2005 Competitive exclusion in poultry-30 years of research, Food Control 16, 657-667.

Smits H.H., Engering A., van der Kleij D., de Jong E.C., Schipper K., van Capel T.M., Zaat B.A., Yazdanbakhsh M., Wierenga E.A., van Kooyk Y., et al. 2005 Selective probiotic bacteria induce IL-10-producing regulatory T-cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J. Allergy Clin. Immunol.115,1260–1267.

Sokolova, 2009. Apoptosis in molluscan immune defense. ISJ 6, 49–58.

Taoka, Y., Maeda, H., Jo, J.Y. 2006 Growth, stress tolerance and non-specific immune response of Japanese flounder (Paralichthys olivaceus) to probiotics in a closed recirculating system. Fish Science 72:310–321.

Tovar-Ramirez D, Zambonino J, Cahu C, Gatesoupe FJ, Vazquez-Juarez R, Lesel R, 2002 Effect of live yeast incorporation in compound diet on digestive enzyme activity in sea bass (Dicentrarchus labrax) larvae. Aquaculture 204:113–123.

Vasta GR, Ahmed H, Tasumi S et al (2007) Biological roles of lectins in innate immunity: molecular and structural basis for diversity in self/non-self recognition. Adv Exp Med Biol 598,389–406.

Villamil, Tafalla, Figueras, Novoa, 2002. Evaluation of Immunomodulatory Effects of Lactic Acid Bacteria in Turbot (Scophthalmus maximus). Clin Diagn Lab Immun 9, 1318–1323.

Vinderola G, Matar C, Perdigón G 2005 Role of the epithelial cells in the immune effects mediated by Gram-positive probiotic bacteria. Involvement of Toll-like receptors. Clin Diag Lab Immunol 12,1075–1084.

Vine N.G., Leukes W.D., Horst K., 2006 Probiotics in marine larviculture. FEMS Microbiol Rev 30, 404–427.

Ye JD, Wang K, Li FD, Sun YZ, 2011 Single or combined effects of fructo and mannan oligosaccharide supplements and Bacillus clausii on the growth, feed utilization, body composition, digestive enzyme activity, innate immune response and lipid metabolism of the Japanese flounder (Paralichthys olivaceus). Aquac Nutr 17, 902–911.

Wang, L., Song, X., Song, L., 2018. The oyster immunity. Developmental & Comparative Immunology 80, 99–118.
Xue Q, Itoh N, Schey KL et al., 2009 Evidence indicating the existence of a novel family of serine protease inhibitors that may be involved in marine invertebrate immunity. Fish Shellfish Immunol 27:250–259.

Zhang, L., Li, L., Zhu, Y., Zhang, G., Guo, X., 2014. Transcriptome Analysis Reveals a Rich Gene Set Related to Innate Immunity in the Eastern Oyster (Crassostrea virginica). Mar Biotechnol 16, 17–33.

Zhang, L., Li, L., Guo, X., Litman, G.W., Dishaw, L.J., Zhang, G., 2015. Massive expansion and functional divergence of innate immune genes in a protostome. Sci. Rep. 5.

Zhao, W., Dao, C., Karim, M., Gomez-Chiarri, M., Rowley, D., Nelson, D., 2016. Contributions of tropodithietic acid and biofilm formation to the probiotic activity of Phaeobacter inhibens. BMC Microbiol 16, 1.
CHAPTER 2

USE OF FORMULATED PROBIOTIC *Bacillus pumilus* RI06-95 FOR PREVENTING VIBRIOSIS IN LARVICULTURE OF THE EASTERN OYSTER *Crassostrea virginica*

Authors: Saebom Sohn\(^1\), Tejashree Modak\(^1\), Victor Schmidt\(^1\), Christine Dao\(^2\), Meagan Hamblin\(^2\), Marta Gómez-Chiarri\(^1\), David R. Worthen\(^2\), Kathryn Markey Lundgren\(^3\), Karin Tammi\(^3\), Roxanna Smolowitz\(^3\), Lauren Gregg\(^4\), Standish K. Allen Jr.\(^4\), David R. Nelson\(^5\), and David C. Rowley\(^2\)*

Affiliation: \(^1\)Department of Fisheries, Animal and Veterinary Sciences, University of Rhode Island, 120 Flagg Road, Kingston, RI 02881, USA; \(^2\)Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, 7 Greenhouse Road, Kingston, RI 02881, USA; \(^3\)Department of Biology, Roger Williams University, 1 Old Ferry Road, Bristol, RI 02809, USA; \(^4\)Virginia Institute of Marine Science, College of William & Mary, Gloucester Point, VA 23062, USA; \(^5\)Department of Cell and Molecular Biology, University of Rhode Island, 120 Flagg Road, Kingston, RI 02881, USA

* Corresponding Author

David C. Rowley, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, 7 Greenhouse Road, Kingston, RI 02881

Phone 1-401-874-9228; E-mail address: drowley@uri.edu

This manuscript is in preparation for submission to the Journal of Shellfish Research.
T. Modak contributions: Design and performance of hatchery trial with spray-dried formulation (Envera); further compilation with previous results for final manuscript.

Abstract

Vibriosis is a major disease affecting larval eastern oysters, *Crassostrea virginica*, causing sudden and massive larval mortalities. A candidate probiotic strain, *Bacillus pumilus* RI06-95, was previously investigated as a disease prevention method and found to reduce mortality due to vibriosis in oyster larvae and juveniles. The goal of this research was to develop a stable formulation of probiotic RI06-95 to facilitate storage and delivery in a hatchery setting. Three types of formulations (granulated, lyophilized and spray dried) of RI06-95 were developed. Cell viability of all formulations remained above $10^5$ colony forming units (CFU) per mL for up to 8 weeks of storage. The granulated and spray-dried formulation had no adverse impacts on larval oyster survival and provided protection against challenge with the bacterial pathogen *Vibrio coralliilyticus* RE22 (Relative Percent Survival, RPS, as compared to probiotic untreated control: 69 ± 1 % and 52 ± 35 % respectively). However, treatment of larval oysters with the lyophilized formulation led to a significant decrease in survival compared to non-treated controls and afforded no protection. Daily treatment of oyster larvae with the spray dried formulation in pilot-scale hatchery trials provided significant protection against laboratory challenge with RE22 (RPS 43 ± 4 %). These results demonstrate that a sprayed-dried formulation for probiotic RI06-95 can be safely and effectively used for disease prevention in shellfish hatcheries.
Introduction

The bivalve shellfish (oysters, clams, scallops, and mussels) industry is an important and rapidly expanding area of aquaculture production. The total landings for oysters, clams and scallops in United States alone valued at $859 million (NMFS 2016). A primary requisite for the aquaculture of most bivalve shellfish species is an abundant, reliable, and inexpensive supply of seed/small juveniles (Helm et al. 2004). Shellfish larvae, however, are prone to infectious diseases, which can result in a rapid and high rate of larval mortality in commercial hatcheries (Elston 1998), leading to substantial economic losses. For instance, pathogenic strains from several *Vibrio* spp. including *V. alginolyticus, V. anguillarum, V. coralliilyticus, V. ordalii, V. splendidus, V. tubiashii*, and others, cause bacillary necrosis of larval bivalve shellfish. Clinical signs of vibriosis in bivalves include necrosis of mantle epithelium, clumping of the cilia, and rapid mortality (Tubiash et al. 1965; Berthe 2004; Gomez-Leon et al. 2005; Kesarcodi-Watson et al. 2009).

Given the absence of an adaptive immune system in bivalves allowing for the use of vaccines as disease prevention tools, the use of probiotics is one of the most promising management strategies for shellfish disease prevention and control (Elston 1998; Verschuere et al. 2000; Prado et al. 2010). Probiotics are defined as live, non-pathogenic microorganisms which, when administered in adequate amounts, confer a health benefit to the host (Food and Agricultural Organization of the United States 2006). The most widely used probiotics in human and animal health belong to *Bacillus*...
spp., *Bifidobacterium* spp., and lactic-acid bacteria such as *Lactobacillus* spp. (Hong *et al.* 2005, Cutting S 2011). In particular, *Bacillus* spp. are attractive for commercial products because they are aerobic, spore-forming bacteria. Spores are capable of surviving extreme conditions such as the high temperatures and pressure conditions sometimes used for formulating a commercial probiotic product. Formulations of *Bacillus* spp. are stable for long periods without significant loss in viability because spores enable survival in harsh conditions until germination and proliferation occur in more favorable environments (Lalloo *et al.* 2010; Cutting 2011; Azevedo de & Tavares Brag 2012; Sorokulova 2013; Edna *et al.* 2014).

We previously reported that marine *Bacillus pumilus* RI06-95, a producer of the antibiotic amicoumacin (Socha 2008), antagonized growth of the shellfish pathogen *V. coralliilyticus* RE22 *in vitro* and protected eastern oyster *Crassostrea virginica* and bay scallop *Argopecten irradians* larvae against experimental challenge with *V. coralliilyticus* RE22 (Karim *et al.* 2013b; Sohn *et al.* 2016a). It was also shown that daily treatment of larval rearing tanks in a hatchery with RI06-95 led to a decline in the levels of *Vibrio* spp. on tank surfaces and an increase in the survival of larval oysters when challenged with a pathogen (Sohn *et al.* 2016a). *Bacillus* spp., have shown promise as probiotic bacteria to improve host survival, growth, and development in aquaculture (Queiroz & Boyd 1998; Luis-Villaseñor *et al.* 2011; Martínez Cruz *et al.* 2012; Li *et al.* 2014). Additionally, some bacilli exhibit antagonistic effects against pathogenic *Vibrio* spp. (Decamp & Moriarty 2006; Vaseeharan & Ramasamy 2003). Whole genome analysis of RI06-95 reveals that it is most closely related to *B. pumilus* SAFR-32 (Hamblin *et al.* 2015), a strain isolated as a contaminant in spacecraft
assembly facilities (Gioia et al. 2007). *B. pumilus* strains have been isolated from a wide range of habitats, from aquatic and terrestrial hosts (Hill et al. 2009) to desert basalt (Benardini et al. 2003), and have been suggested as probiotics for plants, humans, crustaceans, and finfish (Duc et al. 2004; Hill et al. 2009; Sun et al. 2010; Murugappan et al. 2013).

Although many studies have shown promising results for the use of probiotics in shellfish aquaculture, no commercial products are available with demonstrated safety and efficacy in bivalve larviculture. Probiotics typically are available in several types of commercial formulations, including dry materials (such as wettable powders, dusts, and granules) and liquid products (such as cell suspensions in water, oils, and emulsions) (Austin et al. 1995; Schisler et al. 2004; Salinas et al. 2006; Savini et al. 2010; Dagá et al. 2013). An appropriate formulation should offer several advantages in addition to host protection, including: the stabilization of microorganisms during distribution and storage; ease in handling and delivery of the product; protection of the microbes from adverse environmental factors; and safety to the aquaculture species. Therefore, the successful development of an appropriate probiotic formulation requires testing for efficacy, safety, and stability, especially in bivalve hatchery facilities.

Here, we evaluate three novel formulations of the candidate shellfish probiotic *B. pumilus* RI06-95. We determine storage and usage potential, and test each formulation along with fresh cultures of the same probiotic bacterium for safety and host protection in both laboratory and in semi-commercial scale hatchery experiments. While all three formulations resulted in stable products with suitable shelf lives, only a spray-dried formula provided a high level of safety and efficacy desired for a
commercially viable product. Our results demonstrate a safe, stable, and easy-to-use formulation for *C. virginica* larval aquaculture production.

**Methods**

**Oyster larvae**

Laboratory challenge experiments: For the bacterial challenge experiments, eastern oysters, *C. virginica*, (4 - 6 day old) were obtained from the Blount Shellfish Hatchery at Roger Williams University (Bristol, RI, USA) or Virginia Institute of Marine Science (VIMS) (Wachapreague, VA, USA). Oyster larvae were transported to the laboratory at the University of Rhode Island (Kingston, RI, USA) and acclimated at room temperature (~20°C) for at least 24 h before treatment. The larvae were fed instant algae Shellfish Diet 1800<sup>TM</sup> (Reed Mariculture Inc., San Jose, CA. USA) during the experiments.

Hatchery trials: Adult eastern oysters were spawned at the Blount Shellfish Hatchery for Trials I, II, III and V and at the VIMS Shellfish Hatchery at the Aquaculture Genetics & Breeding Technology Center (ABC), VIMS for Trial IV. Larval oysters were distributed into 100-120 L conical tanks at the Blount Shellfish Hatchery 2 days after fertilization and fed live microalgae, a mix of *Tisochrysis lutea* (CCMP1324; formerly *Isochrysis* sp., Tahitian strain) and *Pavlova lutheri* (CCMP1325), daily. Larvae were distributed into 60 L tanks at the VIMS Shellfish hatchery, and fed *Pavlova* sp. days 1 - 4 and a mix of *Pavlova* sp. and *Chaetocerus gracilis* from day 5 on.

**Pathogen and probiotic strains**
V. coralliilyticus RE22 was supplied by H. Hasegawa, Department of Biomedical Sciences, Oregon State University (USA). The freshly cultured B. pumilus RI06-95 for comparison with formulated versions was cultured in the laboratory. Both bacteria were maintained as stocks in 50% glycerol at -80 °C until use. They were cultured on yeast peptone with 3% NaCl (YP30) media (5 g L⁻¹ of peptone, 1 g/L of yeast extract, 30 g/L of ocean salt (Red Sea Salt, Ohio, USA)) at 28 °C with shaking at 175 rpm as described in Karim et al. 2013a.

Formulation process

Granulated Product Formulation (RI-G)

Probiotic B. pumilus RI06-95 was incubated in 2.25% NaCl (YP22.5) broth (yeast extract 1 g/L, peptone 5 g/L, 22.5 g/L ocean salt, Instant Ocean) at 25 °C and 175 rpm. An initial culture was incubated for 2 d, then transferred to fresh YP22.5 and incubated for 4 d. The culture was partitioned into 50 mL sterile centrifuge tubes and centrifuged for 10 min at 2,350 × g. After centrifugation, cell pellets were transferred into a sterile petri dish (100 × 15 mm), and dishes were swirled with 2-3 mL culture media to ensure that the surfaces were completely covered in cells. The dishes were then covered with single ply, light duty paper (Kimwipes®) and placed in a convection oven to dry at 30 °C with constant airflow for 24-48 h, depending on initial volume. The dry cell mass was extruded through three particle size (40s, 80s, and 325s) USA Standard Sieve stainless steel screens (Cole Palmer, Illinois, USA), yielding products with average particle sizes of 43, 177, and 420 µm, respectively. The resulting granulated products were transferred into sterile glass vials and stored at 4 °C. For hatchery trials the granulated formulations were scaled up following the same formulation procedure
as above except bacterial cultures were centrifuged at 9,300 × g for 10 min and the final cell pellet was dried at room temperature (22 ± 3 °C) for approximately 2 days.

**Lyophilized Product Formulation (RI-L)**

Probiotic *B. pumilus* RI06-95 was cultured from frozen stocks and then centrifuged as above. After discarding the liquid supernatant, 25 mL of Sugar Salt Solution (SSS) (2.5 g/L Instant Ocean, 200 mM sucrose, filtered deionized (DI) water (pre-filtered through a 0.2 μm filter)) was added to each tube, and the cell pellet was re-suspended using a vortex. The re-suspended cells were frozen at -20 °C for 12 h, and then lyophilized for 48 h (Labconco FreeZone 4.5 lyophilizer, Kansas City, MO, USA). The tubes were stored at 4 °C until use. 100 mM sucrose was used as a cryoprotectant during the lyophilization process. For hatchery trials, individual tubes with a single dose of formulation for a target dose of 5 × 10⁴ CFU/mL for 100 L were prepared.

**Spray-dried formulations (RI-SD)**

Spray-dried formulations were prepared by Envera LLC (West Chester, PA) using a proprietary formula. Computer controlled fermentation vessels were used to grow the probiotic and pasteurized to make 100% spore-based product. After pasteurization, the probiotic was centrifuged and spray dried into a fine powder that can be easily hydrated with seawater. The final concentration of the probiotic in the formulation was 8.6 × 10¹¹ CFU/mg of powder. For the hatchery trial, tubes of the appropriate amount of formulation for a target dose of 5 × 10⁴ CFU/mL in each 100 L tank were prepared. At the hatchery seawater was added to the tubes and mixed thoroughly. The mixed formulation was then added to the tanks daily during feeding.

**Fresh culture controls (RI)**
In order to determine the influence of the formulation process itself on the effectiveness of the probiotic in vivo, we tested simultaneous treatments of freshly cultured B. pumilus RI06-95 (cultures prepared as described in Sohn et al. 2016b) alongside formulated treatments in all lab and hatchery trials.

**Viability and stability of formulated products**

Viability and stability of each formulation was measured by counting colony forming units (CFU) on 2.5% yeast peptone agar plates using serial dilutions. Pre-formulation cell concentrations in CFU/mL were measured from culture aliquots directly before centrifugation. The RI-L product was re-suspended in 50 mL filtered sterile seawater (FSSW). The RI-G was suspended at 5 mg/mL in FSSW for 10 min and then vortexed for 1 min. The RI-SD was suspended using 0.1 g into 50 mL FSSW, followed by 10-fold serial dilutions. The percent cell viability in the formulations was calculated as follows: 

\[
\% \text{ Viability} = \left( \frac{\text{sample formulation CFU/mL}}{\text{pre-formulation CFU/mL}} \right) \times 100\%
\]

RI-L was stored at 4 °C, while samples of RI-G were stored at either room temperature or 4 °C and RI-SD stored at room temperature. The stability of the formulated probiotics was measured immediately after formulation (t = 0) and 1, 2, 5, and 8 weeks after formulation, except RI-SD. Each assay was performed in triplicate.

**Laboratory pathogen challenge experiments**

Laboratory challenge assays were conducted following protocols outlined in (Karim et al. 2013a). Briefly, larval oysters were placed into six-well plates with 5 mL of filtered sterile sea water (FSSW, 28 psu). Probiotic treatments were added to the larvae at a concentration of \(10^4\) CFU/mL and incubated at room temperature with gentle
shaking. After 24 h, the larvae were placed onto a 42 μm nylon mesh and washed gently using FSSW, then placed back into the original wells. Finally, *V. coralliilyticus* RE22 was added to each well, with the exception of the non-challenged controls, at a final concentration of $10^5$ CFU/mL. Larval survival was quantified ~24 h after the pathogen was added using the neutral red technique (Gómez-León et al. 2008). Survival was calculated by using the formula: Survival (%) = $100 \times$ (number of live larvae/total number of larvae).

The relative percent survival (RPS) of probiotic pretreatment compared to the challenged control was calculated using the formula: RPS (%) = $[1 - (\% \text{ survival challenged control treatment} / \% \text{ survival challenged treatment})] \times 100$ as described in Karim et al., 2013.

**Hatchery trials**

Hatchery experiments were conducted at Roger William University (RWU), Bristol, RI or the Aquaculture Breeding Center at the Virginia Institute of Marine Sciences (ABC), following standard operating procedures at each hatchery. For each trial, twelve 60 L (ABC) or 100 L (RWU) conical larval rearing tanks were used. We performed four independent trials at RWU between January 2014 and July 2016, and one trial at VIMS in June 2015 (Trial IV), testing each of the formulations at least once. Each trial was initiated by adding 8-10 larvae/mL (800,000 to 1,000,000 initial larvae) per tank 1-2 d post-fertilization to the conical tanks. Tanks were randomly assigned to treatments and probiotic formulations were added daily at the time of feeding mixed with the algal food. Larvae were kept in static conditions and tanks were drained-down
every other day, cleaned, and re-stocked with fresh water. Treatments, number of tanks per treatment, and trial duration for each trial is shown in Table 1.

**Larval survival and growth during hatchery trial**

Data was collected at the time of selected drain-down events. Oyster larvae were passed through different sized mesh screens (35, 55, 75, and/or 105 µm for Trials I, II, and III; 35, 48, or 63 µm for Trial IV; 35 or 75 µm for Trial V) depending on the age and size of the larvae. Oyster larvae retained in each of the screens were collected in a container, seawater was adjusted to a fixed volume (1 – 5 L depending on the amount of larvae), and aliquot samples (1 mL each) were placed in Sedgewick Rafter counting chambers (Graticules ® S50). Larvae were fixed with Lugol’s iodine (Trials I-III) or temporarily immobilized with a 2:1 mixture of freshwater: 70% isopropyl alcohol (Trials IV, V). Larvae were counted under a microscope and the presence of live and dead larvae were recorded. After counting, 50 larvae from each tank (25 from top screen, 25 from bottom screen) from Trial I and 25 larvae from each tank from Trials II, III, and V were randomly selected from the slides and photographed with an Olympus BX51 microscope (Olympus) and measured using an Olympus DP25 camera and CellSens Standard 1.6 image software (Olympus). During Trial IV, 5 larvae from each tank were randomly selected and measured on a Nikon E200 microscope. A random sample from each culture was photographed using a Nikon DS-Fi2 camera and DS-L3 camera control unit. Interval survival rate was determined by dividing the number of live larvae at each time point by the number of live larvae returned to the tank on the previous time point.

**Laboratory pathogen challenge of probiotic-treated larvae from hatchery**
An aliquot of larvae from each tank collected at selected drain-down events was transported to the laboratory at University of Rhode Island. Oysters (about 40 – 50 larvae) were placed in six-well plates and then challenged with *V. coralliilyticus* RE22 at a final concentration of $10^5$ CFU/mL following the methods described in the laboratory challenge section. Oyster larvae from Trial IV could not be challenged since very low number of oyster larvae were left in the probiotic treated groups at the hatchery.

**Determination of levels of *Vibrio* spp in the hatchery**

Total number of *Vibrio* spp. was evaluated using a plate count method on thiosulfate-citrate-bile salts-sucrose medium (TCBS, Difco) (Sohn et al. 2016a). Samples were collected from water in the rearing tank (3 x 10 mL), tank surfaces (by swabbing), and oysters (about 1,000) when the tanks were drained. Swab samples (3 per tank) of tank surfaces (about 48 cm in length in total) were collected from each tank for all except Trial V. Each cotton swab was placed into a sterile Falcon tube containing 1 ml of FSSW and then mixed vigorously. Oyster larvae were rinsed with FSSW, homogenized using a sterile pestle, and suspended in FSSW. Ten-fold serial dilutions of each sample were prepared in triplicate, and then triplicate 10 µL of each dilution were plated on TCBS agar plates. After a ten-fold serial dilution, 10 µL samples of each of the dilutions were spotted evenly onto TCBS agar plates in triplicate for all except trial 5. The inoculated plates were incubated for 16 - 20 h at 28 °C and the colony forming units (CFU) were calculated. Results are expressed as CFU/mL, where 1 mL corresponds to 1 mL of water in the tank, 1 mL of swab suspension, or 1 mL of water
contacting about 1,000 larvae. Determination of *Vibrio* spp. levels could not be performed on larvae from trial IV due to very low numbers of surviving larvae.

**Statistical Analysis**

Larval oyster survival data were subjected to arcsine square root transformation prior to statistical analysis. The one-way analysis of variance (ANOVA) was used to determine significance between treatments within each time point. The two-way ANOVA was also used to determine significance between groups with time and treatment as factors. The Tukey’s or Sidak’s multiple comparison tests were used for post-hoc pairwise comparisons. A p-value < 0.05 was considered to be statistically significant.

Formulation cell viability data were analyzed by two-way ANOVA followed by Tukey’s Test for each temperature and each time point. All statistical analyses were performed using Graphpad Prism, version 6.0 (Graphpad Software, Inc.). Differences were considered to be significant at values of $p < 0.05$.

**Results**

**Viability and stability of formulated products**

The stability of the three formulated products was assessed after storage for 8 weeks (RI-G and RI-L) (Figure 1) or 16 weeks (RI-SD) at ambient temperature. The three formulated products varied in their final CFU/ml following storage. RI-L and RI-G had similar pre-formulation concentrations of $1 \times 10^8$ CFU/mL and $1.27 \times 10^8$ CFU/mL, respectively. We observed a loss in viability immediately after the RI-G formulation process (data for RI-SD not available), and then again one week after storage at both 4
and 27 °C. However, we note strong stability after this initial loss. The spray dried formulation had a concentration ~200-250-fold higher at $2.65 \times 10^{10}$ CFU/mL 16 weeks post formulation.

**Effectiveness of B. pumilus RI06-95 formulations at promoting survival after a pathogen challenge**

**Laboratory challenge experiments:** Pretreatment with fresh or formulated probiotic had no adverse impact on larval survival (i.e. in the absence of pathogens) over a 48h period aside from a single instance (L, Fig. 2B), where the formulation reduced larval survival by 46% compared to the unchallenged control. In the same trial, treatment of sucrose alone also showed significant reduction in larval survival (L, Fig. 2B). The ability of formulations to protect oyster larvae from exposure to the pathogen *V. coralliilyticus* RE22 was either higher or equal to that of fresh cultures in all experiments conducted, except in the one instance where sucrose alone was shown to reduce larval survival (Table 2, L, Fig. 2B). Larval survival was significantly greater in both fresh and formulated treatments versus controls for one of the three L treatments (Fig.2D), the G treatment (Fig.2A), and both SD treatments (Fig. 2E, F) (Table 2). In only two instances was there a significantly higher protection by formulation against the pathogen challenge than the fresh culture (Table 2, L III and SD II, Fig. 2D and 2F respectively).

**Hatchery Trials:**

*Effect of daily treatment with probiotics in the hatchery on larval growth and survival*
Based on successful protection from pathogen challenges in laboratory trials, all three formulations were tested in a hatchery. Treatments included in each hatchery trial and the length of treatment is described in Table 1. The formulations did not have an effect on the larval growth as shown by larval size measurements compared to control except for Trial IV with RI-L (Figure 3). None of the formulations had a significant detrimental impact on survival in the hatchery (Figure 4) except Trial I (RI-G) that showed a significant negative effect of the probiotic additions. None of the trials showed a significantly positive effect on larval survival due to probiotic addition (Figure 4). Of the three formulations, the spray-dried product had the smallest impact on larval survival. Thus, the SD-formulation is safe for use with oyster larvae in the hatchery.

*Effect of daily treatment with probiotics in the hatchery on larval survival to bacterial challenge*

Larvae from the hatchery experiments were tested for improved survival following challenge with *V. coralliilyticus* RE22. Since pathogens could not be introduced into the hatchery, larvae were collected and subjected to laboratory challenges as described in methods section. Larvae exposed to the granulated or lyophilized probiotics in the hatchery did not show significantly higher survival to a 24 h bacterial (*V. coralliilyticus* RE22) challenge as compared to non-treated challenged larvae (One-way ANOVA; *p* > 0.05) (Figure 5). A fresh culture of RI06-95 offered some protection on day 12 in Trial II (One-way ANOVA; *p* < 0.05; Figure 5 D). Relative percent survival (RPS) provided by the fresh culture of RI06-95 in this trial was 36 ± 6 % on day 12 (Table 3). On the other hand, trial V showed significantly improved survival both with RI-SD and fresh culture of RI06-95 as compared to controls (One-way ANOVA; *p* < 0.05; Figure 5 G).
The relative percent survival (RPS) with fresh culture was 28 ± 6% and RI-SD was 43±4% (Table 3).

Effect of daily treatment with probiotics in the hatchery on levels of total Vibrio spp.

In general, daily treatment of tanks with either formulation of B. pumilus RI06-95 did not lead to a significant decrease in the levels of total Vibrio spp. in water, tank surfaces, or oyster larvae as compared to control groups at each of the time points (Figure 6 and Figure 7). High levels of variability were observed between tanks and trials within treatments. Interestingly, levels of Vibrio in the water were lower than $10^3$ CFU/mL in Trial I (Figure 6A) and none were detected on the tank surfaces during this trial (Figure 6D). Trial I was performed in January, a month in which lower levels of Vibrios are present in coastal waters in the region (and therefore in water being pumped into the hatchery) (Duan & Su 2005, Parveen et al. 2008). Similarly, very low levels of Vibrios were found in Trial V in the water (Fig 6G). Levels of Vibrios on tank surfaces and larvae were not measured during Trial V. Overall the results show that certain days probiotic treated tanks (formulated or fresh) show reduced level of Vibrios spp. as compared to control but there is no significant trend to specifically ascertain that effect.

Discussion

We outline three formulation protocols, a granulation process (G), a lyophilization process (L), and a commercial spray-dried process (SD). Variation in terms of success
was achieved for each of the formulations, with the spray-dried formulation showing overall the best performance.

Granulation process: A traditional approach for formulating microorganisms is air-convective drying, which is a cost-effective process for the dehydration of microorganisms (Fu & Chen 2011, Guergoletto et al. 2012). Granulation after an air-convective drying is necessary to prevent segregation of the constituents of the powder and to provide consistent particulate sizes. The loss of viability of probiotic bacteria during granulation is associated with granulation operating conditions such as temperature, mechanical and moisture stress, and the characteristics of the selected microorganisms (Hiolle et al. 2010). This process did cause an immediate loss in viability from fresh cultures over the short term, as dehydration of bacterial cells poses serious physiological challenges to the survival of cells, such as conformational and chemical changes in structural proteins and membrane lipids (Ananta 2005, Santivarangkna et al. 2008, Ohtake & Wang 2011). However, after these initial short-term losses the cell count stabilized and remained consistent over 8 weeks. Storage conditions such as temperature and humidity have also been shown to affect the stability of granulated probiotic product (Ananta 2005). Mortality of probiotic bacteria during storage is associated with various stress factors such as temperature, oxygen/air, light, moisture/humidity, and package material, a combination of which tends to damage or destroy cells (Wang et al. 2004, Ananta 2005, Chávez & Ledeboer 2007). Our results, however, suggest that beyond an initial decrease in viability, the granulated product of RI06-95 could be stored at either 4 °C or room temperature and maintain viability for up to for 8 weeks. The stability of the granulated product during storage may be due to
the adaptation of *Bacillus* spp. to extreme environmental stress by spore-formation characteristics (Desmond et al. 2002, Driks 2002, Hong et al. 2005, Cutting 2011).

RI-G showed protection in laboratory experiments and did not show any detrimental effect on the larvae in any of the laboratory assays. However, in the hatchery trial formulation treated larvae showed reduced survival as compared to control and freshly grown probiotic. It demonstrated protection from pathogen challenge in laboratory trials but was unsuccessful in doing so in the hatchery trial. Despite the favorable results from viability and storage of the granulation protocol, research on the granulated product was discontinued in this study due to a negative influence on survival of larval oysters in hatchery settings.

**Lyophilization:** The lyophilized formulation (L) did not significantly impact cell viability after the formulation process. Lyophilization has previously been investigated as a way of preserving and formulating *Bacillus* spp. as probiotic products (Henn et al. 2015). To ensure sufficient viability after freeze-drying, a disaccharide cryoprotectant such as sucrose or trehalose is typically added to provide structural support to cell membranes and proteins (Leslie et al. 1995). We successfully used sucrose at a concentration of 100 mM that provided stability and viability over time.

RI-L led to variable results in larval survival in hatchery trials. It failed to provide protection from pathogen challenge in the 2 out of 3 laboratory experiments and the hatchery trial. It produced no observable negative effect on water quality. Our results suggest that the addition of sucrose may be responsible for the negative impact on larval survival, as sucrose alone (without *B. pumilus* RI06-96) lowered larval survival in 2 of
4 trials where it was investigated. Because a wide range of bacterial taxa can readily use sucrose, we suggest that its addition to the formulated product may encourage antagonistic bacterial growth, and presents greater risks than advantages.

Spray drying: Of the three formulations tested, the commercially prepared spray dried formulation was found to maintain the highest concentration at room temperature over time while also showing no negative impact on larval oysters in the laboratory or in the hatchery trials. After 16 weeks at room temperature, the SD-product still contained $>2.65 \times 10^{10}$ CFU/g. Previous research has shown that probiotic concentrations of *Bacillus* products at around $1 \times 10^4$ CFU/ml provide optimal performance (Karim *et al.* 2013a; Sohn *et al.* 2016a), meaning to reach a final target concentration of $1 \times 10^4$ CFU/ml in a 1,000 L commercial tank, only ~0.4 g of RI-695 would need to be added. This would be extremely cost effective for use at a larger scale. Another added benefit of the formulation is its ease of use. The powder quickly suspends in seawater and is added to the tank very easily.

The spray-dried formulation was also shown to perform as well or better than freshly prepared *B. pumilus* RI06-95 in both laboratory experiments and hatchery trials. In hatchery experiments, RI-SD showed no significant reduction in larval survival, water quality or larval growth. In fact, it increased survival compared to freshly prepared culture in the hatchery trial by day 12. RI-SD also performed well in pathogen challenge experiments, increasing survival of larvae after the challenge at the same rate or greater as compared to freshly prepared culture.
As seen in previous hatchery experiments (Sohn et al. 2016), high levels of variability were seen between tanks and trials within a treatment. The variation in results within and/or between experiments in this study could be due to several factors: (1) a different quality and health status of larvae from each trial; (2) the impact of various environmental and biological factors such as salinity, pH, temperature/season at the hatchery; (3) variability in the characteristics of different rearing systems, such as tank, source or treatment of water, and location of hatchery (Balcazar et al., 2006; Gatesoupe, 1999; Martínez Cruz et al., 2012; Utting and Millican, 1997); and 4) the effect of variability in the composition of microbial communities and how these communities may interact with the probiotic. Due to above factors the variability is more pronounced in hatchery trials than controlled laboratory experiments. Although variability is seen within and/or between experiments in this study for RI-G and RI-L, it is highly minimized in the trials using RI-SD. More importantly there is consistency in the goal of achieving protection from pathogen challenge with use of RI-SD.

The use of probiotics as a disease control mechanism has particular and critical relevance to shellfish hatcheries, where disease losses are high, vaccination is not possible and use of antibiotics is not recommended. Our results demonstrate successful formulation of the candidate probiotic *B. pumilus* RI06-95 for its use in shellfish hatcheries using the spray drying method. It also demonstrates the challenge in formulating the probiotic and the need of thorough testing in both laboratory and hatchery setting to confirm the effect of formulation. The laboratory and hatchery trials confirm that the RI-SD formulation is stable over a long term, remains viable and shows comparable performance to freshly grown cultures of the probiotic. It is suitable for
storage, transportation and can be easily applied in a hatchery by mixing with sea water. Although the addition of RI-SD did not show reduction in *Vibrio* spp. in general, this might not be a strategy used by the probiotic as its mechanism of action. Probiotics are known to modulate the immune system of the host (Hardy et al., 2013, Mortha et al., 2014, Sanchez et al., 2015). This could be one the strategies used by *B. pumilus* RI06-95 to provide protection in the event of vibriosis.

Future research in mechanism of action of the probiotic would help in optimization of the use formulation in terms of dosage timing and frequency.
Figure 1. Impact of formulation processing (granulation or lyophilization) and temperature storage on the stability of *Bacillus pumilus* RI06-95. Cell count in the reconstituted formulation after storage for up to 8 weeks was determined using a plating method. Data expressed as mean ± SEM of CFU/mg of formulation.

| Hatchery Trial | Treatments         | Tanks per treatment | Treatment period (days) | Dates performed       |
|----------------|--------------------|---------------------|-------------------------|-----------------------|
| I              | Control, RI-G      | 6                   | 14                      | 01/03/14 – 01/24/14   |
| II             | Control, ConwS, RI, RI-L | 3                   | 12                      | 01/29/15 – 02/10/15   |
| III            | Control, ConwS, RI, RI-L | 3                   | 12                      | 02/22/15 – 03/06/15   |
| IV             | Control, RI-L      | 4 (control), 3(RI-L) | 10                      | 06/24/15 – 07/08/15   |
| V              | Control, RI, RI-SD | 3                   | 12                      | 06/06/16– 06/17/16    |

Table 1: Treatments included in each hatchery trial and the total length of treatment in days. Abbreviations: controls (no probiotic provided); ConwS = 100 mM sucrose (no
probiotic, control for lyophilized formulation); RI-G = granulated formulation; RI-L = lyophilized formulations (in 100 mM sucrose); RI-SD = spray-dried formulation; RI = RI06-95 freshly cultured in lab.

| Treatment        | Relative Percent Survival (RPS, % ± SEM) | Plots |
|------------------|-----------------------------------------|-------|
| Granulated       | RI-G                                     | 69 ± 1| (Figure 2 A) |
|                  | RI-L                                     | -93 ± 86 |
| Lyophilized I    | RI                                       | 26 ± 5| (Figure 2 B) |
|                  | RI-L                                     | 22 ± 11| (Figure 2 C) |
| Lyophilized II   | RI                                       | 25 ± 6| (Figure 2 D) |
| Lyophilized III  | RI                                       | 56 ± 4| (Figure 2 E) |
|                  | RI-L                                     | 74 ± 1|
| Spray-dried I    | RI                                       | 23 ± 6| (Figure 2 F) |
|                  | RI-SD                                    | 21 ± 13|
| Spray-dried II   | RI                                       | 75 ± 5|
|                  | RI-SD                                    | 83 ± 2|

Table 2. Laboratory challenged experiments results: Effect of pre-incubation of oyster larvae for 24 h with RI06-95 formulated products on survival (RPS, % ± SEM) after challenge with *V. coralliilyticus* RE22. Survival was measured 24 h after challenge and 48 h after addition of the probiotic. Data is expressed as Relative Percent Survival (RPS, % ± SEM) of challenged oysters exposed to probiotics compared to *V. coralliilyticus* RE22 challenged control. Abbreviations: RI-G = granulated formulation; RI-L = lyophilized formulation (in 100 mM sucrose); RI-SD = spray dried formulation, RI = fresh; RE22 = *V. coralliilyticus* RE22.
Figure 2. Laboratory challenged experiments results: Effect of pre-incubation of oyster larvae with *Bacillus pumilus* RI06-95 formulated products for 24 h on survival (% ± SEM) after challenge with *V. coralliilyticus* RE22. Survival was measured 24 h after challenge and 48 h after addition of the probiotic. (A) Exposure to a granulated product of *Bacillus pumilus* RI06-95; (B), (C), and (D) Exposure to lyophilized formulations
(representative experiments) (E) and (F) Exposure to spray dried formulations. Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G = granulated formulation; RI-L = lyophilized (in 100 mM sucrose) formulation 5; RI = fresh RI06-95; RE22 = *V. coralliilyticus* RE22. Different letters indicate statistically significant differences between the treatments.

**Figure 3.** Effect of daily treatment with different formulations of *Bacillus pumilus* RI06-95 of larval eastern oysters (*Crassostrea virginica*) in the hatchery on mean larval size (µm ± SEM) at selected time points. (A) Trial I; (B) Trial II; (C) Trial III; (D) Trial IV and (E) Trial V. Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G = granulated formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI-SD
Figure 4. Effect of daily treatment with probiotics in the hatchery on interval survival (% ± SEM) of oyster larvae between selected time points. (A) Trial I; (B) Trial II; (C) Trial III; (D) Trial IV and (E) Trial V. Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G = granulated formulation; RI-L = lyophilized (in 100 mM sucrose)
formulation; RI-SD = spray dried formulation; RI = fresh RI06-95. An asterisk (*) indicates statistical significances between treatments.
**Figure 5.** Effect of daily probiotic treatment in the hatchery on larval survival to a laboratory challenge with the pathogen *Vibrio coralliilyticus* RE22. Larvae were brought to the laboratory and survival was measured 24 h after challenge with RE22. (A) Larvae collected on Day 3 after fertilization in Trial I; (B) Day 7 in Trial I; (C) Day 5 in Trial II; D) Day 12 in Trial II; E) Day 5 in Trial III; F) Day 12 in Trial III. (G) Day 8 in Trial V. Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G = granulated formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI-SD = spray-dried formulation; RI = fresh R106-95; RE22 = *V. coralliilyticus* RE22. A different letter indicates a significant difference between treatments (One-way ANOVA; p < 0.05).

| Trial | Treatments | Relative Percent Survival (RPS, % ± SEM) |
|-------|------------|------------------------------------------|
|       |            | Day 3                               | Day 7                   |
| I     | RI-G+RE22  | -10 ± 2                                | -78 ± 88                |
|       |            | Day 5                               | Day 12                  |
| II    | RI+RE22    | 36 ± 9                                 | 36 ± 6                  |
|       | RI-L+RE22  | 46 ± 3                                 | 2 ± 5                   |
Table 3. Effect of daily exposure to formulations of *B. pumilus* RI06-95 in the hatchery on larval oyster survival (%) 24 h after challenge with *Vibrio coralliilyticus* RE22. Data is expressed as Relative Percent Survival (RPS, % ± SEM) of challenged oysters exposed to probiotics compared to *V. coralliilyticus* RE22 challenged control. Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G = granulated formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI-SD = spray dried formulation, RI = fresh RI06-95; RE22 = *V. coralliilyticus* RE22.
Figure 6. Effect of daily treatment with probiotics on total vibrio levels (Log_{10}(CFU/mL) ± SEM) in water (A, B, C, G) and tank surfaces (D, E, F) in a hatchery. (A and D) Trial I (no bacteria were detected in tank surfaces in Trail I); (B and E) Trial II; and (C and F) Trial III. (G) Trial V. Abbreviations; C = no probiotic; ConwS = 100 mM sucrose; RI-G = granulated formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI-SD = spray-dried formulation; RI = fresh RI06-95; RE22 = V. coralliilyticus RE22. An asterisk (*) indicates significant differences between treatments (mean ± SEM, p < 0.05; Two-way ANOVA).
Figure 7. Effect of daily treatment with probiotics on total vibrio levels ($\log_{10}(\text{CFU/mL}) \pm \text{SEM}$) on oyster larvae in the hatchery. (A) Trial I; (B) Trial II; and (C) Trial III. Abbreviations: C = no probiotic; ConvS = 100 mM sucrose; RI-G = granulated formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI = fresh RI06-95; RE22 = V. coralliilyticus RE22. An asterisk (*) indicates significant differences between treatments (mean ± SEM, $p < 0.05$; Two-way ANOVA).
Literature Cited

Ananta E (2005) Impact of environmental factors on viability and stability and high pressure pretreatment on stress tolerance of Lactobacillus rhamnosus GG (ATCC 53103) during spray drying. Dr. Ing. Thesis, Prozesswissenschaften der Technischen Universität, Berlin.

Austin B, Stuckey LF, Robertson PAW, Effendi I, Griffith DRW (1995) A probiotic strain of *Vibrio alginolyticus* effective in reducing diseases caused by *Aeromonas salmonicida, Vibrio anguillarum* and *Vibrio ordalii*. J Fish Dis 18:93–96.

Azevedo RV de, Tavares Brag LG (2012) Use of Probiotics in Aquaculture. In: Rigobelo E (ed) Probiotic in Animals. InTech, DOI: 10.5772/50056.

Balcazar J, Blas I, Ruizzarzuela I, Cunningham D, Vendrell D, Muzquiz J (2006) The role of probiotics in aquaculture. Vet Microbiol 114:173–186.

Benardini James. N., John Sawyer John, Kasthuri Venkateswaran Kasthuri, and Wayne L. Nicholson Wayne. L. (2004) Astrobiology 3(4): 709-717. https://doi.org/10.1089/153110703322736033.

Berthe F (2004) Report about mollusc disease. Mediterr Aquac Diagn Lab 49:33–48.
Chávez BE, Ledeboer AM (2007) Drying of Probiotics: Optimization of Formulation and Process to Enhance Storage Survival. Dry Technol 25:1193–1201.

Cutting SM (2011) Bacillus probiotics. Food Microbiol 28:214–220.

Dagá P, Feijoo G, Moreira MT, Costas D, Villanueva AG, Lema JM (2013) Bioencapsulated probiotics increased survival, growth and improved gut flora of turbot (Psetta maxima) larvae. Aquac Int 21:337–345.

Decamp O, Moriarty D (2006) Probiotics as alternative to antimicrobials: limitations and potential. World Aquac 37(4):60-62.

Desmond C, Stanton C, Fitzgerald GF, Collins K, Paul Ross R (2002) Environmental adaptation of probiotic lactobacilli towards improvement of performance during spray drying. Int Dairy J 12:183–190.

Driks A (2002) Overview: development in bacteria: spore formation in Bacillus subtilis. Cell Mol Life Sci CMLS 59:389–391.

Duan J, Su Y-C (2005) Occurrence of Vibrio parahaemolyticus in Two Oregon Oyster-growing Bays. J Food Sci 70:M58–M63.
Duc, L. H., Hong, H. A., Barbosa, T. M., Henriques, A. O., & Cutting, S. M. (2004). Characterization of Bacillus Probiotics Available for Human Use. Applied and Environmental Microbiology, 70(4), 2161–2171. http://doi.org/10.1128/AEM.70.4.2161-2171.2004.

Edna M, Roets Y, Gardiner N, Laloo R (2014) The use and benefits of Bacillus based biological agents in aquaculture. In: Hernandez-Vergara M (ed) Sustainable aquaculture techniques. InTech, Murcia, Spain.

Elston R (1998) Shellfish diseases and their management in commercial recirculating systems. In: Proceedings of the second international conference on recirculating aquaculture, Roanoke, Virginia.

Estes R, Friedman C, Elston R, Herwig R (2004) Pathogenicity testing of shellfish hatchery bacterial isolates on Pacific oyster Crassostrea gigas larvae. Dis Aquat Organ 58:223–230.

Fu N, Chen XD (2011) Towards a maximal cell survival in convective thermal drying processes. Food Res Int 44:1127–1149.

Gatesoupe F. (1999) The use of probiotics in aquaculture. Aquaculture 180:147–165.
Gioia J, Yerrapragada S, Qin X, Jiang H, Igboeli OC, et al. (2007) Paradoxical DNA Repair and Peroxide Resistance Gene Conservation in *Bacillus pumilus* SAFR-032. PLOS ONE 2(9): e928. https://doi.org/10.1371/journal.pone.0000928.

Gomez-Leon J, Villamil L, Lemos ML, Novoa B, Figueras A (2005) Isolation of *Vibrio alginolyticus* and *Vibrio splendidus* from aquacultured carpet shell clam (*Ruditapes decussatus*) larvae associated with mass mortalities. Appl Environ Microbiol 71:98–104.

Gómez-León J, Villamil L, Salger S, Sallum R, Remacha-Triviño A, Leavitt D, Gómez-Chiarri M (2008) Survival of eastern oysters *Crassostrea virginica* from three lines following experimental challenge with bacterial pathogens. Dis Aquat Organ 79:95–105.

Guergoletto KB, Tsuruda AY, Hirooka EY, Martins EP, Souza JCB de, Sivieri K, Roig SM, Garcia S (2012) Dried probiotics for use in functional food applications, food industrial processes - Methods and equipment, Dr. Benjamin Valdez (Ed.), ISBN: 978-953-307-905-9, InTech, Available from: http://www.intechopen.com/books/food-industrial-processes-methods-and-equipment/dried-probiotics-for-use-in-functional-food-applications.

Hamblin, M., Spinard, E., Gomez-Chiarri, M., Nelson, D. R., & Rowley, D. C. (2015). Draft Genome Sequence of the Shellfish Larval Probiotic *Bacillus pumilus* RI06-
95. GenomeAnnouncements, 3(5), e00858–15. http://doi.org/10.1128/genomeA.00858-15.

Hardy, H., Harris, J., Lyon, E., Beal, J., & Foey, A. D. (2013). Probiotics, Prebiotics and Immunomodulation of Gut Mucosal Defences: Homeostasis and Immunopathology. Nutrients, 5(6), 1869–1912. http://doi.org/10.3390/nu5061869

Helm MM, Bourne N, Lovatelli A (2004) Hatchery culture of bivalves: a practical manual. Food and agriculture organization of the United Nations, Rome.

Henn MR, Von Maltzahn G, D’onofrio AM, Litcofsky KD, Berry DA, Cook DN, Afeyan NB, Aunins JG (2015) Synergistic bacterial compositions and methods of production and use thereof. U.S. Patent Application No. 14/592,481.

Hill, J. E., Baiano, J. C. F. and Barnes, A. C. (2009), Isolation of a novel strain of Bacillus pumilus from penaeid shrimp that is inhibitory against marine pathogens. Journal of Fish Diseases, 32: 1007–1016. doi:10.1111/j.1365-2761.2009.01084.x.

Hiolle A, Sampsonis C, Auclair E, Lenoir C (2010) Stable probiotic granulate, and method for preparing same. U.S. Patent Application No. 13/255,110.

Hong HA, Duc LH, Cutting SM (2005) The use of bacterial spore formers as probiotics: Table 1. FEMS Microbiol Rev 29:813–835.
Karim M, Zhao W, Rowley D, Nelson D, Gomez-Chiarri M (2013) Probiotic strains for shellfish aquaculture: Protection of Eastern oyster, *Crassostrea virginica*, larvae and juveniles against bacterial challenge. J Shellfish Res 32:401–408.

Kesarcoli-Watson A, Kaspar H, Lategan MJ, Gibson L (2009) Two pathogens of Greenshell™ mussel larvae, *Perna canaliculus*: *Vibrio splendidus* and a *V. coralliilyticus/neptunius*-like isolate. J Fish Dis 32:499–507.

Lalloo R, Maharajh D, Görgens J, Gardiner N (2010) A downstream process for production of a viable and stable *Bacillus cereus* aquaculture biological agent. Appl Microbiol Biotechnol 86:499–508.

Leslie SB, Israeli E, Lighthart B, Crowe JH, Crowe LM (1995) Trehalose and sucrose protect both membranes and proteins in intact bacteria during drying. Appl Environ Microbiol 61:3592–3597.

Li J, Xu Y, Jin L, Li X (2014) Effects of a probiotic mixture (*Bacillus subtilis* YB-1 and *Bacillus cereus* YB-2) on disease resistance and non-specific immunity of sea cucumber, *Apostichopus japonicus* (Selenka). Aquaculture Research 46(12), 3008-3019.
Luis-Villaseñor IE, Macías-Rodríguez ME, Gómez-Gil B, Ascencio-Valle F, Campa-Córdova ÁI (2011) Beneficial effects of four Bacillus strains on the larval cultivation of *Litopenaeus vannamei*. Aquaculture 321:136–144.

Martínez Cruz P, Ibáñez AL, Monroy Hermosillo OA, Ramírez Saad HC (2012) Use of Probiotics in Aquaculture. ISRN Microbiol 2012:1–13.

Mortha, A., Chudnovskiy, A., Hashimoto, D., Bogunovic, M., Spencer, S., Belkaid, Y., and Merad, M. (2014). Microbiota-Dependent Crosstalk Between Macrophages and ILC3 Promotes Intestinal Homeostasis. Science 343, 1249288.

Murugappan, R., Begum, S.B. & Roobia, R.R. Symbiosis (2013) 60: 91. https://doi.org/10.1007/s13199-013-0244-0.

National Marine Fisheries Service (NMFS). Annual Commercial Landing Statistics, Fisheries Statistics; 2016.

Ohtake S, Wang YJ (2011) Trehalose: Current use and future applications. J Pharm Sci 100:2020–2053

Parveen S, Hettiarachchi KA, Bowers JC, Jones JL, Tamplin ML, McKay R, Beatty W, Brohawn K, DaSilva LV, DePaola A (2008) Seasonal distribution of total and pathogenic *Vibrio parahaemolyticus* in Chesapeake Bay oysters and waters. Int J Food Microbiol 128:354–361.
Prado S, Romalde JL, Barja JL (2010) Review of probiotics for use in bivalve hatcheries. Vet Microbiol 145:187–197.

Queiroz JF, Boyd CE (1998) Effects of a Bacterial Inoculum in Channel Catfish Ponds. J World Aquac Soc 29:67–73.

Salinas I, Díaz-Rosales P, Cuesta A, Meseguer J, Chabrillón M, Moriñigo MÁ, Esteban MÁ (2006) Effect of heat-inactivated fish and non-fish derived probiotics on the innate immune parameters of a teleost fish (Sparus aurata L.). Vet Immunol Immunopathol 111:279–286.

Sánchez, B., Gueimonde, M., Peña, A. S., & Bernardo, D. (2015). Intestinal Microbiota as Modulators of the Immune System. Journal of Immunology Research, 2015, 159094. http://doi.org/10.1155/2015/159094.

Santivarangkna C, Higl B, Foerst P (2008) Protection mechanisms of sugars during different stages of preparation process of dried lactic acid starter cultures. Food Microbiol 25:429–441.

Savini M, Cecchini C, Verdenelli MC, Silvi S, Orpianesi C, Cresci A (2010) Pilot-scale Production and Viability Analysis of Freeze-Dried Probiotic Bacteria Using Different Protective Agents. Nutrients 2:330–339.
Schisler D, Slininger P, Behle R, Jackson M (2004) Formulation of *Bacillus* spp. for biological control of plant diseases. Phytopathology 94:1267–1271.

Socha AM (2008) Chemistry of Antibiotics from Atlantic *Actinomycete* and *Bacillus* bacteria. Doctoral dissertation, University of Rhode Island.

Sohn S, Lundgren KM, Tammi K *et al.* (2016a) Efficacy of probiotics in preventing *Vibriosis* in the larviculture of different species of bivalve shellfish. *Journal of Shellfish Research*, 35, 319–328.

Sohn S, Lundgren KM, Tammi K *et al.* (2016b) Probiotic strains for disease management in hatchery larviculture of the Eastern Oyster *Crassostrea virginica*. *Journal of Shellfish Research*, 35, 307–317

Sorokulova I (2013) Modern Status and Perspectives of *Bacillus* Bacteria as Probiotics. J Probiotics Health 1:1-5.

Sun Yun-Zhang, Yang Hong-Ling, Ma Ru-Long, Lin Wen-Yan, Probiotic applications of two dominant gut *Bacillus* strains with antagonistic activity improved the growth performance and immune responses of grouper *Epinephelus coioides*, (2010) *Fish & Shellfish Immunology*, Volume 29, Issue 5, Pages 803-809, ISSN 1050-4648, https://doi.org/10.1016/j.fsi.2010.07.018.
Teasdale ME, Liu J, Wallace J, Akhlaghi F, Rowley DC (2009) Secondary Metabolites Produced by the Marine Bacterium *Halobacillus salinus* That Inhibit Quorum Sensing-Controlled Phenotypes in Gram-Negative Bacteria. Appl Environ Microbiol 75:567–572.

Tubiash HS, Chanley PE, Leifson E (1965) Bacillary necrosis, a disease of larval and juvenile bivalve mollusks I. Etiology and epizootiology. J Bacteriol 90:1036–1044.

Utting SD, Millican PF (1997) Techniques for the hatchery conditioning of bivalve broodstocks and the subsequent effect on egg quality and larval viability. Aquaculture 155:45–54.

Vaseeharan B, Ramasamy P (2003) Control of pathogenic Vibrio spp. by Bacillus subtilis BT23, a possible probiotic treatment for black tiger shrimp *Penaeus monodon*. Lett Appl Microbiol 36:83–87.

Verschuere L, Rombaut G, Sorgeloos P, Verstraete W (2000) Probiotic Bacteria as Biological Control Agents in Aquaculture. Microbiol Mol Biol Rev 64:655–671.

Wang Y-C, Yu R-C, Chou C-C (2004) Viability of lactic acid bacteria and bifidobacteria in fermented soymilk after drying, subsequent rehydration and storage. Int J Food Microbiol 93:209–217.
WHO (2006) Probiotics in food: health and nutritional properties and guidelines for evaluation. FAO Food Nutr. Pap. 85, Food and Agriculture Organization of the United Nations and World Health Organization, Rome.
CHAPTER 3

CHARACTERIZATION OF CRASSOSTREA VIRGINICA LARVAL RESPONSE TO VIBRIO CORALLILYTICUS RE22

Authors: Tejashree Modak¹, Marta Gomez-Chiarri²

Affiliation: ¹Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI 02881, USA; ²Department of Fisheries, Animal and Veterinary Sciences, University of Rhode Island, Kingston, RI 02881, USA

* Corresponding Author
Marta Gómez-Chiarri, Department of Fisheries, Animal and Veterinary Sciences, University of Rhode Island, 169 CBLS, 120 Flagg Road, Kingston, RI 02881
Phone 1-401-874-2917; Email Address: gomezchi@uri.edu

This manuscript is in preparation for submission to Developmental and Comparative Immunology
Abstract

*Vibrio* spp. are ubiquitous in marine environments and, in the case of pathogenic species, responsible for causing disease in several marine organisms. *Vibrio coralliilyticus* has emerged as a pathogen affecting a variety of invertebrate species. In corals, certain strains cause bleaching, while *V. coralliilyticus* RE22 causes massive and rapid mortality of eastern oysters (*Crassostrea virginica*) larvae. Such mortality events in hatcheries where oyster larvae are reared, lead to heavy losses and subsequent shortage of oyster seed for the grow-out industry. A better knowledge of oyster-pathogen interactions and the mechanisms involved in RE22 pathogenicity may aid the development of effective management strategies. This study aims to characterize the larval immune response to experimental challenge by *V. coralliilyticus* RE22. Six to ten-day old *C. virginica* larvae were exposed to *V. coralliilyticus* RE22 for 6 hours to understand the host response in the early stages of the disease. Transcriptomes were obtained by high throughput sequencing of cDNA from three replicate experiments. Comparison of RE22 treated larval transcriptomes to untreated control larvae yielded 1,534 differentially expressed transcripts (*p* ≤ 0.05). Overall, transcriptomic data showed evidence of suppression of key immune signaling pathways but possibly activated antiviral pathways. The larval response to RE22 lacked production of protease inhibitors, hypothesized to be involved in providing protection against the proteases that are a key virulence factor of RE22. In addition, transcriptomic data suggests modulation of mucus and cytoskeletal components. The transcriptomic response was also
characterized by differential expression of metabolic genes, suggesting high metabolic demand and oxidative stress contributing to larval mortality. This study fills a major gap in our knowledge on the immune responses in larval stages of this economically and ecologically important species. This information could aid in developing solutions to control disease and design better management practices for hatcheries.
1. Introduction

*Vibrio* spp. are common pathogens causing disease in a wide variety of aquatic species, including several species of mollusks. Strains of *V. coralliilyticus* also cause disease in corals, leading to bleaching (Ben-Haim et al., 2003, Wilson et al., 2013). *V. coralliilyticus* RE22, previously known as *V. tubiashii* RE22, causes vibriosis in bivalve larvae (Richards et al., 2015). The disease resulted in heavy mortalities that severely affected oyster seed production of shellfish hatcheries (Elston et al., 2008).

Infection by vibrios in bivalve larvae is dramatically rapid in progression and characterized with signs of bacillary necrosis, reduced feeding, and swarming of bacteria around the moribund larvae (Tubiash et al., 1965). An investigation of the colonization and infection process in Manila clam (*Ruditapes philippinarum*) larvae using a GFP-tagged *Vibrio* sp. showed pathogen entry through ingestion, with infection quickly spreading to other organs and followed by colonization and proliferation in the entire body (Dubert et al., 2016). The genome of *V. coralliilyticus* RE22 shows that it encodes several extracellular metalloproteases, serine proteases, hemolysins and type secretion systems as virulence factors (Hasegawa et al., 2008, Hasegawa et al., 2009, Spinard et al., 2015). Experimental infection of *C. virginica* larvae and juveniles with *V. coralliilyticus* RE22 showed differences in susceptibility based on the age and genetic background of the oysters (Gómez-León et al., 2008).

*V. coralliilyticus* YB1 specifically infects coral *Pocillopora damicornis* causing coral tissue lysis at higher seawater temperatures (26-29°C) and its virulence factors include
a potent extracellular protease (Ben-Haim and Rosenberg, 2002, Ben-Haim et al., 2003a) whose production is also temperature regulated (Ben-Haim et al., 2003b). V. coralliilyticus P1 genome and mutant studies demonstrated presence of 17 metalloproteases, serine protease, hemolysin-related protein RbmC, chitinase and effector genes including vgrG, hlyA and hcp (Santos et al., 2011). Transcriptomic studies investigating the responses of coral Pocillopora damicornis to V. coralliilyticus YB1 reported immunosuppression of the host as a pathogenesis strategy of YB1 (Vidal-Dupiol. et al., 2014) including repression of the antimicrobial damicornin (Vidal-Dupiol et al., 2011a). Innate immunity related genes involved in P. damicornis responses to V. coralliilyticus YB1 include lectins, cystatin B, ferretin, and selenium-binding protein (Vidal-Dupiol et al., 2011b).

Several studies have characterized changes in gene expression patterns in larval stages of bivalves during development including Pinctada fucata (Li et al., 2016), C. angulata (Qin et al., 2012) and in response to vibrio infection in Crassostrea gigas (Hasegawa et al., 2008) and C. virginica (Genard et al., 2012). This study aims to enhance knowledge on bivalve-vibrio interactions by analyzing the transcriptomic response of larval eastern oysters, an economically and ecologically important species, to infection with V. coralliilyticus RE22, a bacterial pathogen capable of causing rapid and high levels of mortality in bivalve hatcheries. The goals of this study are to (1) characterize the response of C. virginica larvae to experimental challenge with V. coralliilyticus RE22; and (2) provide hypotheses on possible strategies used by V. coralliilyticus RE22 to overcome larval immune defenses. This information will aid in developing solutions to control disease and design better management practices for hatcheries.
2. Materials and methods

2.1 *Vibrio coralliilyticus* RE22 culture:

The pathogen (supplied by H. Hasegawa, Department of Biomedical Sciences, Oregon State University) was maintained and stored in 50% glycerol stocks at -80°C until use. Inocula from freezer stocks were plated on yeast peptone with 3% NaCl (YP30; 5 g L$^{-1}$ of peptone, 1 g L$^{-1}$ of yeast extract, 30 g L$^{-1}$ of ocean salt, Instant Ocean) agar plates for 2 d, then transferred to 5 mL of YP3 broth incubated at 25°C on a shaker (134 rpm) for 1 d. Cultures were washed using Artificial Filtered Sterile Seawater (AFSW, 28-30 psu salinity) twice by centrifugation at 23,000 rpm for 10 min. The OD at 550 nm was measured and the stock was diluted such as to obtain a sub lethal concentration of $5 \times 10^4$ CFU mL$^{-1}$ for transcriptome analysis and a lethal concentration (Karim et al., 2013) of $5 \times 10^5$ CFU mL$^{-1}$ for disease progression analysis.

2.2 Oyster larvae:

*C. virginica* larvae were obtained from shellfish hatcheries on the east coast of United States. Larvae 6-10 days old were collected at the hatchery and shipped overnight to the lab at the University of Rhode Island on a wet filter. Upon arrival to the laboratory, larvae were washed with AFSW on top of a 40 µm nylon mesh and placed in stock containers containing AFSW. Larvae were acclimatized to the laboratory environment (room temperature) for 24 h prior to the experiments.

2.3 Effect of *V. coralliilyticus* RE22 on mortality of *C. virginica* larvae
In order to understand the rate of progression of disease, *C. virginica* larvae were experimentally challenged with $5 \times 10^5$ CFU mL$^{-1}$ *V. coralliilyticus* RE22 (Karim et al., 2013). Larval density (larvae/mL) of the stock was determined using a Nikon E200 microscope. Larvae (~100) were distributed in wells of a 6-well plate with 5 mL AFSW and maintained at 22 - 23 °C with gentle rocking. Two treatments (control and challenge) were each conducted in triplicate. Larval mortality was recorded at 6, 9, 14, 18 and 20h post addition of *V. coralliilyticus* RE22 by evaluation of active swimming and/or gut and cilia movement using a Nikon E200 microscope.

### 2.4 Effect of pathogen exposure on larval gene expression

#### 2.4.1 Experimental set up

For biological replicates, the complete set up as explained below was performed using larvae from three different hatcheries (n = 3 experiments, operationally designated as K, M, and V). Larvae from the stocks were distributed into tissue culture flasks (~10,000 per flask) in 500 mL AFSW and kept on a shaker with gentle shaking at ~50 rpm at room temperature. Larvae were acclimatized to the experimental set up for an additional 24h prior to challenge. Each treatment (control and challenge) was conducted in duplicate to serve as technical replicates. Larvae were fed with 1 mL of instant algae Shellfish Diet 1800™ (20,000 cells/mL; Reed Mariculture Inc., San Jose, CA. USA) immediately prior to treatment in order to promote pathogen ingestion. Challenge with *V. coralliilyticus* RE22 was performed with a sub lethal concentration of $5 \times 10^4$ CFU mL$^{-1}$ for 6h.
2.4.2 Larval Collection post treatments

Control larvae were collected at 0h and RE22 treatments were collected 6h post challenge. Larvae were aspirated gently from the flasks using a 100mL serological pipette, and filtered through a 40 µm sterile filter for collection. Since dead larvae settle to the bottom, the last 25 mL of each flask was not collected to avoid bias in transcriptomic response. Larvae were washed with 2mL of AFSW on a 40µm filter, followed by a wash using 2mL of RNAlater™, aspirated from the filter using a pipette, placed in labeled 2 ml RNase free microfuge tubes, and held at 4°C for 24h in RNAlater™ followed by storage at -20°C.

2.4.3 RNA extraction, cDNA prep and sequencing

Tri-reagent™ (Sigma-Aldrich) was used for extracting total RNA from all the samples following manufacturer’s instructions (TRI Reagent™ Protocol, Sigma-Aldrich). RNA extracts were DNase treated using the DNA-free™ DNA removal kit from Ambion and purity and concentration of RNA was assessed using a Nanodrop 8000 spectrophotometer (Thermo Scientific). RNA from technical replicates was pooled at equimolar concentration. The quality and quantity of the pools were assessed using Agilent 2100 Bioanalyzer and High Sensitivity D1000 ScreenTape®. RNA samples were selectively enriched for poly-A containing mRNA and cDNA libraries were prepared using the PrepX RNAseq library Prep Kit (Takara Bio USA, inc). Samples were sequenced on Illumina HiSeq platform with 2x125 reads at a targeted sequencing
coverage of 20-30M per sample at the Harvard University, FAS Center for Systems Biology, MA.

2.4.4 Assembly, annotation and analysis

Raw reads obtained from sequencing were filtered, trimmed and adapters were removed using bbduk program in BBTools suite from Joint Genome Institute and viewed in FASTQC (Andrews, 2010). Processed reads were aligned to *C. virginica* reference genome (version 3.0) via HISAT2 2.1.0 (Kim et al., 2015) and assembly was performed using Stringtie (Pertea et al., 2016) using default parameters. To compare the depth of sequencing across all samples preseq package was used (Daley and Smith., 2013). Differential gene expression analysis was performed by comparing transcript counts between RE22 6 h treatment (replicates K, M, V) vs control 0 h (replicates K, M, V) using DESeq2 (Love et al., 2014). Transcripts with Benjamini-Hochberg adjusted p value ≤ 0.05 and log fold change of ≥ 2 or ≤ -2 were considered significantly differentially expressed. This analysis design only allowed for the most conservative estimates and only showed differentially expressed genes representing all the biological replicates. Annotation for differentially expressed genes (DEGs) was performed by mapping to NCBI protein non-redundant (NR) database using BLASTx (Altschul et al., 1997) with an e-value cutoff of 1e-3 and hit number threshold of 20. Mapping DEGs to GO terms was conducted using BLAST2GO v4.1.9 (Conesa et al., 2005) and functional enrichment was done using topGO (Alexa et al., 2006) with default parameters. ReviGO (Supek et al., 2011) was used to plot and visualize results obtained from topGO with default parameters (allowed similarity was set to medium). Significantly enriched GO
terms were obtained by using Fishers exact test ($p \leq 0.01$). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations were also obtained using the KEGG Automatic Annotation Server (KAAS).

3. Results

3.1 Effect of V. coralliilyticus RE22 on mortality of C. virginica larvae

Mortality in larval oysters exposed to $5 \times 10^5$ CFU mL of V. coralliilyticus RE22 was initially seen at 14h after challenge, increasing exponentially after that (Figure 1a). The larvae appeared normal at 6h, but 9h after challenge many showed reduced motility and feeding (Figure 1b).

3.2 Transcriptome alignment

Depth of sequencing for all the transcriptomes ranged from 16,617,375 – 39,681,499 paired end reads. Sequencing saturation curves for all transcriptomes were close to full saturation, indicating that all but the rarest transcripts would be represented in the transcriptome (Figure 2). The alignment rate to the Crassostrea virginica reference genome using HISAT2 ranged from 85 – 89 % (Table 1).

3.3 Differential expression Analysis

Comparison of transcriptomes obtained from RE22 treated (6h) larvae to control (0h) larvae using DESeq yielded 1,534 differentially expressed transcripts ($p \leq 0.05$, upregulation: log fold change $\geq 2$, downregulation: log fold change $\leq -2$). Refer to supplementary data tables in appendix for descriptions and log fold change values.
3.4 GO and KEGG annotation

A Gene Ontology (GO) term enrichment analysis was performed on all the differentially expressed transcripts in response to RE22 challenge. There were 22 biological processes significantly enriched (p<0.05) that mainly belonged to metabolism and signaling, but none related to immunity (Table 2, Figure 3); 17 metabolic functions significantly enriched (p<0.05) including “receptor activity” (Figure 4) and membrane related terms significantly enriched in the cellular component (CC). The highest number of DEGs mapped to KEGG annotations belonged to signal transduction (Table 3).

3.6 Differentially expressed immune genes in response to RE22

3.6.1 Immune related genes

Described below are some of the important immune-related genes showing differential expression in RE22 exposed larvae (6h) as compared to control (0h) (Table 4).

Transcripts corresponding to immune receptors upregulated in response to RE22 included TLR receptors (TLR4, TLR13 and TLR Tollo isoform X2), lectin and fucolectin, and leucine-rich repeats (LRRs). Transcripts identified as scavenger receptor, complement C1q-like protein 2 and 4, LRR9, and fibronectin type III domain-containing protein 2 were downregulated.

Transcripts related to the TLR signaling pathway, including myeloid differentiation primary response protein MyD88-like (MyD88), TNF receptor-associated factor 4-like (TRAF4), mitogen-activated protein kinase kinase kinase 7-like (TAK1) and toll-interacting protein-like (TOLLIP), showed downregulation in response to RE22 exposure. Important members of the NF-kB pathway that were downregulated included
NF-kappa-B-activating protein-like (NKAP) and IkB-alpha. An essential component of the MAP kinase signal transduction pathway, dual specificity mitogen-activated protein kinase kinase 7-like (MKK7), was upregulated. Surprisingly, transcripts related to antiviral pathways including stimulator of interferon genes protein-like (STING) and ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 (USP25) and some members of the JAK-STAT pathway were upregulated in response to RE22.

In terms of immune effectors, some mucin transcripts were differentially expressed in response to RE22, showing a mixed response (both up and downregulation).

In addition, cytoskeleton related transcripts including cytoplasmic actin and septin-11-like were downregulated, but dynamin-1-like transcripts showed high levels of upregulation.

### 3.6.2 Cell death

Transcripts corresponding to autophagy related gene ATG9A were highly upregulated in response to RE22. Several transcripts that belong to the apoptosis pathway were differentially expressed in response to RE22 including transcripts identified as death domain-containing protein CRADD-like, caspases (1, 2, 6, 7-like) and IAP3 were upregulated while caspase 3 and IAP2 were downregulated (Table 4).

### 3.6.3 Metabolism and oxidative stress

Transcripts involved in metabolism that were differentially expressed included Cyp450 and Cyt c subunits I and III. Heat shock proteins HSP12A and HSP12B were
highly upregulated, while a few limited antioxidant enzymes were upregulated in response to RE22 (Table 4).

4. Discussion

Both differential expression and functional enrichment analyses of oyster larvae 6h after challenge with the bacterial pathogen V. coralliilyticus RE22 suggest increased metabolic demand and activated pattern recognition receptors but repression of immune signaling pathways, preventing production of immune effectors against RE22. This pattern of gene expression is in line with the rapid disease progression observed, with clinical signs evident 14h after challenge, and heavy mortality by 24h. This acute pattern of infection allows for a very short window to activate immune responses. Therefore, the host likely relies on a strong constitutive response and a rapid induction of immune effectors to combat infection. Such rapid progression of disease in larvae is characteristic of Vibrio spp. (Tubiash et al., 1965, Dubert et al., 2016). These results are in accordance with immunosuppressive response to V. coralliilyticus YB1 as seen in coral Pocillopora damicornis (Vidal-Dupiol et al., 2011a, Vidal-Dupiol et al., 2014) as well as those seen in C. gigas in response to virulent Vibrio spp (Decker and Saulnier, 2011).

4.1 Differentially expressed immune genes in response to RE22

Highlights of the immunological response of C. virginica larvae to V. coralliilyticus RE22 at 6h of exposure include pathogen detection via activated pathogen recognition receptors. However, along with an increased expression of immune receptors, an overall
suppression of key immune signaling pathways and lack of specific immune effectors against RE22 was seen, suggesting that the pathogen is able to neutralize the immune response of the larval host.

Pattern recognition receptors (PRRs) are extremely important to innate immune system that recognize conserved pathogen-associated molecular patterns (PAMPs) and trigger signaling pathways that produce a variety of antimicrobials (Akira et al., 2006). Activation of TLR receptors indicate larvae can detect presence of bacteria especially via TLR4, which detects LPS (Chow et al., 1999) and hence Gram-negative pathogens like RE22. Activation of TLRs (Lorgeril et al., 2011, Zhang et al., 2011, Wang et al., 2016b), lectin (Chen et al., 2011, Genard et al., 2013) and C1q domain containing proteins (Lv et al., 2018) by several Vibrio spp. and parasitic exposures (Tanguy et al. 2004) have been demonstrated in bivalves. Lectins can activate the complement system and promote phagocytosis and killing of potential pathogens (Fujita et al., 2004). However, downregulation of complement C1q-like protein 2 and 4 in response to RE22 suggest suppression of recognition via C1q proteins by RE22.

Consistent with the observed response to V. coralliilyticus YB1 in coral Pocillopora damicornis (Vidal-Dupiol et al., 2014), key immune signaling pathways in larval oysters such as TLR, NF-kB, and IL-17 were also downregulated by RE22. Myeloid differentiation primary response protein 88 (MyD88) is currently the only known adaptor protein in bivalves (Gerdol et al., 2017) that modulates functioning of TLR pathway to promote activation of NF-kB pathway (Janssens and Beyaert, 2002). Downregulation of this fundamental signaling mediator suggests suppression of TLR pathway. However, MyD88 was upregulated at 24h and TRAF at 48h post challenge
with *V. coralliilyticus* LPI 06/210 (10^4 bacteria/mL in final concentration) in *C. gigas* larvae with 13 and 17% mortality rate in challenged larvae as compared to 5 and 7% in control at 24 and 48h respectively (Genard et al., 2013). It is possible that a later upregulation of these transcripts upon *V. coralliilyticus* RE22 exposure may also occur in eastern oysters, but our analysis was limited to the early time points. Disturbance of host immune responses leading to downregulation of immune genes was reported in 2yr old *C. gigas* post challenge with virulent *Vibrio* sp, *V. splendidus* LGP32-GFP and *V. aesturianus* 02/041 during first 6h of challenge (Decker and Saulnier, 2011).

### 4.2 Unexpected differentially expressed immune genes in response to RE22

#### 4.2.1 Conflicting immune gene responses:

Along with the general agreement of suppressed immune recognition and signaling pathways based on the differentially expressed transcripts, there are some results that deviate from this observation. Interestingly, toll-interacting protein (TOLLIP), an important regulator of TLR pathway that represses the TLR pathway (Zhang and Ghosh., 2002) was downregulated. Zhang et al., (2015) also found downregulation of TOLLIP at 6h of *V. anguillarum* infection in Yesso scallop (*Patinopecten yessoensis*) but upregulated in the acute phase at 3h. It is possible that our experiment missed the acute stage of the disease and the very early responses to infection.

TRAFIP2 plays a role similar to MyD88 leading to NF-kB activation through IRAK in the TLR signaling pathway and it can mediate MAPK pathway via MAPK9 or cJun N-terminal kinase (Rosani et al., 2015). Its upregulation in response to RE22 may suggest activation of NF-kB pathway and production of pro-inflammatory cytokines (Gu et al.,
2013). This contradicts the earlier notion of suppressed NF-kB pathway. Upregulation of MKK7 as seen here can lead to activation of MAPK pathway via stimulation of JNK followed by c-Jun transcriptional activity (Lu et al., 1997). This is in contrast to abalone challenge with virulent V. harveyi ORM4 and response of coral P. damicornis to V. coralliilyticus YB1 where induction of the MAPK pathway was delayed (Travers et al., 2009, Vidal-Dupiol et al., 2014). Both MAPK and NF-kB activation was seen in surviving C. gigas post challenge with virulent Vibrio spp., suggesting their importance in host defense (Lorgeril et al., 2011). Since this transcriptome is obtained from a pool of larvae perhaps these conflicting signals are derived from the presence of both susceptible and resistant larvae to RE22 exposure in the pools of oysters used in our experiments.

4.2.2 Antiviral immune gene responses:

Although, differentially expressed transcripts in response to RE22 indicate majority of the key immune signaling pathways to be suppressed, antiviral pathways seem to remain active. STING is a key regulator for sensing intracellular single- or double-stranded nucleic acids. STING via the cGAS-STING pathway complex with TAK1 and trigger expression of interferon genes. cGAS is activated whenever foreign DNA (both bacterial and viral nucleic acids) is detected in the cytoplasm (He et al., 2015, Gerdol, 2017). These results suggest the possibility of an intracellular invasion by RE22 that could lead to activation of STING or effectors of type secretion systems of RE22 (T6SS or T1SS) inadvertently leading to activation of these pathways. A special STING homolog LvSTING was activated in shrimp in response to V. parahaemolyticus infections that participates in antimicrobial peptide production (Li et al., 2017).
Similarly, activation of JAK-STAT pathway has been reviewed in bivalves as an antiviral response (Green et al., 2015) but microbial activation of this pathway has been shown in Chinese mitten crab *Eriocheir sinensis* (Li et al., 2013).

**4.2.3 Effectors**

Extracellular metalloproteases in *V. coralliilyticus* RE22 are shown to be important in its pathogenicity to *C. gigas* larvae (Hasegawa et al., 2008). Therefore, the observation of lack of serine protease inhibitors in challenged larvae, as well as the lack of upregulation of other types of protease inhibitors, was unexpected. It is possible that protease inhibitors are not differentially expressed at the time point tested (6 h) but might be at a later time point. Expression of metalloprotease of *V. tubiashii* 07/118 T2 was shown to be downregulated during early infection stage in *C. gigas* larvae (3 - 6 h) but significantly upregulated (20 fold) at 16 - 18 h post infection with ~60% mortality at 24h post-infection (Mersni-Achour et al., 2015).

Mucus is the first line of defense in oysters besides the closed oyster shell. Mucus was one of the few immune effectors shown to be upregulated in larval oysters exposed to *V. coralliilyticus* RE22. Some pathogenic *Vibrio* spp. require binding to mucin in the gut epithelium as a part of their pathogenesis (Bhowmick et al., 2008, Jang et al., 2016), so it is possible that modulation of host mucus production or composition may allow RE22 to bind better and breach host defenses in larval oysters.

**4.3 Cytoskeletal reorganization**

Downregulation of septin-11 associated with the cytoskeleton in response to RE22 suggests possible disruption of cytoskeleton by RE22, but the functional implications
of this downregulation is not clear. Both actin and septin 8B were shown to be upregulated by challenge with *V. splendidus* LGP32 in *C. gigas* (Duperthuy et al., 2011) and soft-shell clams, *Mya arenaria* (Araya et al., 2010) for hemocyte invasion. Cytoskeletal disruption using upregulation of β-actin due to *V. tapetis* challenge in *Ruditapes philippinarum* has also been demonstrated (Brulle et al., 2012). We need to know more about nature of RE22 pathogenesis in cytoskeletal modulation to fully understand this.

### 4.4 Cell death

It is difficult to interpret whether apoptosis is inhibited or enhanced in response to RE22 treatment due to modulation of both pro (caspases) and anti-apoptotic (apoptosis inhibitor) genes. This was also the case in surviving *C. gigas* on exposure of different strains of virulent *Vibrio* spp. (Lorgeril et al., 2011). IAPs were modulated in both susceptible and resistant *C. virginica* families in response to *A. crassostreae* (McDowell et al., 2014). The mechanisms underlying pathogen-induced modulation of apoptosis in mollusks are not well understood.

### 4.5 Metabolism and oxidative stress

Differential expression of heat shock proteins and cytochrome oxidases during RE22 challenge suggests that larvae are experiencing stress and high metabolic demand due to the inability to rapidly clear RE22 infection. Higher stress levels and lower metabolic rates have been seen in late responses (24-48h) of *V. coralliilyticus* LPI 06/210 in *C. gigas* (Gernard et al., 2013). Moreover, no increase in expression of antioxidant
enzymes, necessary to deal with oxidative stress from activated metabolism, was seen in our study. These results suggest that oyster larvae, which already possess a high metabolic demand to sustain the processes of rapid growth and development, may not be able to cope with the additional metabolic demand associated with infection. Moreover, reduced feeding in infected moribund larvae may not allow replenishment of energy to mount an expensive immune response (Gernard et al., 2011). It has been shown for several *V. tubiashii* strains affecting bivalves that the pathogen enters the host through ingestion, proliferates in the gut, then spreads to other organs, including the cilia that are involved in swimming and capturing particles (Tubiash et al., 1965).

5. Conclusion:

The observed absence of induced expression of protease inhibitors, antimicrobial peptides or other immune effectors able to block RE22 virulence factors, along with other indications of a suppressed immune system, suggest that larvae are left highly susceptible to disease and then succumb to infection. Additionally, differential gene expression analysis indicative of a high metabolic demand and oxidative stress are consistent with the rapid mortality observed during RE22 infection in oyster larvae. Further in-depth studies are required to tease out details of the mechanisms used by RE22 to manipulate the immune system of oyster larvae.
Figure 1a: Effect of challenge with *V. coralliilyticus* RE22 on mortality of *C. virginica* larvae. Cumulative percent mortality +/- standard error in oyster larvae after 6 – 20 h of challenge with 5x10^5 CFU/mL of RE22. Data was averaged over six replicates. Mortality was first observed at 14 h after challenge, and rapidly increasing thereafter.

![Figure 1a](image1.png)

Figure 1b: Effect of *Vibrio coralliilyticus* RE22 on mortality of *C. virginica* larvae. (A) Actively swimming healthy control larvae (B) Active larva with cilia showing signs of some clumping at 6h (C) Moribund larva with retracted cilia showing reduced movement at 9h (D) Dead larva with empty shell at 14h

![Figure 1b](image2.png)
Figure 2: Sequencing saturation curves for control and challenged larval transcriptomes showing comparable depth of sequencing for all transcriptomes. Three independent experiments (K, M, V) with two treatments (Control, C; RE22 treatment, RE22) were performed.
Table 1. Oyster larval transcriptomes in response to a 6h challenge with *Vibrio corallilyticus* RE22 challenge. Number of paired end reads per sample and % alignment rate to *Crassostrea virginica* reference genome using HISAT2. Three independent experiments (K, M, V) with two treatments (Control, C; RE22 treatment, RE22) were performed in duplicate.

| Sample  | # paired reads | % Alignment to *Crassostrea virginica* genome |
|---------|----------------|---------------------------------------------|
| C_K_0   | 22,963,376     | 89                                          |
| C_M_0   | 16,617,375     | 87                                          |
| C_V_0   | 20,674,506     | 86                                          |
| RE_K_6  | 19,379,823     | 86                                          |
| RE_M_6  | 21,118,821     | 89                                          |
| RE_V_6  | 39,681,499     | 85                                          |

Table 2: Gene Ontology (GO) terms of biological functions significantly (p<0.05) enriched in oyster larvae in response to pathogen challenge (RE22).

| GO Term                                      | Significant number of transcripts mapped | classicFisher p value |
|----------------------------------------------|-----------------------------------------|-----------------------|
| macromolecule modification                   | 83                                      | 0.0074                |
| cellular protein modification process        | 81                                      | 0.0098                |
| protein modification process                 | 81                                      | 0.0098                |
| cellular protein metabolic process          | 104                                     | 0.0125                |
| biological regulation                       | 201                                     | 0.0144                |
| cellular macromolecule catabolic process     | 17                                      | 0.0202                |
| regulation of biological process            | 189                                     | 0.0204                |
| protein metabolic process                    | 127                                     | 0.0221                |
| regulation of cellular process               | 169                                     | 0.0271                |
| regulation of cell communication            | 29                                      | 0.0319                |
| regulation of signaling                     | 29                                      | 0.0319                |
| phosphorus metabolic process                 | 86                                      | 0.0339                |
| phosphate-containing compound metabolic process | 86                                      | 0.0339                |
| Term                                      | Count | p-value  |
|-------------------------------------------|-------|----------|
| protein catabolic process                 | 14    | 0.0406   |
| cellular protein catabolic process        | 14    | 0.0406   |
| proteolysis involved in cellular protein...| 14    | 0.0406   |
| cell communication                        | 112   | 0.0409   |
| protein phosphorylation                    | 39    | 0.0416   |
| signaling                                 | 111   | 0.0451   |
| single organism signaling                 | 111   | 0.0451   |
| regulation of signal transduction         | 27    | 0.0453   |
| positive regulation of cellular process   | 27    | 0.0453   |

Figure 3: Functional enrichment of differentially expressed transcripts using Gene Ontology terms in Biological Process. The color scale in the legend shows level of significance, with colder colors indicating higher significance and the size of the bubble corresponds to the number of significant transcripts mapped to the term.
Figure 4: Functional enrichment of differentially expressed transcripts using Gene Ontology terms in Metabolic Function. The color scale in the legend shows level of significance, with colder colors indicating higher significance and the size of the bubble corresponds to the number of significant transcripts mapped to the term.
Table 3: Mapping of differentially expressed transcripts to biological pathways in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Numbers indicate number of transcripts mapped to each category.

| Pathway                                           | RE22(6h) |
|---------------------------------------------------|----------|
| **Metabolism**                                     |          |
| Carbohydrate metabolism                           | 29       |
| Energy metabolism                                 | 5        |
| Lipid metabolism                                  | 36       |
| Nucleotide metabolism                             | 21       |
| Amino acid metabolism                             | 25       |
| Metabolism of other amino acids                    | 8        |
| Glycan biosynthesis and metabolism                 | 12       |
| Metabolism of cofactors and vitamins               | 7        |
| Metabolism of terpenoids and polyketids           | 4        |
| Biosynthesis of other secondary metabolites        | 4        |
| Xenobiotics and biodegradation metabolism          | 7        |
| **Genetic information processing**                 |          |
| Transcription                                      | 10       |
| Translation                                        | 16       |
| Folding sorting and degradation                    | 13       |
| Replication and repair                             | 3        |
| **Environmental processing**                       |          |
| Membrane transport                                 | 2        |
| Signal transduction                                | 199      |
| Signaling molecules and interaction                | 10       |
| **Cellular processes**                             |          |
| Transport and catabolism                           | 41       |
| Cell growth and death                              | 39       |
| Cellular community-eukaryotes                      | 42       |
| Cellular community-prokaryotes                     | 2        |
| Cell motility                                      | 6        |
| **Organismal systems**                             |          |
| Immune system                                      | 93       |
| Endocrine system                                   | 112      |
| Circulatory system                                 | 20       |
| Digestive system | 37 |
| Excretory system | 11 |
| Nervous system | 44 |
| Sensory system | 23 |
| Development | 19 |
| Aging | 8 |
| Environmental adaptation | 17 |

Table 4: Comparison of expression of selective differentially expressed genes (DEGs) as compared to control categorized by immune processes ($p \leq 0.05$, upregulation: log fold change $\geq 2$, downregulation: log fold change $\leq -2$). Colors denote level of expression as compared to control. Red: all transcripts upregulated, orange: some transcripts upregulated while some downregulated and yellow: all transcripts downregulated. DEGs with * denote highly differentially expressed gene.

| DEGs | Expression as compared to control |
|------|----------------------------------|
| **Recognition** | |
| **TLRs** | |
| TLR4 | |
| TLR4 isoform X1 | |
| TLR13 | |
| TLR Tollo isoform X2 | |
| TOLLIP (toll-interacting protein-like isoform X3) protein toll-like | |
| myeloid differentiation primary response protein MyD88-like | |
| **Lectins** | |
| lectin-like * | |
| fucolectin-like | |
| **Scavenger receptors** | |
| scavenger receptor class B member 1 isoform B | |
| **LRR** | |
| leucine-rich repeat transmembrane neuronal protein 3-like isoform X1 | |
| leucine-rich repeat-containing protein 74B-like isoform X2 | |
| leucine-rich repeat-containing protein 9-like isoform X2 | |
| **Fibronectin type III domain** | |
| **fibronectin type III domain-containing protein 2-like isoform X3** |
| **Complement** |
| complement C1q-like protein 2 |
| complement C1q-like protein 4 |
| **Metabolic Enzymes with New Role of Carbohydrate Binding** |
| hexokinase-2-like isoform X2 |
| **B cell receptor** |
| dapp1 dual adaptor for phosphotirosine* |
| **Signaling pathways in Immune response** |
| **TLR pathway** |
| myeloid differentiation primary response protein MyD88-like |
| TNF receptor-associated factor 4-like isoform X5 (TRAF4) |
| mitogen-activated protein kinase kinase kinase 7-like isoform X3 (TAK1) |
| **JAK-STAT** |
| tyrosine-protein kinase JAK2-like (JAK) |
| son of sevenless homolog 2-like * (SOS2) |
| tyrosine-protein phosphatase non-receptor type 4-like isoform X4 (PTPN4) |
| tyrosine-protein phosphatase non-receptor type 23-like (PTPN23) |
| **NF-kB signaling pathway** |
| NF-kappa-B-activating protein-like (NKAP) |
| NF-kappa-B inhibitor alpha-like isoform X1 (IκB) |
| TNFAIP3-interacting protein 1-like * (TNIP1) |
| adapter protein CIKS-like isoform X4 (TRAF3IP2/Act1/CIKS) |
| **Mitogen-Activated Protein Kinases (MAPK) pathway** |
| dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 (MKK7) |
| mitogen-activated protein kinase kinase kinase 7-like isoform X3 (TAK1) |
| **cGAS-STING pathway** |
| stimulator of interferon genes protein-like (STING) |
| **Signal transduction** |
| death domain-containing protein 1-like |
| death domain-containing protein CRADD-like * |
| ubiquitin carboxyl-terminal hydrolase 14-like |
| ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 * (USP25) |
| 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1-like isoform X4 (PLCG1) |
| **Effectors**                  |  |
|-------------------------------|------------------|
| Signaling mucin HKR1          |                  |
| mucin-12-like *               |                  |
| mucin-2-like                  |                  |
| mucin-5B-like                 |                  |
| mucin-19-like, partial        |                  |
| septin-11-like isoform X2     |                  |
| **Apoptosis**                 |                  |
| Caspase 1                     |                  |
| Caspase 2                     |                  |
| Caspase 3                     |                  |
| Caspase 6                     |                  |
| Caspase 7                     |                  |
| Caspase 7 Isoform X1          |                  |
| Caspase 7 Isoform X3          |                  |
| baculoviral IAP repeat-containing protein 2-like |                  |
| baculoviral IAP repeat-containing protein 3-like isoform X1 * |                  |
| putative inhibitor of apoptosis* |                  |
| death domain-containing protein CRADD-like * |                  |
| XK-related protein 8-like isoform X2 * |                  |
| XK-related protein 6, partial * |                  |
| cAMP-dependent protein kinase catalytic subunit |                  |
| TPA_inf: DeltaNp63gamma       |                  |
| epidermal growth factor receptor-like isoform X2 |                  |
| **Autophagy**                 |                  |
| autophagy-related protein 9A-like isoform X1 * |                  |
| DNA damage-regulated autophagy modulator protein 1-like* |                  |
| phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like isoform X1* |                  |
| toll-interacting protein-like isoform X3 (TOLLIP) |                  |
| next to BRCA1 gene 1 protein-like isoform X1 |                  |
| **Phagosome**                 |                  |
| cation-dependent mannose-6-phosphate receptor-like * |                  |
| cytoplasmic dynein 2 light intermediate chain 1-like * |                  |
| **Lysosome**                  |                  |
| cation-dependent mannose-6-phosphate receptor-like * |                  |
| AP-1 complex subunit gamma-1-like isoform X2 |                  |
| **Endocytosis**               |                  |
| phosphatidylinositol-binding clathrin assembly protein LAP-like * |                  |
| **Peroxisome** |  |
| --- | --- |
| D-aspartate oxidase-like isoform X1 |  |
| peroxisome proliferator-activated receptor delta-like isoform X1* |  |
| peroxisome proliferator-activated receptor gamma coactivator 1-alpha-like |  |
| prostaglandin E2 receptor EP4 subtype-like [Crassostrea virginica] |  |

| **Antioxidant enzymes** |  |
| --- | --- |
| maleylacetoacetate isomerase-like* |  |
| gamma-glutamyltranspeptidase 1-like |  |
| thioredoxin domain-containing protein 15-like |  |
| thioredoxin domain-containing protein 3 homolog isoform X15 |  |
| thioredoxin-related transmembrane protein 2 homolog |  |

| **Acute phase proteins** |  |
| --- | --- |
| Heat shock 70 kDa protein 12A* |  |
| heat shock 70 kDa protein 12A-like |  |
| heat shock 70 kDa protein 12A-like isoform X1 |  |
| heat shock 70 kDa protein 12B-like |  |
| heat shock 70 kDa protein 12B-like isoform X4 * |  |

| **Cholinergic immunomodulation** |  |
| --- | --- |
| Glutamate receptor * |  |
| glutamate receptor ionotopic |  |
| muscarinic acetylcholine receptor M3-like |  |
| neuronal acetylcholine receptor subunit alpha-2-like |  |
| neuronal acetylcholine receptor subunit alpha-5-like |  |
| neuropeptide Y receptor type 2-like* |  |
| RYamide receptor-like |  |
| acetylcholinesterase-like isoform X1* |  |

| **Cytoskeletal reorganization** |  |
| --- | --- |
| septin-11-like isoform X2 |  |
| dynamin-1-like isoform X6 |  |

| **PI3K-Akt signaling pathway** |  |
| --- | --- |
| PH domain leucine-rich repeat-containing protein phosphatase 2-like isoform X2 * |  |
| phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like isoform X1* |  |
| phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2A-like isoform X4 |  |
| RAC-gamma serine/threonine-protein kinase-like isoform X1 |  |

| **Others** |  |
| --- | --- |
| multidrug resistance protein 1-like isoform X6 |  |
| Protein Name                                                                 | Isoform | Notes                                    |
|----------------------------------------------------------------------------|---------|------------------------------------------|
| glycine receptor subunit alpha-3-like isoform X5                           |         |                                          |
| gamma-glutamyltranspeptidase 1-like                                        |         |                                          |
| 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase                  |         |                                          |
| gamma-1-like isoform X4                                                    |         |                                          |
| Hemicentin-1                                                               |         |                                          |
| Hemicentin-1 like                                                          |         |                                          |
| Hemicentin-1 like isoform X2                                                |         |                                          |
| Hemicentin-1 like isoform X21                                               |         |                                          |
| Hemicentin-1 like isoform X34                                               |         |                                          |
| hemicentin-2-like isoform X2                                                |         |                                          |
| histamine H2 receptor-like                                                 |         |                                          |
| oxidative stress-induced growth inhibitor 2-like                           |         |                                          |
| cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]          |         |                                          |
| cytochrome c oxidase subunit I                                             |         |                                          |
| cytochrome c oxidase subunit III (mitochondrion)                           |         |                                          |
| cytochrome P450 27C1-like                                                  |         |                                          |
| cytochrome P450 2C28-like isoform X2                                       |         |                                          |
| cytochrome P450 2F5-like                                                   |         |                                          |
| dual specificity protein phosphatase 18-like [Crassostrea virginica]       |         |                                          |
| dual specificity protein phosphatase 7-like [Crassostrea virginica]        |         |                                          |
| protein phosphatase 1 regulatory subunit 16A-like isoform X3               |         |                                          |
| protein phosphatase 1 regulatory subunit 37-like                           |         |                                          |
| Tripartite motif-containing protein 2                                      |         |                                          |
| tripartite motif-containing protein 2-like                                 |         |                                          |
| tripartite motif-containing protein 2-like isoform X4                      |         |                                          |
| tripartite motif-containing protein 3-like                                 |         |                                          |
| tripartite motif-containing protein 45-like                                |         |                                          |
| cAMP-dependent protein kinase catalytic subunit                            |         |                                          |
| PREDICTED: stress protein DDR48-like [Salmo salar]                         |         |                                          |
| **Biomineralization**                                                      |         |                                          |
| perlucin-like isoform X1                                                   |         |                                          |
| perlucin-like protein isoform X1*                                           |         |                                          |
| Chitin synthase 3*                                                         |         |                                          |
References

Akira, S., Uematsu, S., Takeuchi, O., 2006. Pathogen recognition and innate immunity. Cell 124, 783e801.

Araya, M., Markham, F., Mateo, D., McKenna, P., Johnson, G., Berthe, F., Siah, A., 2010. Identification and expression of immune-related genes in hemocytes of soft-shell clams, Mya arenaria, challenged with *Vibrio splendidus*. Fish Shellfish Immun 29, 557–564.

Barbieri, J., Riese, M., Aktories, K., 2002. Bacterial toxins that modify the actin cytoskeleton. Annual Review of Cell and Developmental Biology 18, 315–344.

Barber, G.N., 2015. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–70.

Ben-Haim, Rosenberg, 2002. A novel Vibrio sp. pathogen of the coral *Pocillopora damicornis*. Marine Biology 141, 47–55.

Ben-Haim, Y., Thompson, FL, Thompson, CC, Cnockaert, MC, Hoste, B., Swings, J., Rosenberg, E., 2003a. *Vibrio coralliilyticus* sp. nov., a temperature-dependent pathogen of the coral *Pocillopora damicornis*. International journal of systematic and evolutionary microbiology 53, 309–315.

Ben-Haim, Y., Zicherman-Keren, M., Rosenberg, E., 2003b. Temperature-regulated bleaching and lysis of the coral *Pocillopora damicornis* by the novel pathogen *Vibrio coralliilyticus*. Applied and Environmental Microbiology 69, 4236–4242.

Bhowmick, R., Ghosal, A., Das, B., Koley, H., Saha, D.R., Ganguly S., Nandy, R.K., Bhadra, R.K., Chatterjee, N.S. 2008 Intestinal adherence of *Vibrio cholerae* involves a coordinated interaction between colonization factor GbpA and mucin. Infect Immun. 76, 4968–77.

Böhmer, F.-D., Friedrich, K., 2014. Protein tyrosine phosphatases as wardens of STAT signaling. Jak-stat 3, e28087.

Brulle, F., Jeffroy, F., Madec, S., Nicolas, J.-L., Paillard, C., 2012. Transcriptomic analysis of *Ruditapes philippinarum* hemocytes reveals cytoskeleton disruption after in vitro *Vibrio tapetis* challenge. Dev Comp Immunol 38, 368–376.

Burns, K., Clatworthy, J., Martin, L., Martinon, F., Plumpton, C., Maschera, B., Lewis, A., Ray, K., Tschopp, J., and Volpe, F. 2000. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol 2, 346–351.
Chow, J., Young, D., Golenbock, D., Christ, W., Gusovsky, F., 1999. Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction. J Biol Chem 274, 10689–10692.

Chen, D., Li, Z., Yang, Q., Zhang, J., Zhai, Z., Shu, H.-B., 2003. Identification of a nuclear protein that promotes NF-κB activation. Biochem Bioph Res Co 310, 720–724.

Chen, J., Xiao, S., Yu, Z., 2011. F-type lectin involved in defense against bacterial infection in the pearl oyster (Pinetada martensii). Fish Shellfish Immunology. 30, 750e754.

Decker, S., Saulnier, D., 2011. Vibriosis induced by experimental cohabitation in Crassostrea gigas: Evidence of early infection and down-expression of immune-related genes. Fish Shellfish Immun 30, 691–699.

Dubert, J., Nelson, D.R., Spinard, E.J., Kessner, L., Gomez-Chiarri, M., Costa, F. da, Prado, S., Barja, J.L., 2016. Following the infection process of vibriosis in Manila clam (Ruditapes philippinarum) larvae through GFP-tagged pathogenic Vibrio species. Journal of Invertebrate Pathology 133, 27–33.

Duperthuy, M., Schmitt, Paulina., Garzón, E., Caro, A., Rosa, R D., Le Roux, F., Lautréoud-Audouy, N., Got, P., Romestand, B., de Lorgeril, J., Kieffer-Jaquinod, S., Bachère, E., Destoumieux-Garzón, D., 2011. Use of OmpU porins for attachment and invasion of Crassostrea gigas immune cells by the oyster pathogen Vibrio splendidus. PNAS 108, 7, 2993 – 2998.

Elston, Hasegawa, Humphrey, Polyak, Häse, 2008. Re-emergence of Vibrio tubiashii in bivalve shellfish aquaculture: severity, environmental drivers, geographic extent and management. Dis Aquat Organ 82, 119–134.

Espinosa, E., Koller, A., Allam, B., 2016. Proteomic characterization of mucosal secretions in the eastern oyster, Crassostrea virginica. Journal of Proteomics 132, 63–76.

Fujita, T., Matsushita, M., Endo, Y., 2004. The lectin-complement pathway--its role in innate immunity and evolution. Immunol. Rev. 198, 185–202.

Genard, B., Pernet, F., Lemarchand, K., Boudry, P., Moraga, D., Tremblay, R., 2011. Physiological and biochemical changes associated with massive mortality events occurring in larvae of American oyster (Crassostrea virginica). Aquatic Living Resources 247–260.

Genard, B., Moraga, D., Pernet, F., David, É., Boudry, P., Tremblay, R., 2012. Expression of candidate genes related to metabolism, immunity and cellular stress
during massive mortality in the American oyster *Crassostrea virginica* larvae in relation to biochemical and physiological parameters. Gene 499, 70–75.

Gerdol. M., 2017. Immune-related genes in gastropods and bivalves: A comparative overview. Invertebrate Survival Journal. 14, 95-111.

Green, T., Raftos, D., Speck, P., Montagnani, C., 2015. Antiviral immunity in marine molluscs. J Gen Virol 96, 2471–2482.

Green, T., Speck, P., 2018. Antiviral Defense and Innate Immune Memory in the Oyster. Viruses 10, 133.

Gu, C., Wu, L., Li, X., 2013. IL-17 family: Cytokines, receptors and signaling. Cytokine 64, 477–485.

Hasegawa, Lind, Boin, Hase, 2008. The Extracellular Metalloprotease of Vibrio tubiashii Is a Major Virulence Factor for Pacific Oyster (*Crassostrea gigas*) Larvae. Applied and Environmental Microbiology 74, 4101–4110.

Hasegawa, H., Gharaibeh, D., Lind, E., Häse, C., 2009. Virulence of metalloproteases produced by Vibrio species on Pacific oyster *Crassostrea gigas* larvae. Dis Aquat Organ 85, 123–31.

He, Y., Jouaux, A., Ford, S., Lelong, C., Sourdaine, P., Mathieu, M., Guo, X., 2015. Transcriptome analysis reveals strong and complex antiviral response in a mollusc. Fish & Shellfish Immunology 46, 131–44.

Hu, H., Sun, S.-C., 2016. Ubiquitin signaling in immune responses. Cell Research 26, 457.

Huang, Q., Yu, M., Chen, H., Zeng, M., Sun, Y., Saha, T., Chen, D., 2018. LRFN (leucine-rich repeat and fibronectin type-III domain-containing protein) recognizes bacteria and promotes hemocytic phagocytosis in the Pacific oyster *Crassostrea gigas*. Fish & Shellfish Immunology 72, 622–628.

Jang, K.K., Gil, S.Y., Lim, J.G., Choi, S.H., 2016. Regulatory Characteristics of *Vibrio vulnificus* *gbpA* Gene Encoding a Mucin-binding Protein Essential for Pathogenesis. J Biol Chem. 291, 5774–87.

Janssens, S., Beyaert, R., 2002. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci 27, 474–482.

Li, X., Cui, Z., Liu, Y., Song, C., Shi, G., 2013. Transcriptome Analysis and Discovery of Genes Involved in Immune Pathways from Hepatopancreas of Microbial Challenged Mitten Crab *Eriocheir sinensis*. Plos One 8, e68233.
Li, H., Zhang, B., Huang, G., Liu, B., Fan, S., Zhang, D., Yu, D., Li, H., Zhang, B., Huang, G., Liu, B., Fan, S., Zhang, D., Yu, D., 2016. Differential Gene Expression during Larval Metamorphic Development in the Pearl Oyster, *Pinctada fucata*, Based on Transcriptome Analysis. International Journal of Genomics.

Li, H., Wang, S., Lü, K., Yin, B., Xiao, B., Li, S., He, J., Li, C., 2017. An invertebrate STING from shrimp activates an innate immune defense against bacterial infection. Febs Lett 591, 1010–1017.

Lorgeril, J. de, Zenagui, R., Rosa, R., Piquemal, D., Bachère, E., 2011. Whole Transcriptome Profiling of Successful Immune Response to Vibrio Infections in the Oyster *Crassostrea gigas* by Digital Gene Expression Analysis. PLoS ONE 6, e23142.

Lu, X., Nemoto, S., Lin, A., 1997. Identification of c-Jun NH2-terminal Protein Kinase (JNK)-activating Kinase 2 as an Activator of JNK but Not p38. J Biol Chem 272, 24751–24754.

Lv, Z., Qiu, L., Wang, M., Jia, Z., Wang, W., Xin, L., Liu, Z., Wang, L., Song, L., 2018. Comparative study of three C1q domain containing proteins from pacific oyster *Crassostrea gigas*. Dev Comp Immunol 78, 42–51.

Marinho, F., Benmerzoug, S., Oliveira, S., Ryffel, B., Quesniaux, V.F.J., 2017. The Emerging Roles of STING in Bacterial Infections. Trends Microbiol 25, 906–918.

Mersni-Achour, R., Cheikh, Y., Pichereau, V., Doghri, I., Etien, C., Dégremont, L., Saulnier, D., Fruitier-Arnaudin, I., Travers, M.-A., 2015. Factors other than metalloprotease are required for full virulence of French *Vibrio tubiashii* isolates in oyster larvae. Microbiology+ 161, 997–1007.

Mukhopadhyay, S., Gordon, S., 2004. The role of scavenger receptors in pathogen recognition and innate immunity. Immunobiology 209, 39–49.

Pagliuso, A., Tham, T., Stevens, J., Lagache, T., Persson, R., Salles, A., Olivo- Marin, J., Oddos, S., Spang, A., Cossart, P., Stavru, F., Pagliuso, A., Tham, T., Stevens, J., Lagache, T., Persson, R., Salles, A., Olivo- Marin, J., Oddos, S., Spang, A., Cossart, P., Stavru, F., 2016. A role for septin 2 in Drp1- mediated mitochondrial fission. EMBO reports.

Qin, J., Huang, Z., Chen, J., Zou, Q., You, W., Ke, C., 2012. Sequencing and de novo Analysis of *Crassostrea angulata* (Fujian Oyster) from 8 Different Developing Phases Using 454 GSFLx. PloS one 7, e43653.

Richards, G., Watson, M., Needleman, D., Church, K., Häse, C., 2015. Mortalities of Eastern and Pacific Oyster Larvae Caused by the Pathogens *Vibrio corallilyticus* and *Vibrio tubiashii*. Appl Environ Microb 81, 292–297.
Richards, G., Kingham, B., Shevchenko, O., Watson, M., Needleman, D., 2018. Complete Genome Sequence of *Vibrio coralliilyticus* RE22, a Marine Bacterium Pathogenic toward Larval Shellfish. Microbiol Resour Announc 7, e01332–18.

Rosani, U., Varotto, L., Gerold, M., Pallavicini, A., Venier, P., 2015. IL-17 signaling components in bivalves: Comparative sequence analysis and involvement in the immune responses. Dev Comp Immunol 52, 255–268.

Santos, E. de, Jr, N., Dias, G., Mazotto, A., Vermeio, A., Vora, G., Wilson, B., Beltran, V., Bourne, D., Roux, F., Thompson, F., 2011. Genomic and proteomic analyses of the coral pathogen *Vibrio coralliilyticus* reveal a diverse virulence repertoire. Isme J 5, 1471.

Snyder, M., 2000. Cytochrome P450 enzymes in aquatic invertebrates: recent advances and future directions. Aquatic Toxicology 48, 529–547.

Spinard, E., Kessner, L., Gomez-Chiarri, M., Rowley, D., Nelson, D., 2015. Draft Genome Sequence of the Marine Pathogen *Vibrio coralliilyticus* RE22. Genome Announcements 3, e01432–15.

Suzuki, J., Denning, D., Imanishi, E., Horvitz, H., Nagata, S., Suzuki, J., Denning, D., Imanishi, E., Horvitz, H., Nagata, S., 2013. Xk-Related Protein 8 and CED-8 Promote Phosphatidylserine Exposure in Apoptotic Cells. Science.

Tanguy, A, Guo X., Ford S.E., 2004. Discovery of genes expressed in response to Perkinsus marinus challenge in Eastern (*Crassostrea virginica*) and Pacific (*C. gigas*) oysters. Gene 338(1):121–131

Torraca, V., Mostowy, S., 2016. Septins and Bacterial Infection. Frontiers in Cell and Developmental Biology 4, 127.

Travers, M., Bouffant, R., Friedman, C., Buzin, F., Cougard, B., Huchette, S., Koken, M., Paillard, C., 2009. Pathogenic *Vibrio harveyi*, in contrast to non-pathogenic strains, intervenes with the p38 MAPK pathway to avoid an abalone haemocyte immune response. Journal of Cellular Biochemistry 106, 152–160.

Tubiash, Chanley, Leifson, 1965. Bacillary necrosis, a disease of larval and juvenile bivalve mollusks. I. Etiology and epizootiology. Journal of bacteriology 90, 1036–44.

Vidal-Dupiol, J., Ladrière, O., Destoumieux-Garzón, D., Sautière, P.-E., Meistertzheim, A.-L., Tambutté, E., Tambutté, S., Duval, D., Fouré, L., Adjeroud, M., Mitta, G., 2011a. Innate Immune Responses of a Scleractinian Coral to Vibriosis. J Biol Chem 286, 22688–22698.
Vidal-Dupiol, J., Ladrière, O., Meistertzheim, A.-L., Fouré, L., Adjeroud, M., Mitta, G., 2011b. Physiological responses of the scleractinian coral Pocillopora damicornis to bacterial stress from Vibrio coralliilyticus. J Exp Biol 214, 1533–1545.

Vidal-Dupiol, J., Dheilly, N., Rondon, R., Grunau, C., Cosseau, C., Smith, K., Freitag, M., Adjeroud, M., and Mitta, G. 2014. Thermal stress triggers broad Pocillopora damicornis transcriptomic remodeling, while Vibrio coralliilyticus infection induces a more targeted immuno-suppression response. PLoS ONE 9, e107672.

Wang, W., Zhang, T., Wang, L., Xu, J., Li, M., Zhang, A., Qiu, L., Song, L., 2016a. A new non-phagocytic TLR6 with broad recognition ligands from Pacific oyster Crassostrea gigas. Dev. Comp. Immunol. 65, 182–190.

Wang, Z., Wang, B., Chen, G., Jian, J., Lu, Y., Xu, Y., Wu, Z., Wang, Z., Wang, B., Chen, G., Jian, J., Lu, Y., Xu, Y., Wu, Z., 2016b. Transcriptome analysis of the pearl oyster (Pinctada fucata) hemocytes in response to Vibrio alginolyticus infection. Gene.

Wang, L., Song, X., Song, L., 2018. The oyster immunity. Developmental & Comparative Immunology 80, 99–118.

Woodward, J.J., Iavarone, A.T., Portnoy, D.A., 2010. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 328, 1703–5.

Zhang, R., Li, R., Wang, J., Wang, S., Zhang, M., Hu, X., Zhang, L., Wang, S., Wang, R., Bao, Z., 2015. Identification, characterization and expression profiling of the Tollip gene in Yesso scallop (Patiniopecten yessoensis). Genes Genet Syst 90, 99–108.

Zhang, G., Ghosh, S., 2002. Negative Regulation of Toll-like Receptor-mediated Signaling by Tollip. J Biol Chem 277, 7059–7065.

Zhang, L., Li, L., Zhang, G., 2011. A Crassostrea gigas Toll-like receptor and comparative analysis of TLR pathway in invertebrates. Fish Shellfish Immunology. 30, 653e660.

Zhang, R., Liu, R., Xin, L., Chen, H., Li, C., Wang, L., Song, L., 2016. A CgIFNLP receptor from Crassostrea gigas and its activation of the related genes in human JAK/STAT signaling pathway. Dev Comp Immunol 65, 98–106.

Zhao, W., Dao, C., Karim, M., Gomez-Chiarri, M., Rowley, D., Nelson, D., 2016. Contributions of tropodithietic acid and biofilm formation to the probiotic activity of Phaeobacter inhibens. Bmc Microbiol 16, 1.

Zhong, B., Liu, X., Wang, X., Chang, S., Liu, X., Wang, A., Reynolds, J., Dong, C., 2012. Negative regulation of IL-17-mediated signaling and inflammation by the ubiquitin-specific protease USP25. Nat Immunol 13, 1110.
CHAPTER 4

IMMUNOLOGICAL RESPONSE OF CRASSOSTREA VIRGINICA LARVAE TO PROBIOTICS BACILLUS PUMILUS RI06-95 AND PHAEOBACTER INHIBENS S4.

Authors: Tejashree Modak¹ and Marta Gomez-Chiarri*²

Affiliation: ¹Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI 02881, USA; ²Department of Fisheries, Animal and Veterinary Sciences, University of Rhode Island, Kingston, RI 02881, USA

* Corresponding Author

Marta Gómez-Chiarri, Department of Fisheries, Animal and Veterinary Sciences, University of Rhode Island, 169 CBLS, 120 Flagg Road, Kingston, RI 02881

Phone 1-401-874-2917; Email Address: gomezchi@uri.edu

This manuscript is in preparation for submission to Developmental and Comparative Immunology

100
Abstract

The eastern oyster *Crassostrea virginica* is an ecologically and economically important species. Bacterial pathogens like vibrios cause heavy mortalities in oyster larvae in hatcheries. Probiotics are an inexpensive, practical, and natural method of disease control. Pretreatment of larval oysters with probiotics *Bacillus pumilus* RI06-95 and *Phaeobacter inhibens* S4 significantly decreases mortality caused by experimental challenge with the pathogen *Vibrio coralliilyticus* RE22. The aim of this study was to understand the oyster larval immune response to probiotics RI06-95 and S4 and the role it may play in protecting larvae from pathogen challenge. *C. virginica* larvae were exposed to each probiotic in two settings: controlled 6 and 24 hours laboratory exposures and 5 to 16 days exposure in a hatchery. Transcriptomes were sequenced using high throughput RNA sequencing and aligned to the *C. virginica* reference genome. Differential expression analysis compared probiotic treated transcriptomes to unexposed controls. Key features of the host immune response were shared despite the length of probiotic exposure, type of probiotic exposure and the type of environment in which exposures were conducted. Transcriptome analysis showed increased expression of genes for receptors involved in environmental sensing and detection of pathogens, immune signaling pathways, and immune effectors including serine protease inhibitor, mucins and perforin-2. In addition, patterns of differential gene expression suggest that inhibition of apoptosis, enhanced autophagy, and cytoskeletal reorganization may play a supplemental role in bacterial clearance. Thus, results from this study suggest that larval oysters show a robust and effective immune response to probiotic exposure, contributing to clearance of the probiotic within 24 hours after exposure.
antibacterial immune effectors by probiotics, when provided 6 – 24 hours prior to bacterial challenge, may play an important role in protecting larvae from mortality by *V. coralliilyticus* RE22. However, for continued effective protection, probiotics should be applied repeatedly and for at least 6 hours prior to RE22 challenge. This is the first time that immune responses of larval stages of *C. virginica* to bacteria are studied using a larval transcriptome. This research provides important new insights into host-microbe interactions in larval oysters that could be applied in the design of improved strategies for use of probiotic organisms for disease control in hatcheries.
1. Introduction

The eastern oyster *Crassostrea virginica* is an economically and ecologically important species (Newell 2004, NMFS 2014). Rearing of oyster larvae is a critical step to ensure a healthy and sufficient supply of seed for aquaculture industry. Bacterial diseases commonly described in larval stages are associated with high mortalities in hatcheries (Lauckner et al. 1983, Sinderman et al. 1990). Vibriosis is one such disease that leads to mortality in oyster larvae and juveniles (Tubiash et al, 1965). Bacteria of the genus *Vibrio* are ubiquitous within marine environments and detected in tissues of many marine organisms including abalones, bivalves, corals, fish, shrimp, sponges, squid, and zooplankton (Thompson et al. 2004). *Vibrio* can cause larval mass mortalities in hatcheries in a short period of time leaving few options for treatment (Helm and Lovatelli 2006). In order to eliminate *Vibrios* and sanitize the facility, hatcheries need to shut down for several days after a disease outbreak before production is resumed (Helm and Lovatelli 2006). In particular, *V. coralliilyticus* RE22 (previously *V. tubiashii* RE22) has caused high larval and juvenile mortality in hatcheries (Elston et al. 2008). Vibrios are known to produce potent exotoxins that affects larval motility in oysters. Incapacitated ciliary movement affects feeding, leading to death due to starvation (DiSalvo et al., 1978, Brown and Roland, 1984, Kennedy, 1996). The extracellular metalloprotease secreted by *V. coralliilyticus* is toxic and induces mortality in oyster larvae (Hasegawa et al., 2008).

Practices to reduce mortality due to bacterial disease include treatment with antibiotics and disinfection of seawater. Water treatment, however, is expensive and could be toxic to the larvae if not properly done, while antibiotic treatment can lead to bacterial
resistance. Treatment with antibiotics raises environmental and human health concerns as well (Prado et al. 2009, Akinbowale et al., 2016, Ho et al., 2000). Therefore, alternative methods need to be developed to manage good larval rearing environment and to control bacterial diseases in bivalve shellfish hatcheries.

Probiotics are defined as a live microbial food supplement that, when administered in a sufficient amount, confers a health benefit on the host (Food and Agricultural Organization of the United States 2006). Probiotics are known to benefit the host by a variety of means, including production of antimicrobials, improving water quality, enhancing the immune responses of host, and competing for space with pathogenic bacteria (Verschuere et al. 2000). There is growing evidence that probiotics show immunomodulatory effects in fish and shellfish (De et al., 2014, Newaj-Fyzul et al., 2015).

The benefits of probiotics have already been shown in Pacific oysters, *Crassostrea gigas* (Douillet and Langdon 1994) and the eastern oyster *C. virginica* (Karim et al. 2013). Pretreatment of larval and juvenile *C. virginica* with probiotic organisms *Phaeobacter inhibens* S4 (isolated from the inner shell of oysters) (referred to as S4) and *Bacillus pumilus* RI06-95 (isolated from a marine sponge from the Narrow River in Rhode Island) (referred to as RI) before exposure to the bacterial pathogens *Alliroseovarius crassostreae* and *Vibrio coralliilyticus* RE22 (referred to as RE22) improves oyster survival rate (Karim et al., 2013). Additionally, probiotics are not harmful to oysters in absence of pathogens (Karim et al., 2013).

S4 is a Gram-negative organism and production of the antibiotic tropodithietic acid (TDA) and biofilm formation are two mechanisms utilized by S4 for protecting oysters
from infection. Mutants of S4 unable to produce TDA and with decreased ability to produce biofilms, however, still provide some level of protection (Zhao et al. 2016), suggesting that other mechanisms are also potentially involved. RI is a Gram-positive organism and produces the antibiotic amicoumacin, but this antibiotic does not inhibit the growth of RE22 in an in vitro assay, indicating that other mechanisms of action are also likely involved in RI’s protection of larvae against bacterial challenge (Karim et al., 2013). Probiotics are known to act as immunomodulators (Hardy et al., 2013, Mortha et al., 2014, Sanchez et al., 2015). For example, a strain of B. pumilus has been shown to improve immune responses of Orange-spotted grouper Epinephelus coioides (Sun et al., 2010), so immunomodulation may be one of the mechanisms involved in the probiotic activity of RI.

Transcriptomic analysis of C. virginica larval immune responses to pathogen V. coralliilyticus RE22 showed evidence of suppression of important immune signaling pathways and decreased expression of genes for immune effectors such as protease inhibitors, increased metabolic demand, and modulation of mucins in the early stages of infection (Modak et al, in prep; Chapter 3 of this dissertation). Immunosuppression as a pathogenesis strategy was also demonstrated in responses of coral Pocillopora damicornis to V. coralliilyticus YB1 (Vidal-Dupiol., et al., 2014). Similarly, immune response of soft-shell clams, Mya arenaria, to V. splendidus strain LGP32 showed an overall downregulation of immune genes such as ficolin, killer cell lectin-like receptor, natural resistance-associated macrophage protein 1 (Nramp-1), and mitogen-activated protein kinases (MAPK) (Araya et al., 2010). Our hypothesis is that pre-treatment of
oyster larvae with probiotics may cause an activated immune state in larvae that would serve to counteract the immunosuppressive effects of RE22.

Not much is known about the impact of friendly or beneficial bacteria on the immune system of oysters. The goal of this study is to determine the immunological response of *C. virginica* larvae to exposure to two probiotic bacterial species that differ in Gram character, in order to understand the potential role of immunomodulation as a potential mechanism of action of the probiotics in providing protection against *V. coralliilyticus* RE22.
2. Materials and methods

2.1 Probiotic Bacterial strains:
Probiotic isolates S4 and RI were maintained and stored in 50 % glycerol stocks at -80°C until use. Bacteria were cultured by plating out freezer stocks on yeast peptone with 3% NaCl (YP30) agar plates for 1 d then transferred to 5 mL of YP30 broth (5 g L⁻¹ of peptone, 1 g L⁻¹ of yeast extract, 30 g L⁻¹ of ocean salt, Instant Ocean) incubated at 28°C on a shaker (134 rpm) for 2 d. Cultures were washed using Artificial Filtered Sterile Seawater (AFSW, 28 - 30 psu salinity) twice by centrifugation at 23,000 g for 10 min. The OD at 550 nm was measured and the stock was diluted to obtain a concentration of $5 \times 10^4$ colony forming units (CFU) mL⁻¹ as previously described (Karim et al., 2013).

2.2 Oyster larvae:
C. virginica larvae were obtained from three shellfish hatcheries on the east coast of United States including Oyster Seed Holdings, VA, Virginia Institute of Marine Science, VA and Aeros Cultured Oyster Company, NY that served as three biological replicates. Larvae 6-10 days old were collected at the hatchery and shipped to the laboratory at the University of Rhode Island on a wet filter overnight. Upon arrival to the laboratory, larvae were washed with AFSW on top of a 40 μm pore size nylon filter to prepare a stock. The stock of larvae from each hatchery was used for probiotic exposures as described below. The same stock was also used for characterizing immune
2.3 Effect of length of probiotic pretreatment on protection against bacterial challenge

Previous research on the effect of probiotics on protection against challenge with the bacterial pathogen *V. coralliilyticus* RE22 was performed using a 24 h pre-incubation period with the probiotics prior to bacterial challenge (Karim et al. 2013). In order to determine if a shorter pre-incubation period with probiotics would confer protection against bacterial challenge, ~100 larvae were placed in each well of a 6 well plate in 5 mL of AFSW and incubated with $10^4$ CFU mL$^{-1}$ of probiotics S4 or RI06-95 for 6 or 24 h prior to bacterial challenge with $10^5$ CFU mL$^{-1}$ of RE22. Larval survival was determined 24 h after challenge using previously described methods (Karim et al. 2013). Survival rate was calculated as follows: $\text{Survival rate (\%)} = 100 \times \frac{\text{number of live larvae}}{\text{total number of larvae}}$. One-way analysis of variance (ANOVA) was used to determine significance between treatments and Tukey's multiple comparison tests were used for post-hoc pairwise comparisons ($p < 0.05$) (Sohn et al., 2016).

2.4. Effect of short-term exposure to probiotics on larval gene expression

2.4.1 Experimental set up for laboratory-scale experiments: For biological replicates, three independent experiments were performed using larvae from three different hatcheries. Larval density (larvae mL$^{-1}$) of the stock was determined using the Nikon E200 microscope. Two parallel exposures were performed with each set of larvae: (i)
a large-scale incubation for collection of larvae for transcriptome analysis, and (ii) a small-scale experiment in 6 well plates for evaluation of the effect of probiotic exposure on protection against bacterial challenge.

(i) Set up for transcriptome analysis: Larvae were distributed into tissue culture flasks (~10,000 per flask) in 500 mL AFSW based on the larval density (larvae/mL) and kept on a shaker with gentle shaking at ~50 rpm at room temperature. Larvae were acclimatized to the laboratory environment for 24 h. Each treatment was set up in duplicate as separate flasks to serve as technical replicates. There were five treatment groups in total viz. Control(0h), RI09-95(6 h), RI09-95(24 h), S4(6 h) and S4(24 h). Probiotics were applied at a concentration of $10^4 \text{ CFU mL}^{-1}$. Larvae were fed with instant algae Shellfish Diet 1800™ (20,000 cells/mL; Reed Mariculture Inc., San Jose, CA, USA) just prior to treatment in order to promote probiotic ingestion.

(ii) Set up for verification of protection by probiotics: Oyster larvae (~100) were placed in each well of a 6 well plate in 5 mL of AFSW and incubated with $10^4 \text{ CFU mL}^{-1}$ of probiotics S4 or RI for 6 or 24 h prior to bacterial challenge with $10^5 \text{ CFU mL}^{-1}$ of RE22, as described in section 2.3 above.

2.4.2 Larval Collection post treatments:

After incubation with probiotics, larvae from the flask set up for the transcriptome experiment were aspirated gently using a 100 mL serological pipette and filtered through a 40 µm sterile filter for collection. Since the dead larvae settle to the bottom, the last 25 mL of each flask was not collected to avoid bias in transcriptomic response. Larvae were washed with 2 mL of AFSW followed by 2 mL of RNAlater™. Larvae
retained on the filter were aspirated with a pipette using 1.5 mL of RNALater, placed in labeled 2 mL RNase free microfuge tubes, and held at 4°C for 24 h in RNALater followed by storage at -20°C.

2.4.3 RNA extraction, cDNA prep and sequencing:

Tri-reagent™ (Sigma-Aldrich) was used for extracting total RNA from all the samples following manufacturer’s instructions (TRI Reagent™ Protocol, Sigma-Aldrich). RNA extracts were DNase treated using the DNA-free™ DNA removal kit from Ambion and purity and concentration of RNA was checked using a Nanodrop 8000 spectrophotometer (Thermo Scientific). Technical replicates were pooled at equimolar concentration. The quality and quantity of the pools were assessed using Agilent 2100 Bioanalyzer and High Sensitivity D1000 ScreenTape®. RNA samples were selectively enriched for poly-A containing mRNA and cDNA libraries were prepared using the PrepX RNAseq library Prep Kit (Takara Bio USA, Inc). Samples were sequenced on Illumina HiSeq platform with 2×125 reads and sequencing coverage of 20-30M per sample at the Harvard University, FAS Center for Systems Biology, MA.

2.5 Effect of exposure to probiotics in the hatchery on larval gene expression

2.5.1 Experimental set up of hatchery experiments:

Transcriptomes obtained from treatment of larvae with *B. pumilus* RI06-95 will be referred to as HT_RI. Adult eastern oysters were spawned at the Blount Shellfish Hatchery, Roger Williams University, RI. Each trial was initiated by adding 8-10 larvae
mL⁻¹ (800,000 to 1,000,000 initial larvae) per tank 1 day post-fertilization. Larval oysters were distributed into 100 L conical tanks filled with filtered and UV treated seawater (20 – 24 C and 28 – 30 psu salinity) 1 day after fertilization and fed live microalgae daily from a microalgae production greenhouse. Water from Narragansett Bay, RI was filtered and UV treated and used for the larval tanks. Treatments included control and probiotic RI treated at a concentration of 10⁴ CFU mL⁻¹. Each treatment was conducted in triplicate. Probiotics were added daily at the time of feeding.

2.5.2 Larval Collection post treatments:
Larvae for transcriptomes were collected at three time points: 5, 12 and 16 days post fertilization from probiotic-treated and control tanks. Larvae had been treated with probiotics daily starting 1 day after fertilization, as described in Sohn et al. (2016). Tanks were drained on a filter with suitable pore size (75 – 150 µm depending on the age of the larvae) at the time of collection. Using a serological pipette, larvae were aspirated gently and collected in RNase free microfuge tubes with RNAlater™ and stored at -80°C.

2.5.3 Verification of protection by probiotics: A subsample of larvae was collected from each treatment and control tanks on day 8 post-fertilization to determine the effect of exposure to the probiotics in the hatchery on protection against bacterial challenge. Levels of protection were determined using the methods described in 2.3. above, with the following modifications: larvae from each tank were placed in triplicate wells in 6-well plates with ~100 larvae per well V. coralliilyticus RE22 at 10⁵ CFU mL⁻¹ dose.
2.5.4 RNA extraction, cDNA prep and sequencing:

Larvae were processed for RNA extraction as described in 2.4.4 above. cDNA libraries were generated using random hexamer priming that were sequenced on Illumina HiSeq platform with 2×150 reads and sequencing coverage of 50-70M per sample at the McDonnell Genomics Institute, Washington University School of Medicine, MO.

2.6 Assembly, annotation and analysis

Raw reads obtained from sequencing were filtered, trimmed and adapters were removed using bbduk program in BBTools suite from Joint Genome Institute and viewed in FASTQC (Andrews, 2010). Processed reads were aligned to *C. virginica* reference genome (version 3.0) via HISAT2 2.1.0 (Kim et al., 2015) and assembly was performed using Stringtie (Pertea et al., 2016) with default parameters. To compare the depth of sequencing across all samples preseq package was used (Daley and Smith., 2013). Differential gene expression analysis between probiotic (RI or S4) treatment at each time point (6 or 24 h) and control (time 0, common to all treatments) was performed using DESeq2 (Love et al., 2014) and transcripts with Benjamini-Hochberg adjusted pvalue $\leq 0.05$ and log fold change $\geq 2$ or $\leq -2$ were considered significantly differentially expressed. For hatchery transcriptomes, each of the days (5, 12 and 16) were considered as biological replicates and an overall comparison of treatment vs control was conducted. Transcript counts for each replicate were used to determine which DEGs are present in each replicate individually. This analysis design only allowed for the most conservative estimates and only showed differentially expressed genes.
representing all the biological replicates. Annotation for differentially expressed genes (DEGs) was performed by mapping to NCBI protein non-redundant (NR) database using BLASTx (Altschul et al., 1997) with an e-value cutoff of $1 \times 10^{-3}$ and hit number threshold of 20. Mapping DEGs to GO terms was conducted using BLAST2GO v4.1.9 (Conesa et al., 2005) and functional enrichment was done using topGO (Alexa et al., 2006) with default parameters. ReviGO (Supek et al., 2011) was used to plot and visualize results obtained from topGO with default parameters (allowed similarity adjusted to medium). Significantly enriched GO terms were obtained by using Fishers exact test ($p < 0.01$). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations were also obtained using the KEGG Automatic Annotation Server (KAAS).

3. Results

3.1 Effect of length of probiotic pretreatment on protection against bacterial challenge

A short duration of S4 or RI pretreatment (6 h) showed variable levels of protection against bacterial challenge between technical replicates within experiments and between experiments, as reflected in the large standard deviations in the relative percent survival (RPS; Table 1). One out of three experiments showed no protection from probiotic treatment. The 24h probiotic pretreatment showed a more consistent level of protection against RE22 challenge (Table 1). In the hatchery trial, larvae treated daily with probiotics for 8 days in the hatchery showed an increase of $28 \pm 6\%$ in relative percent survival as compared to untreated larvae after a laboratory challenge with *V. coralliilyticus* RE22.
3.2 Transcriptome completeness

Depth of sequencing for all the lab transcriptomes was comparable between samples ranging from 16–25M paired end reads whereas HT_RI transcriptomes ranged from 50-70M reads (Table 2). Sequencing saturation curves for all transcriptomes were close to full saturation, indicating that all but the rarest (least abundant) transcripts would be represented (Figures 1a and b). The alignment rate to the Crassostrea virginica reference genome using HISAT2 ranged from 86–89% (Table 2).

3.3 Differential Expression Analysis

Probiotic treated larval transcriptomes (RI or S4) at each time point (6 or 24 h) were compared to control (0 h) transcriptome for normalization. S4 treated transcriptomes (both 6 h and 24 h) yielded more differentially expressed transcripts when compared to control (0 h) larvae than RI treated larval transcriptomes (p ≤ 0.05) (Table 3). Larvae treated with probiotics for 24 h yielded more differentially expressed transcripts than larvae treated with probiotics for 6 h (Table 3).

Comparison of the number of shared and unique differentially expressed genes across all treatments (Figure 2a) showed a dynamic response to each of the two probiotics. Overall, larvae treated with S4 for 6 or 24 h have a higher number of differentially expressed transcripts than larvae treated with RI at 6h or 24h. The percentage of DEGs shared between S4 and RI is the same (26%) at 6h or 24h suggesting pronounced effect of treatment as compared to time. Out of the total number of differentially expressed transcripts in response to S4 and RI at 6 and 24h, 50% transcripts were unique to S4 treatment and 21% were unique to RI treatment. Comparison of differentially expressed transcripts in hatchery transcriptomes (HT_RI) (Figure 2b) showed 43% transcripts
shared between RI treatments with only 8%, 3% and 8% unique transcripts in RI_5d, RI_12d and RI_16d respectively suggesting more of a treatment effect than time. Refer to supplementary data tables in appendix for descriptions and log fold change values for differentially expressed genes for all comparisons.

3.4 GO annotation

A Gene Ontology (GO) term enrichment analysis was performed on all the differentially expressed transcripts in response to probiotic treatment. S4 treatments at both time points shared terms related to recognition and signaling (Figure 3a, 3b). S4 treatment at 6h showed enrichment in “cellular response to stimulus” whereas at 24h it showed enrichment in processes related to activation of receptors and signaling pathways suggesting a progression of immune response to S4. Very few GO terms were significantly enriched among DEGs detected from comparison between the control and larvae exposed to RI in the laboratory and they were mostly related to larval development (not shown). The HT_RI transcriptomes shared enrichment of the term “cytoskeletal organization” (Figures 3c) with the S4 (24h) transcriptomes, but none with the RI laboratory transcriptomes.

3.5 KEGG annotation

Consistent with the results of the enrichment analysis, most of the KEGG pathways that were represented by differentially expressed C. virginica larval genes related to signal transduction, immune systems, and endocrine system (Table 4).

3.6 Differentially expressed immune genes shared between probiotics

An overview of the immune genes differentially expressed upon exposure to the probiotics is depicted in Figure 4. Transcripts corresponding to the genes for several
types of PRRs were modulated by probiotic treatment, out of which Toll-like receptors (TLRs), lectins, recognition protein, peptidoglycan receptor protein (PGRP) and leucine-rich repeat receptors (LRRs) were upregulated, with TLRs and lectins being most upregulated, while scavenger receptors, leucine rich repeat and fibronectin type III domain-containing proteins (LRFN), fibronectin domain containing proteins and C1-q proteins were downregulated. TLR 4, 6 and 13 were consistently upregulated in response to both probiotics with the exception of HT_RI transcriptome where TLR 13 is downregulated (Table 5).

Consistent with the observation that probiotic treatment led to differential expression of several TLR receptors, several transcripts involved in the TLR signaling pathway, including TNF receptor-associated factor 3-like (TRAF3) and mitogen-activated protein kinase kinase kinase 7-like (TAK1), were differentially expressed upon probiotic treatment (Table 6).

Moreover, DEG patterns suggested activation of the NF-κB and MAPK pathways by probiotic exposure. Activation of the NF-κB pathway was indicated by upregulation of activator B-cell lymphoma/leukemia 10-like (BCL10) and downregulation of inhibitor NF-kappa-B inhibitor alpha-like isoform X1 (IκB). Some of the key players of the MAPK pathway including dual specificity mitogen-activated protein kinase kinase 7-like (MAP2K7), TAK1, extracellular signal-regulated kinase 2-like (ERK2) were also upregulated in probiotic-treated larvae. Transcripts corresponding to a key molecule of the MAPK pathway, MAP2K7, were uniformly upregulated in almost all probiotic treatments (Table 6).
Probiotic treatment unanimously leads to modulation of three types of major effectors: serine protease inhibitor (SPI), mucin and macrophage-expressed gene 1 protein-like (Mpeg1/Perforin-2) (Table 7). Serine protease inhibitor Csspi2 was highly upregulated in all probiotic treatments including HT_RI samples. Digestive cysteine proteinase 2 was highly upregulated in all treatments except HT_RI. Several different types of mucin genes were modulated in larvae due to probiotic treatment. Both secreted gel-forming mucins (MUC2, MUC5A, MUC5B and MUC19) and cell surface mucins (MUC3B, MUC4 and MUC12) were differentially expressed. MUC12 was highly upregulated in almost all probiotic treatments. MUC5AC was highly upregulated in probiotic treatments of 24h and MUC2 was upregulated at 6h. Perforin2 was highly upregulated in all probiotic treated larvae except in HT_RI samples.

Various molecules associated with cytoskeleton reorganization including actin, tubulin, integrin, myosin and septins (Table 8) as well as those related to phagosome, endocytosis, peroxisome and lysosome (Table 10) were differentially expressed in response to probiotics. Prostaglandin G/H synthase 2-like (PTGS2), important in inflammation reaction, was highly upregulated in all but S4(24h) treatment.

3.7 Differentially expressed immune genes unique to each probiotic

Transcripts of alpha-1–macroglobulin-like, integrins and antioxidant enzymes were downregulated in larvae exposed to S4 (Table 9). Transcripts corresponding to Tollo (TLR8) and E3 ubiquitin-protein ligase LRSAM1 were highly upregulated in RI(6h) alone. HT_RI transcriptomes showed upregulation of histone H2B-like and GTPase IMAP family member 7-like (GIMAP7) transcripts that were not seen in any other probiotic treatments.
3.8 Transcripts involved in antiviral responses

Surprisingly, several genes that are involved in antiviral pathways were also differentially expressed due to probiotic treatment. These included upregulation of recognition receptors (TLR3) for detecting intracellular nucleic acids and transcripts involved in the JAK-STAT and cGAS-STING pathways (Table 6). Stimulator of interferon genes protein-like (STING), an important part of the cGAS pathway, was upregulated in all probiotic treatments except HT_RI. Interferon induced protein 44 gene was upregulated in the HT_RI sample. E3 ubiquitin-protein ligase TRIM56 was heavily modulated in larvae from both probiotic treatments after a 24h exposure.

3.9 Cell death:

Autophagy related ATG9a was highly upregulated in all probiotic treatments except HT_RI (Table 9). Both initiator and executioner caspases in the apoptosis pathway were differentially expressed in probiotic treatments (Table 9). Transcripts for the initiator caspase 2 were upregulated in 6 h treatments while at least one of the executioner caspases 1,3,6 were upregulated in all treatments. Interestingly, caspases 1, 2, 7 and 8 were downregulated and only caspase-14 was upregulated in HT_RI. Several types of baculoviral IAP repeat-containing proteins were differentially expressed in response to probiotic treatments but the type of modulation and type of IAP differed between treatments. Inhibitor of apoptosis was highly up in all probiotic treatments except HT_RI, where GIMAP7 was highly upregulated.

4. Discussion
Exposure of larvae to probiotics S4 and RI induced the expression of a large variety of immune genes, suggesting a strong immune response comprising of heightened pathogen recognition, activation of immune signaling pathways and production of an arsenal of effectors. This probiotic mechanism of larval immunostimulation is consistent with previous observations that probiotics are cleared from the larvae within 12 - 24 h after treatment (Karim et al., 2013). These immune effectors activated in larvae upon probiotic exposure may also serve to provide protection against RE22 infection especially in light of the opposite effect of suppression of signaling pathways and lack of crucial effectors seen in response to RE22 challenge (Modak et al., in prep; Ch3 of this dissertation).

4.1 Mechanisms shared between probiotics

Overall, the immune response of larvae to each of the probiotics shared many features, including: (a) upregulation of a large variety of pathogen recognition receptors involved in environmental sensing and pathogen detection, followed by (b) activation of multiple signaling pathways; which ultimately led to the production of (c) an arsenal of effectors known to have a role in immune defenses against bacterial pathogens (Figures 4 & 5). Several probiotics are known to modulate (either activate or suppress) signaling pathways that benefit the host and protect them from pathogens (reviewed in Llewellyn et al., 2017). Usually, probiotics show a very strain specific response (Baarlen et al., 2011, Llewellyn et al., 2017). In this case however, despite the difference in Gram character between S4 and RI, many immune transcripts, especially effectors, were expressed in response to both probiotics.
Overall, differential expression analysis suggests activation of various immune signaling pathways like TLR, NF-kB and MAPK by both probiotics. The TLR pathway is crucial for bivalve innate immune systems. It recognizes a variety of damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) to activate NF-kB and MAPK pathway that protect the host from infection by producing cytokines, chemokines and other effectors (Gerdol et al., 2018). Our findings showing that TLR3, 4, 6, 8 and 13 were upregulated in response to probiotics are consistent with the important role of this pathway in bivalve immune responses, and indicate the potential of probiotics to provide protection against a broad spectrum of pathogens. Such PRR activation by probiotics due to shared cell envelope components like lipopolysaccharides, peptidoglycan, and β-glucans with pathogens is well known (Pérez-Sánchez et al., 2014). Activation of TLR6 broadens the recognition spectrum to bacteria, fungi, LPS and peptidoglycan (PGN) (Wang et al., 2018). Subsequent activation of the MAPK pathway regulates several important cellular processes like cell proliferation, apoptosis, inflammatory response to pathogens and involved in the innate immunity of oysters (Wang et al., 2018). Activation of host MAPK and NF-kB and other signaling pathways by probiotics is seen in human gut associated probiotics (Thomas & Versalovic et al., 2010, Bermudez-Brito et al., 2012).

This transcriptome analysis also suggests that activation of these pathways leads to increased transcription of a variety of immune effectors. Larvae already equipped with effectors as a result of probiotic treatment can carry out expedited clearing of pathogen upon challenge. Some of these effectors have been shown in previous research to have the potential to be involved in protection against RE22.
Protease inhibitors: All probiotic treatments showed highly upregulated serine protease inhibitor Cvspi2. One of the important virulence factors of RE22 is production of proteases, most notably metalloproteases (Hasegawa et al., 2008), but also potentially serine proteases, which are encoded in the genome (Spinard et al., 2015, Richards et al., 2018). Presence of serine protease inhibitors might neutralize serine protease attack by RE22 in probiotic pretreated larvae thus playing a significant role in their survival from RE22 infection. cvSI-1 has been shown to play an important role in host defense against Perkinsus marinus by inhibiting proliferation of the parasite (LaPeyre et al., 2009, Yu et al., 2011, Nikapitiya et al., 2014) and is also upregulated in resistant oysters in response to challenge with the pathogen Aliiroseovarious crassostreae (McDowell et al., 2014) in C. virginica.

Mucins: Mucus is an important line of defense and plays multiple roles in the host-microbe interaction (Allam and Espinosa., 2016). Both secreted gel forming mucins and cell surface mucins modulated by both probiotics work in concert to clear infection (Linden et al., 2008). Both Gram negative and Gram-positive bacteria have been shown to upregulate mucins in humans (Dohrman et al., 1998) which explains how both probiotics could influence their production. Increased production of mucus could buffer action of proteases (Yan et al., 2017) used by pathogenic Vibrio spp. to penetrate mucus and spread infection (Silva et al., 2003). Probiotics modulate the mucus barrier to aid their adhesion thereby preventing invasion of pathogens (Tuomola et al., 1999, Allam and Espinosa, 2016). In addition, oysters can also benefit from presence of vast array of immune recognition and effector proteins in the mucus (Espinosa et al., 2016). Hence, modulation of mucins can have multiple advantages for probiotic pretreated larvae.
**Perforin-2**: Perforin-2/Mpeg1 was highly upregulated in all lab probiotic treated larvae. Perforin-2 is an important ancient innate immune system effector present in vertebrates as well as invertebrates that functions by forming pores in intracellular and extracellular pathogenic bacteria (McCormack and Podack, 2015). In invertebrates, LPS exposure significantly upregulated a homologue of perforin-2 in a sponge *Suberites domuncula* (Wiens et al., 2005) and in disk abalone *Haliotis discus discus* post *V. parahemolyticus* challenge (Bathige et al., 2014). In *C. gigas*, Cg-Mpeg1 showed significant antibacterial activity to both Gram-negative and positive bacteria and its transcription level was significantly up-regulated following infection with *V. alginolyticus* (He et al., 2011). Thus, elevated activation of perforin-2 in probiotic pretreated *C. virginica* larvae might act as an efficient effector against RE22 upon challenge.

**Cytoskeletal organization**: In addition, differential expression of actin, septin and dynamin 1 were shared by both probiotics suggesting a likelihood of their role in cytoskeletal reorganization (Pagliuso et al., 2016, Sirianni et al., 2016), possibly altering intracellular pathogenic invasion (Torraca and Mostowy, 2016, Mazon et al., 2017). Cytoskeletal rearrangements can help in bacterial sensing, compartmentalization of pathogens (Mostowy & Cossart, 2011), autophagy and apoptosis for host protection (Mostowy and Shenoy, 2015) as well as phagocytosis (Vicente-Manzanares and Sánchez-Madrid., 2004). PTGS2, which was upregulated in almost all probiotic treatments, is a key enzyme producing inflammatory prostaglandins and generation of inflammatory response activating the immune system in advance.

**4.2 Mechanisms unique for each probiotic**

Some unique aspects of the probiotic specific response are discussed below:
Specific response to S4:

In addition to protease inhibition, alpha-1–macroglobulin (which was downregulated only in S4) is also involved in complement and coagulation cascades (Xiao et al., 2000) suggesting possible modulation of complement cascades by S4. Integrins (also downregulated in S4(24h)) have been shown to be used by V. splendidus to enter hemocytes and evade immunity (Duperthuy, M, et al., 2011). Antioxidant enzymes were mostly downregulated with S4 treatment, suggesting that S4 treatment does not lead to oxidative damage, unlike pathogenic exposure (Lorgeril et al., 2008, McDowell et al., 2014).

Specific response to RI:

Tollo (TLR8, upregulated in response to RI) is related to larval innate immune response to Gram negative and positive bacteria and shown to regulate antimicrobial production in Drosophila melanogaster (Akhouayri et al., 2011). E3 ubiquitin-protein ligase LRSAM1 (highly upregulated in RI (6 h)) is a bacterial recognition protein and ubiquitin ligase that defends the cytoplasm from invasive pathogens. It is important for ubiquitin-dependent autophagy against invading intracellular bacterial pathogens (Huett et al., 2012).

Two unique aspects about HT_RI transcriptome were upregulated transcripts identified as histone H2B-like and GIMAP7. Histones show antimicrobial action against Gram negative bacteria like Escherichia coli (Kawasaki et al., 2008) and in C. gigas has been demonstrated to surround and engulf vibrios (Nikapitiya et al., 2013, Poirier et al., 2014). GIMAP7 is member of GTPase of the immune-associated proteins family that
acts an apoptosis regulator (Nitta and Takahama, 2007) and its upregulation suggests inhibition of apoptosis.

4.3 Unexpected responses to probiotics

Interestingly, multiple members of antiviral pathways were also modulated in response to probiotics. STING, an important part of the cGAS pathway, was highly upregulated in all lab probiotic treatments. A special STING homolog LvSTING was activated in shrimp in response to *V. parahaemolyticus* infections that participates in antimicrobial peptide production (Li et al., 2017). Thus, this pathway plays an essential role in host response to pathogen invasion including bacteria, owing to detection of cytosolic DNA recognition and type I IFN production (Tao et al., 2016). Activation of these pathway suggests that probiotic exposure may provide protection against viruses (Thomas et al. 2010, Bermudez-Brito et al., 2012).

4.4 Cell death

ATG9a was highly upregulated by all probiotic treatments suggesting activation of autophagy (He and Klionsky, 2009) consistently by both probiotics. Autophagy and septins together restrict cytosolic bacterial replication (Torraca and Mostowy, 2016) and maybe an additional mechanism of action against RE22 invasion.

Various apoptosis inhibitors were highly upregulated in response to both probiotic treatments suggesting overall inhibition of apoptosis in response to probiotics. However, patterns of expression of apoptotic genes vary across different environmental stressors in bivalves suggesting it is a very complex pathway that is still not completely understood (Gerdol et al., 2018). Surviving *C. gigas* also showed apoptosis inhibition in response to virulent *Vibrio* sp. (Lorgeril et al., 2011). One of the virulence factors of
RE22 is production of hemolysins (Spinard et al., 2015) showing toxic effects on hemocytes (Gómez-León et al., 2008). Inhibition of apoptosis by probiotic pretreatment might result in a higher number of hemocytes (Lee et al., 1993) that can potentially counter the effect of hemolysins secreted by RE22 upon challenge.

4.5 *Length of probiotic pretreatment for effective protection from challenge*

As seen in the results (Table 1), shorter probiotic pretreatment provides variable protection whereas longer pretreatment provides consistent protection from challenge. Comparison of 6h and 24h transcriptomes showed same key effector mechanisms activated at both time points viz upregulation of serine protease inhibitors, mucins and perforin-2. There are however subtle differences for example in types of PRRs, mucins and septins that are upregulated at 6 h compared to those at 24 h. Certain genes involved in biomineralization and larval development and growth were also upregulated at 24 h. This supports the observation that longer exposure provides better protection perhaps due to increased pathogen sensing, additional growth effects and longer time for all larvae to respond to probiotic pretreatment. Previous studies have also shown chronic exposure of probiotics work better (Llewellyn et al., 2017).

5. Conclusion

This study indicates that probiotics use immunomodulation as a mechanism of action that may play a role in the protection conferred against RE22 infection. Although 6 h of pretreatment with probiotics might suffice for some larvae to protect themselves from RE22 challenge, a 24 h pretreatment consistently allows majority of them to elicit the immune responses effective in providing protection. This knowledge might help in
designing better management strategies to control larval mortality in hatcheries by use of probiotics as a natural and environmental friendly solution. In the future, it would be beneficial to use this information to target the functional identification of effectors that serve in protecting larvae against RE22 infection.
Table 1: Effect of varying lengths of probiotic pretreatment on larval survival after experimental challenge with the pathogen *V. coralliilyticus* RE22. Results are expressed as the relative increase in percent survival +/- standard deviation (SD) of larvae pretreated with probiotics as compared to non-treated and challenged larvae. S4 + RE22: Larvae pretreated with *Phaeobacter inhibens* S4 and then challenged with RE22. RI + RE22: Larvae pretreated with *Bacillus pumilus* RI0-695 and then challenged with RE22. - Not Tested.

| Treatment      | RPS (average +/- SD) |
|----------------|----------------------|
|                | 6h       | 24h     | 8d     |
| S4 + RE22     | 37 ± 26  | 41 ± 2  |  -     |
| RI + RE22     | 30 ± 39  | 45 ± 5  | 28 ± 6 |

![Graphs](C_K_0.txt, C_M_0.txt, C_V_0.txt)
Figure 1a: Sequencing saturation curves for RNA-seq samples obtained in laboratory for control, RI treated 6h, RI treated 24h, S4 treated 6h, S4 treated 24h larval transcriptomes. Curves are provided for each experiment (biological replicates; K, M, V).
**Figure 1b**: Sequencing saturation curves for RNA-seq samples obtained in hatchery for control and *B. pumilis* RI06-95 treated oyster larval transcriptomes. Larvae were collected on day 5, 12 and 16 after fertilization, after being treated daily starting 1 day after fertilization.

**Table 2**: Oyster larval transcriptomes in response to probiotic treatment. Laboratory transcriptomes: Oyster larvae were treated with *B. pumilus* RI0-695 and *Phaeobacter inhibens* S4 for 6 or 24 h. Larvae for control (C) transcriptomes were collected at time 0h. Hatchery transcriptomes: Larvae were treated daily in the hatchery with RI06-95 (RI) or not-treated (Con), and collected 5, 12 or 16 d after fertilization. Three independent laboratory experiments (K, M, V) with two treatments (Control: C; RI treatment: RI, S4 treatment: S4) were performed in duplicate. Number of paired end reads per sample and % alignment rates to *Crassostrea virginica* reference genome using HISAT2 are shown.

| Sample  | # paired reads | % Alignment to *Crassostrea virginica* genome |
|---------|----------------|--------------------------------------------|
| Laboratory transcriptomes                              |
| C_K_0   | 22,963,376     | 89                                         |
| C_M_0   | 16,617,375     | 88                                         |
| Comparison | # DEGs |
|------------|--------|
| Lab transcriptomes |  |
| 6h probiotic treatment |  |
| RI vs Con | 1,550 |
| S4 vs Con | 2,269 |
| 24h probiotic treatment |  |
| RI vs Con | 2,139 |
| S4 vs Con | 3,459 |
| Hatchery transcriptome |  |
| 5, 12, 16d post fertilization |  |
| RI vs Con | 2,993 |

**Table 3**: Number of differentially expressed genes per comparison (p \( \leq 0.05 \), upregulation: log fold change \( \geq 2 \), downregulation: log fold change \( \leq -2 \)).
Figure 2a: Venn Diagram of shared and unique differentially expressed genes for each probiotic treatment (B. pumilus RI0-695 and Phaeobacter inhibens S4) at 6 h and 24 h in laboratory samples.
Figure 2b: Plot comparing number of differentially expressed genes in probiotic treatments at 5, 12 and 16 days in a hatchery. Numbers above the highlighted bar (boxed in red) show the number of differentially expressed genes shared in all probiotic treatments.
**Figure 3a:** Functional enrichment of differentially expressed transcripts in S4 (6h) using Gene Ontology terms in Biological Process. The color scale in the legend shows level of significance (warmer colors are less significant than cooler colors) and the size of the bubble corresponds to the number of significant transcripts mapped to the term.
Figure 3b: Functional enrichment of differentially expressed transcripts in S4 (24h) using Gene Ontology terms in Biological Process. The color scale in the legend shows level of significance (warmer colors are less significant than cooler colors) and the size of the bubble corresponds to the number of significant transcripts mapped to the term.
Figure 3c: Functional enrichment of differentially expressed transcripts in hatchery RI transcriptomes using Gene Ontology terms in Biological Process. The color scale in the legend shows level of significance (warmer colors are less significant than cooler colors) and the size of the bubble corresponds to the number of significant transcripts mapped to the term.

Table 4: KEGG annotation of differentially expressed genes

| Metabolism                                | RI(6h) | S4(6h) | RI(24h) | S4(24h) |
|-------------------------------------------|--------|--------|---------|---------|
| Carbohydrate metabolism                   | 27     | 36     | 37      | 68      |
| Energy metabolism                         | 4      | 10     | 13      | 17      |
| Lipid metabolism                          | 25     | 29     | 40      | 48      |
| Nucleotide metabolism                     | 10     | 20     | 16      | 29      |
| Amino acid metabolism                     | 13     | 37     | 26      | 51      |
| Metabolism of other amino acids           | 6      | 9      | 19      | 19      |
| Glycan biosynthesis and metabolism        | 7      | 19     | 20      | 31      |
| Metabolism of cofactors and vitamins      | 6      | 17     | 14      | 16      |
| Metabolism of terpenoids and polyketids   | 3      | 3      | 4       | 5       |
| Category                                           | 1  | 2  | 3  | 4  |
|---------------------------------------------------|----|----|----|----|
| Biosynthesis of other secondary metabolites       | 2  | 8  | 5  | 4  |
| Xenobiotics and biodegradation metabolism         | 9  | 8  | 11 | 13 |
| **Genetic information processing**                |    |    |    |    |
| Transcription                                     | 11 | 20 | 13 | 17 |
| Translation                                       | 16 | 25 | 23 | 44 |
| Folding sorting and degradation                    | 16 | 23 | 25 | 43 |
| Replication and repair                            | 1  | 5  | 8  | 15 |
| **Environmental processing**                      |    |    |    |    |
| Membrane transport                                | 1  | 3  | 2  | 5  |
| Signal transduction                               | 200| 261| 294| 387|
| Signaling molecules and interaction               | 8  | 10 | 17 | 23 |
| **Cellular processes**                            |    |    |    |    |
| Transport and catabolism                          | 45 | 58 | 64 | 87 |
| Cell growth and death                             | 38 | 51 | 64 | 106|
| Cellular community-eukaryotes                     | 48 | 59 | 52 | 70 |
| Cellular community-prokaryotes                    | 1  | 2  | 0  | 1  |
| Cell motility                                     | 8  | 9  | 12 | 17 |
| **Organismal systems**                            |    |    |    |    |
| Immune system                                     | 124| 112| 113| 137|
| Endocrine system                                  | 133| 114| 171| 210|
| Circulatory system                                | 18 | 16 | 29 | 36 |
| Digestive system                                  | 33 | 34 | 41 | 63 |
| Excretory system                                  | 11 | 12 | 14 | 23 |
| Nervous system                                    | 61 | 50 | 75 | 101|
| Sensory system                                    | 20 | 16 | 24 | 31 |
| Development                                       | 22 | 22 | 23 | 31 |
| Aging                                             | 20 | 20 | 19 | 22 |
| Environmental adaptation                          | 30 | 30 | 31 | 34 |
Figure 4: Overview of the immune responses induced in oyster larvae in response to treatment with probiotics S4 and RI, as measured through high-throughput analysis of differential gene expression. Overall, PRRs including TLRs, lectins, PGRPs and LRRs were upregulated while others were downregulated. Signaling pathways including TLR, NF-κB, MAPK and antiviral pathways including JAK-STAT, cGAS-STING were activated. Immune effectors were activated including mucins, protease inhibitor and perforin-2. Autophagy was activated and apoptosis was inhibited. Antioxidant enzymes were downregulated. Cytoskeleton related molecules including septins were modulated by both probiotics.
Figure 5: Hypothesized role of selected effectors of immunity whose expression was found to be upregulated in larval oysters in response to probiotic treatment on providing protection against challenge to *V. coralliilyticus* RE22. Mucin and protease inhibitors provide protection outside the oyster body and perforin-2 providing protection once the pathogen is within oyster tissues.
Table 5: Patterns of differential gene expression of immune receptors in oyster larvae in response to probiotic treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic *Bacillus pumilus* RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h.

| Receptors       | Probiotics | HT_RI | RI_6h | RI_24h | S4_6h | S4_24h |
|-----------------|------------|-------|-------|--------|-------|--------|
| **TLRs**        |            |       |       |        |       |        |
| toll-like receptor 1 |           |       |       |        |       |        |
| TLR3 isoform X1  |            |       |       |        |       |        |
| TLR4            |            |       |       |        |       |        |
| TLR4 isoform X1  |            |       |       |        |       |        |
| toll-like receptor 6 |           |       |       |        |       |        |
| TLR6 isoform X1  |            |       |       |        |       |        |
| TLR13           |            |       |       |        |       |        |
| TLR13 isoform X1 |            |       |       |        |       |        |
| TLR Tollo isoform X2 |         |       |       |        |       |        |
| **Lectins**     |            |       |       |        |       |        |
| C-type lectin domain family 4 member E-like |         |       |       |        |       |        |
| C-type lectin domain family 3 member A-like |         |       |       |        |       |        |
| lectin-like *    |            |       |       |        |       |        |
| lectin BRA-3-like |           |       |       |        |       |        |
| plectin-like isoform X4 |        |       |       |        |       |        |
| Protein Class                  | Protein Name                                                                 |
|-------------------------------|-----------------------------------------------------------------------------|
| **Hepatic lectin like**       | galactose-specific lectin nattectin-like                                    |
|                               | fucolectin-like                                                            |
| **Scavenger receptors**       | scavenger receptor class F member 2-like                                    |
|                               | scavenger receptor class B member 1 isoform B                               |
|                               | scavenger receptor class B member 1-like isoform X1                         |
|                               | Scavenger receptor cysteine-rich type 1 protein M130                        |
|                               | scavenger receptor cysteine-rich type 1 protein M130-like isoform X1        |
|                               | somatomedin-B and thrombospondin type-1 domain-containing protein-like      |
|                               | proteoglycan 4-like isoform X4                                              |
| **PGRP**                      | peptidoglycan-recognition protein SC2-like *                                |
| **LRFN**                      | leucine-rich repeat and fibronectin type III domain-containing protein 1-like |
|                               | leucine-rich repeat and fibronectin type-III domain-containing protein 5-like|
| **LRR**                       | leucine-rich repeat transmembrane neuronal protein 3-like isoform X1        |
|                               | leucine-rich repeat transmembrane protein FLRT1-like                        |
|                               | leucine-rich repeat transmembrane protein FLRT3-like                        |
|                               | leucine-rich repeat-containing protein 24-like                              |
|                               | leucine-rich repeat-containing protein 27-like                              |
|                               | leucine-rich repeat-containing protein 28-like isoform X3                   |
|                               | leucine-rich repeat-containing protein 34-like isoform X2                   |
|                               | leucine-rich repeat-containing protein 40                                   |
| Protein Name                                                                 | Leucine-rich Repeat-Containing Protein 45-like | Leucine-rich Repeat-Containing Protein 49 | Leucine-rich Repeat-Containing Protein 4C-like isoform X1 | Leucine-rich Repeat-Containing Protein 70-like | Leucine-rich Repeat-Containing Protein 71-like isoform X21 | Leucine-rich Repeat-Containing Protein 71-like isoform X22 | Leucine-rich Repeat-Containing Protein 74A-like | Leucine-rich Repeat-Containing Protein 74A-like isoform X2 | Leucine-rich Repeat-Containing Protein 74B-like | Leucine-rich Repeat-Containing Protein 74B-like isoform X2 | Leucine-rich Repeat-Containing Protein 74B-like isoform X3 | Leucine-rich Repeat-Containing Protein 74B-like isoform X6 | Leucine-rich Repeat-Containing Protein 74B-like isoform X2 | Leucine-rich Repeat-Containing Protein 74B-like isoform X2 | Leucine-rich Repeat-Containing Protein 74B-like isoform X2 | Leucine-rich Repeat-Containing Protein 74B-like isoform X2 |
|------------------------------------------------------------------------------|-------------------------------------------------|------------------------------------------|----------------------------------------------------------|-----------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Fibronectin type III domain                                                  |                                                 |                                          |                                                          |                                               |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
| Fibronectin type III domain-containing protein 1-like                      |                                                 |                                          |                                                          |                                               |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
| Fibronectin type III domain-containing protein 2-like                      |                                                 |                                          |                                                          |                                               |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
| Fibronectin type-III domain-containing protein 3A-like isoform X4          |                                                 |                                          |                                                          |                                               |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
| Ankyrin repeat and fibronectin type-III domain-containing protein 1-like  |                                                 |                                          |                                                          |                                               |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
| C1q proteins                                                                |                                                 |                                          |                                                          |                                               |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
| C1q-related factor-like *                                                    |                                                 |                                          |                                                          |                                               |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
| Complement C1q-like protein 2                                                 |                                                 |                                          |                                                          |                                               |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
| Complement C1q tumor necrosis factor-related protein 2-like                |                                                 |                                          |                                                          |                                               |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
| Complement C1q tumor necrosis factor-related protein 4-like                |                                                 |                                          |                                                          |                                               |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |                                                          |
| Cell Function                                | Gene Name                                                                 |
|---------------------------------------------|---------------------------------------------------------------------------|
| Complement C1q tumor necrosis factor-related protein 4-like isoform X3 | complement C1q tumor necrosis factor-related protein 4-like isoform X3 |
| Alpha-1-macroglubulin-like                  | alpha-1-macroglubulin-like                                                |
| Alpha-1-macroglubulin-like isoform X2       | alpha-1-macroglubulin-like isoform X2                                     |
| Macrophage mannose receptor 1              | Macrophage mannose receptor 1                                             |
| Macrophage mannose receptor 1-like isoform X1* | Macrophage mannose receptor 1-like isoform X1*                           |
| Metabolic Enzymes with New Role of Carbohydrate Binding | Metabolic Enzymes with New Role of Carbohydrate Binding                  |
| Phosphoenolpyruvate carboxykinase           | phosphoenolpyruvate carboxykinase                                         |
| Hexokinase-2-like isoform X2                | hexokinase-2-like isoform X2                                              |
| B cell receptor                             | B cell receptor                                                           |
| Dap1 dual adaptor for phosphotirosine*      | dap1 dual adaptor for phosphotirosine*                                   |
| Cholinergic immunomodulation                | Cholinergic immunomodulation                                               |
| Glutamate receptor *                        | glutamate receptor *                                                      |
| Glutamate receptor 2-like                  | glutamate receptor 2-like                                                 |
| Glutamate receptor ionotropic               | glutamate receptor ionotropic                                             |
| Dopamine receptor 2-like                   | dopamine receptor 2-like                                                 |
| Muscarinic acetylcholine receptor M1-like   | muscarinic acetylcholine receptor M1-like                                 |
| Neuronal acetylcholine receptor subunit alpha-6-like | neuronal acetylcholine receptor subunit alpha-6-like                      |
| Neuronal acetylcholine receptor subunit alpha-9-like | neuronal acetylcholine receptor subunit alpha-9-like                      |
| Choline transporter-like protein 2          | choline transporter-like protein 2                                        |
| Apoptogenic protein 1                       | apoptogenic protein 1                                                     |
| Anti-apoptotic protein NR13-like             | anti-apoptotic protein NR13-like                                           |
| Neuropeptide FF receptor 2-like             | neuropeptide FF receptor 2-like                                           |
| Neuropeptide SIFamide receptor-like         | neuropeptide SIFamide receptor-like                                       |
| Neuropeptide Y receptor type 1-like         | neuropeptide Y receptor type 1-like                                       |
| Neuropeptide Y receptor type 2-like*        | neuropeptide Y receptor type 2-like*                                      |
Table 6: Patterns of differential gene expression of immune signaling pathways in oyster larvae in response to probiotic treatment (p \leq 0.05, upregulation: log fold change \geq 2, downregulation: log fold change \leq -2). Yellow denotes downregulation, orange denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic *Bacillus pumilus* RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h.

| Probiotics | HT_RI | RI_6h | RI_24h | S4_6h | S4_24h |
|------------|-------|-------|--------|-------|--------|
| **Signaling pathways in Immune response** |       |       |        |       |        |
| **TLR pathway** |       |       |        |       |        |
| TNF receptor-associated factor 3-like isoform X3 (TRAF3) |   |   |   |   |   |
| tumor necrosis factor receptor superfamily member 1B-like isoform X1 |   |   |   |   |   |
| tumor necrosis factor receptor superfamily member |   |   |   |   |   |
| mitogen-activated protein kinase kinase kinase 7-like isoform X3 (TAK1) |   |   |   |   |   |
| **JAK-STAT** |       |       |        |       |        |
| tyrosine-protein kinase JAK2-like (JAK) |   |   |   |   |   |
| signal transducer and activator of transcription 3-like isoform X6 (STAT3) |   |   |   |   |   |
| Suppressor of cytokine signaling 7 (SOCS) |   |   |   |   |   |
| son of sevenless homolog 2-like * (SOS2) |   |   |   |   |   |
| epidermal growth factor receptor-like (EGFR) |   |   |   |   |   |
| epidermal growth factor receptor-like isoform X2 |  |  |
| epidermal growth factor receptor-like isoform X4 |  |  |
| tyrosine-protein phosphatase non-receptor type 11 isoform X3 (SHP2) |  |  |
| tyrosine-protein phosphatase non-receptor type 4-like isoform X4 (PTPN4) |  |  |
| tyrosine-protein phosphatase non-receptor type 9-like isoform X2 (PTPN9) |  |  |
| tyrosine-protein phosphatase non-receptor type 23-like (PTPN23) |  |  |

**NF-κB signaling pathway**

| NF-kappa-B-activating protein-like (NKAP) |  |  |
| NF-kappa-B inhibitory protein alpha-like isoform X1 (IkB) |  |  |
| smad nuclear interacting protein 1-like (SNIP1) |  |  |
| TNFAIP3-interacting protein 1-like * (TNIP1) |  |  |
| B-cell lymphoma/leukemia 10-like (BCL10) |  |  |
| ELKS/Rab6-interacting/CAST family member 1-like |  |  |
| ELKS/Rab6-interacting/CAST family member 1-like isoform X3 |  |  |
| ELKS/Rab6-interacting/CAST family member 1-like isoform X5* |  |  |
| TRAF-type zinc finger domain-containing protein 1-like * |  |  |
| adapter protein CIKS-like isoform X4 (TRAF3IP2/Act1/CIKS) |  |  |
| NF-kappa-B inhibitory protein-interacting Ras-like protein 1 isoform X8 |  |  |
| nuclear factor NF-kappa-B p105 subunit-like isoform X2 |  |  |
| lipopolysaccharide-induced tumor necrosis factor-alpha factor homolog |  |  |

**Mitogen-Activated Protein Kinases (MAPK) pathway**

| dual specificity mitogen-activated protein kinase kinase 1-like isoform X1 |  |  |
| mitogen-activated protein kinase-binding protein 1-like isoform X4 (MEKK1) |  |  |
| mitogen-activated protein kinase kinase kinase kinase 3-like (MKK3) |  |  |
| Mitogen-activated protein kinase kinase kinase 7 (MKK7) |  |  |
| Protein Name                                                                 | Expression Level |
|----------------------------------------------------------------------------|------------------|
| dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 (M KK7) |                  |
| mitogen-activated protein kinase kinase kinase 7-like isoform X3 (TAK1)          |                  |
| mitogen-activated protein kinase 11-like (MAPK11)                             |                  |
| mitogen-activated protein kinase kinase kinase 13-like isoform X2 (MAPK13)      |                  |
| mitogen-activated protein kinase 14A-like (P38)                                |                  |
| transforming growth factor-beta, partial                                       |                  |
| C-Jun-amino-terminal kinase-interacting protein 4-like *                      |                  |
| extracellular signal-regulated kinase 2-like isoform X4                       |                  |
| stress-activated protein kinase JNK-like isoform X1 (JNK)                     |                  |
| Regulator of G-protein signaling 3                                            |                  |
| cGAS-STING pathway                                                           |                  |
| stimulator of interferon genes protein-like (STING)                           |                  |
| RIG-I pathway related                                                        |                  |
| interferon regulatory factor 2-binding protein-like                           |                  |
| Signal transduction                                                          |                  |
| death domain-containing protein 1-like                                         |                  |
| death domain-containing protein CRADD-like *                                   |                  |
| integrin alpha-2-like isoform X5 *                                            |                  |
| integrin alpha-4-like isoform X1 *                                            |                  |
| integrin beta-3-like [Crassostrea virginica]                                  |                  |
| ubiquitin carboxyl-terminal hydrolase 14-like                                 |                  |
| ubiquitin carboxyl-terminal hydrolase 20-like isoform X2                      |                  |
| ubiquitin carboxyl-terminal hydrolase 22-like *                               |                  |
| ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 * (USP25)            |                  |
| cellular retinoic acid-binding protein 2-like                                  |                  |
Table 7: Patterns of differential gene expression of immune effectors in response to probiotic treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic *Bacillus pumilus* RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h.

| Effectors                                                                 | HT_R I | RI_6h | RI_24h | S4_6h | S4_24h |
|--------------------------------------------------------------------------|--------|-------|--------|-------|--------|
| serine protease inhibitor Cvsi-2-like *                                   |        |       |        |       |        |
| serine protease inhibitor dipetalogastin-like *                          |        |       |        |       |        |
| kunitz-type serine protease inhibitor conotoxin Cal9.1b-like             |        |       |        |       |        |
| digestive cysteine proteinase 2-like*                                     |        |       |        |       |        |
| serine protease 44-like                                                  |        |       |        |       |        |
| interferon-induced protein 44-like isoform X2                            |        |       |        |       |        |
| interleukin-17 receptor D-like                                           |        |       |        |       |        |
| Genes                              | Symbol     | Sequence Length |
|------------------------------------|------------|-----------------|
| Signaling mucin HKR1               |            |                 |
| Integumentary mucin C.1-like       |            |                 |
| Integumentary mucin C.1-like isoform X1 |          |                 |
| Integumentary mucin C.1-like isoform X3 |          |                 |
| Mucin-12-like *                    |            |                 |
| Mucin-17-like isoform X2           |            |                 |
| Mucin-2-like                       |            |                 |
| Mucin-2-like isoform X2            |            |                 |
| Mucin-3B-like isoform X4           |            |                 |
| Mucin-4 isoform X3                 |            |                 |
| Mucin-4-like isoform X7            |            |                 |
| Mucin-4-like isoform X8            |            |                 |
| Mucin-5AC-like *                   |            |                 |
| Mucin-5AC-like isoform X5          |            |                 |
| Mucin-5B-like                      |            |                 |
| Mucin-19-like, partial             |            |                 |
| Mucin-19 isoform X2                |            |                 |
| Predicted: mucin-19 isoform X7     |            |                 |
| IgGFc-binding protein*             |            |                 |
| Septin-2-like                      |            |                 |
| Septin-2-like isoform X1           |            |                 |
| Septin-2-like isoform X8           |            |                 |
| Septin-7 isoform X3                |            |                 |
| Septin-11-like isoform X2          |            |                 |
| Macrophage-expressed gene 1 protein-like * (Perforin-2/Mpeg1) | |
Table 8: Patterns of differential gene expression that are part of cytoskeletal reorganization in oyster larvae in response to probiotic treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic *Bacillus pumilus* RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h.

| Cytoskeletal reorganization | Probiotics |
|----------------------------|------------|
|                            | HT RI | RI 6h | RI 24h | S4 6h | S4 24h |
| antistasin-like             |       |       |        |       |       |
| SH3-domain binding protein 2|       |       |        |       |       |
| alpha-1-macroglobulin-like  |       |       |        |       |       |
| alpha-1-macroglobulin-like isoform X2 |       |       |        |       |       |
| cystatin-A-like             |       |       |        |       |       |

### Probiotics

**HT-RI**

Bacillus pumilus RI0695

**RI_6h**

Larvae exposed to RI for 6h

**RI_24h**

Larvae exposed to RI for 24h

**S4_6h**

Larvae exposed to S4 for 6h

**S4_24h**

Larvae exposed to S4 for 24h
Table 9: Patterns of differential gene expression that are part of apoptosis and autophagy in oyster larvae in response to probiotic treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic Bacillus pumilus RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h.

|          | Probiotics |   |   |   |   |
|----------|------------|---|---|---|---|
|          | HT_RI | RI_6h | RI_24h | S4_6h | S4_24h |
| Apoptosis|       |       |       |       |       |
| Caspase 1|       |   |       |       |       |
| Caspase 2|       |   |       |       |       |
| Caspase 3|       |   |       |       |       |
| caspase-3-like isoform X2|       |   |       |       |       |
| Caspase 6|       |   |       |       |       |
| Caspase 6 Isoform X2|       |       |       |       |       |
| Caspase 7|       |   |       |       |       |
| Caspase 7 Isoform X1|       |   |       |       |       |
| Caspase 7 Isoform X3|       |   |       |       |       |
| Caspase-8|       |   |       |       |       |
| caspase-14-like isoform X2|       |   |       |       |       |
| caspase recruitment domain-containing protein 14-like isoform X5|       |   |       |       |       |
| baculoviral IAP repeat-containing protein 2-like|       |   |       |       |       |
| baculoviral IAP repeat-containing protein 2-like isoform X2|       |   |       |       |       |
| baculoviral IAP repeat-containing protein 2-like isoform X1|       |   |       |       |       |
| baculoviral IAP repeat-containing protein 3-like|       |   |       |       |       |
| baculoviral IAP repeat-containing protein 3-like isoform X1 |       |   |       |       |       |
| Protein Name                                                                 | Status   |
|----------------------------------------------------------------------------|----------|
| baculoviral IAP repeat-containing protein 6-like isoform X5                |          |
| baculoviral IAP repeat-containing protein 7A-like isoform X2               |          |
| baculoviral IAP repeat-containing protein 7-like isoform X3                |          |
| putative inhibitor of apoptosis*                                           |          |
| Apoptosis inhibitor IAP                                                   |          |
| bifunctional apoptosis regulator-like isoform X1                          |          |
| apoptotic protein 1                                                       |          |
| apoptotic protein 3                                                       |          |
| multiple epidermal growth factor-like domains protein 10 isoform X2       |          |
| multiple epidermal growth factor-like domains protein 10 isoform X4       |          |
| multiple epidermal growth factor-like domains protein 6                   |          |
| multiple epidermal growth factor-like domains protein 6 isoform X1       |          |
| death domain-containing protein CRADD-like *                              |          |
| apoptotic chromatin condensation inducer in the nucleus-like              |          |
| cathepsin L-like isoform X2                                               |          |
| cathepsin L1-like                                                         |          |
| cathepsin O-like                                                          |          |
| programmed cell death protein 2-like isoform X1                          |          |
| programmed cell death protein 6-like isoform X2                          |          |
| programmed cell death 6-interacting protein-like isoform X3              |          |
| XK-related protein 8-like isoform X2 *                                    |          |
| XK-related protein 6, partial *                                           |          |
| XK-related protein 4                                                      |          |
| cell death protein 3                                                       |          |
| Gene Name                                                                 | Expression Level |
|--------------------------------------------------------------------------|------------------|
| cell death abnormality protein 1-like                                    |                  |
| cell death-inducing p53-target protein 1-like isoform X5                 |                  |
| cell death specification protein 2                                       |                  |
| FAS-associated factor 1-like                                             |                  |
| serine/threonine-protein kinase/endoribonuclease IRE1-like               |                  |
| inositol 1,4,5-trisphosphate receptor type 1-like isoform X10*            |                  |
| cAMP-dependent protein kinase catalytic subunit                          |                  |
| Actin, cytoplasmic                                                       |                  |
| actin-like                                                               |                  |
| actin-3-like isoform X1                                                  |                  |
| poly [ADP-ribose] polymerase 2-like isoform X2                           |                  |
| poly [ADP-ribose] polymerase 3-like                                      |                  |
| epidermal growth factor receptor-like isoform X2                         |                  |
| epidermal growth factor receptor-like isoform X4                         |                  |
| basic immunoglobulin-like variable motif-containing protein isoform X5   |                  |
| Oxidoreductase HTATIP2                                                   |                  |
| ATP-dependent zinc metalloprotease YME1L1-like                           |                  |
| GIMAP                                                                    |                  |
| tax1-binding protein 1 homolog isoform X3*                               |                  |
| **Autophagy**                                                            |                  |
| autophagy-related protein 9A-like isoform X1 *                           |                  |
| transcription factor SPT20 homolog isoform X1                            |                  |
| vacuole membrane protein 1-like                                          |                  |
| protein kinase C delta type                                              |                  |
| DNA damage-regulated autophagy modulator protein 2-like                  |                  |
|gene expression|upregulation|downregulation|
|---------------|------------|---------------|
|DNA damage-regulated autophagy modulator protein 1-like*|**red**|**red**|
|run domain Beclin-1-interacting and cysteine-rich domain-containing protein-like isoform X3|**yellow**|**orange yellow**|
|phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like isoform X1*|**red**|**red**|
|TOLLIP (toll-interacting protein-like isoform X3)|**red**|**red**|
|serine/threonine-protein kinase/endoribonuclease IRE1-like|**yellow**|**yellow**|
|ubiquitin-like protein ATG12 isoform X1|**yellow**|**yellow**|
|ubiquitin-like-conjugating enzyme ATG10 isoform X3|**yellow**|**yellow**|
|inositol 1,4,5-trisphosphate receptor type 1-like isoform X10*|**yellow**|**yellow**|
|protein kinase C delta type*|**red**|**red**|
|insulin receptor substrate 1-B-like isoform X2 *|**red**|**red**|
|Homeobox protein HD1*|**red**|**red**|
|inositol 1,4,5-trisphosphate receptor type 1-like isoform X10*|**red**|**red**|
|alpha-soluble NSF attachment protein-like|**red**|**red**|
|endophilin-B1-like|**red**|**red**|
|ras-related protein rab7|**red**|**red**|
|hamartin-like isoform X2*|**red**|**red**|
|ras-related protein M-Ras-like|**red**|**red**|
|RAC-gamma serine/threonine-protein kinase-like isoform X1|**red**|**red**|
|UV radiation resistance-associated gene protein-like|**yellow**|**yellow**|
|next to BRCA1 gene 1 protein-like isoform X1|**red**|**red**|

**Table 10:** Patterns of differential gene expression that are part of phagosome, endosome, peroxisome, lysosome, antioxidant enzymes and acute phase proteins in oyster larvae in response to probiotic treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-R1: larvae treated daily with probiotic *Bacillus pumilus* RI0695 (RI) for 5, 12 or 16
days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h.

| Probiotics | HT_RI | RI_6h | RI_24h | S4_6h | S4_24h |
|------------|-------|-------|--------|-------|--------|
| **Phagosome** |       |       |        |       |        |
| Actin, cytoplasmic |       |       |       |       |        |
| actin-like |       |       |       |       |        |
| cathepsin L-like isoform X2 |       |       |       |       |        |
| cathepsin O-like |       |       |       |       |        |
| cation-dependent mannose-6-phosphate receptor-like |       |       |       |       |        |
| Coagulation factor V * |       |       |       |       |        |
| cytoplasmic dynein 1 heavy chain 1-like isoform X1 * |       |       |       |       |        |
| cytoplasmic dynein 2 heavy chain 1-like isoform X4 |       |       |       |       |        |
| cytoplasmic dynein 1 light intermediate chain 2-like isoform X11 * |       |       |       |       |        |
| cytoplasmic dynein 2 light intermediate chain 1-like * |       |       |       |       |        |
| ras-related protein Rab-5B-like isoform X1 |       |       |       |       |        |
| macrophage mannose receptor 1-like isoform X1 |       |       |       |       |        |
| nitric oxide synthase brain-like isoform X2 |       |       |       |       |        |
| digestive cysteine proteinase 2-like* |       |       |       |       |        |
| **Lysosome** |       |       |        |       |        |
| lysosomal acid lipase/cholesteryl ester hydrolase-like |       |       |       |       |        |
| lysosomal acid lipase/cholesteryl ester hydrolase-like isoform X2 |       |       |       |       |        |
| cation-dependent mannose-6-phosphate receptor-like * |       |       |       |       |        |
| sulfatase-modifying factor 1-like |       |       |       |       |        |
| lysosomal-associated transmembrane protein 4A-like |  |
| ADP-ribosylation factor-binding protein GGA1-like * |  |
| ADP-ribosylation factor-binding protein GGA1-like * |  |
| AP-1 complex subunit gamma-1-like isoform X2 |  |
| AP-1 complex subunit sigma-2 isoform X4 * |  |
| clathrin heavy chain 2 isoform X2 |  |
| lysosomal-trafficking regulator-like isoform X4 |  |
| lysosomal alpha-glucosidase-like isoform X1 |  |
| **Endocytosis** |  |
| AP-2 complex subunit mu-1 |  |
| clathrin heavy chain 2 isoform X2 |  |
| tumor susceptibility gene 101 protein-like |  |
| hepatocyte growth factor-regulated tyrosine kinase substrate-like |  |
| syntaxin-7-like isoform X3 |  |
| phosphatidylinositol-binding clathrin assembly protein LAP-like * |  |
| **Peroxisome** |  |
| probable peroxisomal membrane protein PEX13 |  |
| D-aspartate oxidase-like * |  |
| D-aspartate oxidase-like isoform X1 |  |
| phytanoyl-CoA dioxygenase, peroxisomal-like |  |
| enoyl-CoA delta isomerase 2, mitochondrial-like isoform X2 |  |
| peroxisomal acyl-coenzyme A oxidase 1-like |  |
| peroxisomal acyl-coenzyme A oxidase 1-like isoform X2 |  |
| peroxisome proliferator-activated receptor delta-like isoform X1* |  |
| peroxisome proliferator-activated receptor gamma coactivator 1-alpha-like |  |
| **Prostaglandin E synthase 2-like** [Crassostrea virginica] |  |
| prostaglandin E2 receptor EP4 subtype-like [Crassostrea virginica] |  |
| prostaglandin G/H synthase 2-like isoform X2 [Crassostrea virginica] |  |
| prostaglandin reductase 1-like isoform X2 | * |
| peroxisomal carnitine O-octanoyltransferase-like |  |
| **Antioxidant enzymes** |  |
| glutathione peroxidase 7-like [Crassostrea virginica] |  |
| glutathione S-transferase C-terminal domain-containing protein-like isoform X1 [Crassostrea virginica] |  |
| glutathione S-transferase kappa 1-like [Crassostrea virginica] |  |
| glutathione S-transferase omega-1 |  |
| glutathione S-transferase P 2-like |  |
| glutathione S-transferase 3-like |  |
| glutathione-independent glyoxalase HSP31-like |  |
| glutathione S-transferase P 2-like |  |
| maleylacetoacetate isomerase-like* |  |
| gamma-glutamyltranspeptidase 1-like |  |
| Superoxide dismutase [Cu-Zn] |  |
| thioredoxin domain-containing protein 15-like |  |
| thioredoxin domain-containing protein 3 homolog isoform X15 |  |
| thioredoxin domain-containing protein 5-like |  |
| thioredoxin-like |  |
| thioredoxin-like protein 1 |  |
| thioredoxin-related transmembrane protein 1-like isoform X1 |  |
| thioredoxin-related transmembrane protein 2 homolog |  |
| Acute phase proteins                          |  |  |  |
|----------------------------------------------|---|---|---|
| heat shock 70 kDa protein 4*                |  |  |  |
| Heat shock 70 kDa protein 12A*              |  |  |  |
| heat shock 70 kDa protein 12A-like           |  |  |  |
| heat shock 70 kDa protein 12A-like isoform X1|  |  |  |
| heat shock 70 kDa protein 12A-like isoform X3|  |  |  |
| heat shock 70 kDa protein 12B-like           |  |  |  |
| heat shock 70 kDa protein 12B-like isoform X4 |  |  |  |
| heat shock factor protein-like               |  |  |  |
| heat shock protein 30C-like                  |  |  |  |
| heat shock protein HSP 90-beta-like         |  |  |  |
| Stress response protein NhaX                 |  |  |  |

**Table 11:** Patterns of differential gene expression that are part of metabolism, biomineralization and other processes in oyster larvae in response to probiotic treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic *Bacillus pumilus* RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h.
| Others                                                                 | HT_RI | RI_6h | RI_24h | S4_6h | S4_24h |
|-----------------------------------------------------------------------|-------|-------|--------|-------|--------|
| furin-like protease kpc-1 isoform X1                                  |       |       |        |       |        |
| multidrug resistance protein 1-like isoform X1                       |       |       |        |       |        |
| multidrug resistance-associated protein 1-like isoform X3*           |       |       |        |       |        |
| multidrug resistance protein 1-like isoform X6                       |       |       |        |       |        |
| multidrug resistance-associated protein 4-like                       |       |       |        |       |        |
| multidrug resistance-associated protein 5-like                       |       |       |        |       |        |
| multidrug resistance-associated protein 5-like isoform X2            |       |       |        |       |        |
| multidrug resistance-associated protein 7-like                       |       |       |        |       |        |
| laccase-3-like                                                        |       |       |        |       |        |
| laccase-like                                                          |       |       |        |       |        |
| laccase-5-like                                                        |       |       |        |       |        |
| peptidoglycan-recognition protein SC2-like                            |       |       |        |       |        |
| glycine receptor subunit alpha-3-like isoform X5                     |       |       |        |       |        |
| gamma-glutamyltranspeptidase 1-like                                   |       |       |        |       |        |
| 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1-like|       |       |        |       |        |
| cysteine proteinase inhibitor 8-like                                  |       |       |        |       |        |
| Hemicentin-1                                                          |       |       |        |       |        |
| Hemicentin-1 like                                                     |       |       |        |       |        |
| Hemicentin-1 like isoform X2                                          |       |       |        |       |        |
| Hemicentin-1 like isoform X3                                          |       |       |        |       |        |
| Hemicentin-1 like isoform X5                                          |       |       |        |       |        |
| Protein Description                        | Hemicentin-1 like isoform X6 | Hemicentin-1 like isoform X9 | Hemicentin-1 like isoform X21* | Hemicentin-1 like isoform X34* | Hemicentin-1 like isoform X40 | Hemicentin-2-like isoform X2 | histamine H2 receptor-like | oxidative stress-induced growth inhibitor 2-like | cytochrome b [Crassostrea virginica] | cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica] | cytochrome c oxidase subunit I* | cytochrome c oxidase subunit III (mitochondrion)* | cytochrome P450 2C8 | cytochrome P450 2C42-like | cytochrome P450 2C28-like isoform X2* | cytochrome P450 2C42-like | Cytochrome P450 2D14 | cytochrome P450 2F5-like* | cytochrome P450 4F22-like | cytochrome P450 2J5-like isoform X2* | cytochrome P450 3A6-like | Cytochrome P450 3A11 | cytochrome P450 3A24-like isoform X1 | cytochrome P450 3A29-like |
|------------------------------------------|------------------------------|------------------------------|-------------------------------|-------------------------------|------------------------------|------------------------------|-------------------------------|----------------------------------|-----------------------------------|-----------------------------------|---------------------------------|-----------------------------------|---------------------------|--------------------------|-----------------------------|-----------------------------|---------------------------|-------------------------------|-----------------------------|---------------------------|-------------------------------|--------------------------|----------------|------------------------|--------------------------|
| Protein Name                                                                 | Status | Status | Status |
|------------------------------------------------------------------------------|--------|--------|--------|
| cytochrome P450 4A25-like                                                    |        |        |        |
| cytochrome P450 4V2-like isoform X1                                         |        |        |        |
| cytochrome P450 4F22-like *                                                 |        |        |        |
| dual specificity protein phosphatase 1-A-like [Crassostrea virginica]       |        |        |        |
| dual specificity protein phosphatase 14-like isoform X1 [Crassostrea virginica] |        |        |        |
| dual specificity protein phosphatase 18-like [Crassostrea virginica]        |        |        |        |
| dual specificity protein phosphatase 19-like [Crassostrea virginica]        |        |        |        |
| dual specificity protein phosphatase 7-like [Crassostrea virginica]         |        |        |        |
| dual specificity tyrosine-phosphorylation-regulated kinase 4-like isoform X14 [Crassostrea virginica] |        |        |        |
| protein phosphatase 1 regulatory subunit 12A-like isoform X2                |        |        |        |
| protein phosphatase 1 regulatory subunit 12A-like isoform X4                |        |        |        |
| protein phosphatase 1 regulatory subunit 16A-like isoform X3                |        |        |        |
| protein phosphatase 1 regulatory subunit 36-like isoform X1                 |        |        |        |
| protein phosphatase 1 regulatory subunit 37-like                            |        |        |        |
| protein phosphatase 1 regulatory subunit 42-like isoform X1                 |        |        |        |
| Tripartite motif-containing protein 2                                        |        |        |        |
| tripartite motif-containing protein 2-like                                   |        |        |        |
| tripartite motif-containing protein 5-like                                   |        |        |        |
| tripartite motif-containing protein 5-like isoform X2                       |        |        |        |
| tripartite motif-containing protein 2-like isoform X2                       |        |        |        |
| tripartite motif-containing protein 2-like isoform X4                       |        |        |        |
| tripartite motif-containing protein 2-like isoform X1                       |        |        |        |
| tripartite motif-containing protein 3-like                                   |        |        |        |
| tripartite motif-containing protein 3-like isoform X1                       |        |        |        |
| tripartite motif-containing protein 45-like                                 |        |        |        |
| Protein Name | Status |
|--------------|--------|
| tripartite motif-containing protein 55-like | |
| universal stress protein A-like protein isoform X5 | |
| epididymal secretory protein E1-like * | |
| perilipin-2-like isoform X3* | |
| nitric oxide synthase brain-like isoform X2 | |
| Ig-like and fibronectin type-III domain-containing protein 2 * | |
| macrophage migration inhibitory factor-like | |
| retinoic acid receptor RXR-gamma isoform X1 | |
| NAD-dependent protein deacetylase sirtuin-1-like * | |
| cAMP-dependent protein kinase catalytic subunit | |
| PREDICTED: stress protein DDR48-like [Salmo salar] | |
| B-cell lymphoma 6 protein homolog isoform X3 | |
| 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1-like isoform X12 | |
| cell wall integrity and stress response component 3-like isoform X3 | |
| histone H2B-like | |
| **Biomineralization** | |
| perlucin-like | |
| perlucin-like isoform X1 * | |
| perlucin-like isoform X2 | |
| perlucin-like protein | |
| perlucin-like protein isoform X1* | |
| Chitin synthase 3* | |
| Chitin synthase C | |
| putative carbonic anhydrase-like protein 1 | |
References

Akhouayri, I., Turc, C., Royet, J., Charroux, B., 2011. Toll-8/Tollo Negatively Regulates Antimicrobial Response in the Drosophila Respiratory Epithelium. Plos Pathog 7, e1002319.

Allam, B., Espinosa, E., 2016. Bivalve immunity and response to infections: Are we looking at the right place? Fish & Shellfish Immunology 53, 4–12.

Alexa, A., Rahnenführer, J., Lengauer, T., 2006. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 22, 1600–1607.

Allam, B., Espinosa, E., 2016. Bivalve immunity and response to infections: Are we looking at the right place? Fish & Shellfish Immunology 53, 4–12.

Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, et al., 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389–3402.

Andrews S., 2010 FastQC: A quality control tool for high throughput sequence data. Available online at (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/)

Araya, M., Markham, F., Mateo, D., McKenna, P., Johnson, G., Berthe, F., Siah, A., 2010. Identification and expression of immune-related genes in hemocytes of soft-shell clams, Mya arenaria, challenged with Vibrio splendidus. Fish Shellfish Immun 29, 557–564.

Baarlen, P. van, Troost, F., Hemert, S. van, Meer, C. van der, Vos, W. de, Groot, P. de, Hooiveld, G., Brummer, R.-J., Kleerebezem, M., 2009. Differential NF-κB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc National Acad Sci 106, 2371–2376.

Baarlen, P. van, Troost, F., Meer, C. van der, Hooiveld, G., Boekschoten, M., Brummer, R., Kleerebezem, M., 2011. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc National Acad Sci 108, 4562–4569.

Bermudez-Brito, M., Plaza-Díaz, J., Muñoz-Quezada, S., Gómez-Llorente, C., Gil, A., 2012. Probiotic Mechanisms of Action. Ann Nutr Metab 61, 160–174.

Böhmer, F.D., Friedrich, K., 2014. Protein tyrosine phosphatases as wardens of STAT signaling. Jak-stat 3, e28087.
Espinosa, E., Koller, A., Allam, B., 2016. Proteomic characterization of mucosal secretions in the eastern oyster, Crassostrea virginica. Journal of Proteomics 132, 63–76.

Conesa, A., Götz, S., García-Gómez, J.M., Terol, J., Talón, M., Robles, M., 2005. Blast2GO: a universal tool for annotation, visualization and analysis in functional genomics research. Bioinformatics 21: 3674–3676.

Daley, T., and Smith, A.D., 2013. Predicting the molecular complexity of sequencing libraries. Nature Methods 10, 325–327.

DiSalvo, L.H., Bleoka, J. & Zebal, R. 1978. Vibrio anguillarum and larval mortality in a California coastal shellfish hatchery. Appl. Environ. Microbiol., 35: 219 - 221

Duperthuy, M., Schmitt, Paulina., Garzón, E., Caro, A., Rosa, R D., Le Roux, F., Lautrédou-Audouy, N., Got, P., Romestand, B., de Lorgeril, J., Kieffer-Jaquinod, S., Bachère, E., Destoumieux-Garzón, D., 2011. Use of OmpU porins for attachment and invasion of Crassostrea gigas immune cells by the oyster pathogen Vibrio splendidus. PNAS 108, 7, 2993 – 2998.

Dohrman, A., Miyata, S., Gallup, M., Li, J.D., Chapelin, C., Coste, A., Escudier, E., Nadel, J., Basbaum, C., 1998. Mucin gene (MUC 2 and MUC 5AC) upregulation by Gram-positive and Gram-negative bacteria. Biochim. Biophys. Acta 1406, 251–9.

Genard, B., Moraga, D., Pernet, F., David, É., Boudry, P., Tremblay, R., 2012. Expression of candidate genes related to metabolism, immunity and cellular stress during massive mortality in the American oyster Crassostrea virginica larvae in relation to biochemical and physiological parameters. Gene 499, 70–75.

Genard, B., Miner, P., Nicolas, J.-L., Moraga, D., Boudry, P., Pernet, F., Tremblay, R., 2013. Integrative Study of Physiological Changes Associated with Bacterial Infection in Pacific Oyster Larvae. PLoS ONE 8, e64534.

Gerdol M. et al., 2018 Immunity in Molluscs: Recognition and Effector Mechanisms, with a Focus on Bivalvia. In: Cooper E. (eds) Advances in Comparative Immunology. Springer, Cham

Gómez-León, J., Villamil, L., Salger, S., Sallum, R., Remacha-Triviño, A., Leavitt, D., Gómez-Chiarri, M., 2008. Survival of eastern oysters Crassostrea virginica from three lines following experimental challenge with bacterial pathogens. Diseases of aquatic organisms 79, 95–105.

Hamblin, M., Spinard, E., Gomez-Chiarri, M., Nelson, D., Rowley, D., 2015. Draft Genome Sequence of the Shellfish Larval Probiotic Bacillus pumilus RI06-95. Genome Announcements 3, e00858–15.
Hasegawa, Lind, Boin, Hase, 2008. The Extracellular Metalloprotease of Vibrio tubiashii Is a Major Virulence Factor for Pacific Oyster (Crassostrea gigas) Larvae. Applied and Environmental Microbiology 74, 4101–4110.

Hauser, Hoffmann, 1992. P-domains as shuffled cysteine-rich modules in integumentary mucin C.1 (FIM-C.1) from Xenopus laevis. Polydispersity and genetic polymorphism. The Journal of biological chemistry 24620–4.

Häcker, H., Redecke, V., Blagoev, B., Kratchmarova, I., Hsu, L.-C., Wang, G.G., Kamps, M.P., Raz, E., Wagner, H., Häcker, G., 2006. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439, 204.

He, C., Klionsky, D., 2009. Regulation Mechanisms and Signaling Pathways of Autophagy. Annu Rev Genet 43, 67–93.

He, X., Zhang, Y., Yu, Z., 2011. An Mpeg (macrophage expressed gene) from the Pacific oyster Crassostrea gigas: molecular characterization and gene expression. Fish Shellfish Immunol. 30, 870–876.

Hoebe, K., Beutler, B., 2006. TRAF3: a new component of the TLR-signaling apparatus. Trends Mol Med 12, 187–189.

Huett, A., Heath, R., Begun, J., Sassi, S., Baxt, L., Vyas, J., Goldberg, M., Xavier, R., 2012. The LRR and RING Domain Protein LRSAM1 Is an E3 Ligase Crucial for Ubiquitin-Dependent Autophagy of Intracellular Salmonella Typhimurium. Cell Host Microbe 12, 778–790.

Karim, M., Zhao, W., Rowley, D., Nelson, D., Gomez-Chiarri, M., 2013. Probiotic Strains for Shellfish Aquaculture: Protection of Eastern Oyster, Crassostrea virginica, Larvae and Juveniles Against Bacterial Challenge. Journal of Shellfish Research 33, 401–408.

Kawasaki, H., Koyama, T., Conlon, J., Yamakura, F., Iwamuro, S., 2008. Antimicrobial action of histone H2B in Escherichia coli: Evidence for membrane translocation and DNA-binding of a histone H2B fragment after proteolytic cleavage by outer membrane proteinase T. Biochimie 90, 1693–1702.

Kim, D., Langmead, B., Salzberg, S., 2015. HISAT: a fast spliced aligner with low memory requirements. Nature Methods 12, nmeth.3317.

Laycock, Hirama, Hasnain, Watson, Storer, 1989. Purification and characterization of a digestive cysteine proteinase from the American lobster (Homarus americanus). Biochem J 263, 439–444.
Lee, A., Whyte, M., Haslett, C., 1993. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukocyte Biol 54, 283–288.

Li, H., Zhang, B., Huang, G., Liu, B., Fan, S., Zhang, D., Yu, D., Li, H., Zhang, B., Huang, G., Liu, B., Fan, S., Zhang, D., Yu, D., 2016. Differential Gene Expression during Larval Metamorphic Development in the Pearl Oyster, Pinctada fucata, Based on Transcriptome Analysis. International Journal of Genomics.

Li, H., Wang, S., Lü, K., Yin, B., Xiao, B., Li, S., He, J., Li, C., 2017. An invertebrate STING from shrimp activates an innate immune defense against bacterial infection. Febs Lett 591, 1010–1017.

Linden, S.K., Sutton, P., Karlsson, N.G., Korolik, V., McGuckin, M.A., 2008. Mucins in the mucosal barrier to infection. Mucosal Immunol 1, 183–97.

Llewellyn, A., Foey, A., 2017. Probiotic Modulation of Innate Cell Pathogen Sensing and Signaling Events. Nutrients 9, 1156.

Lorgeril, J. de, Zenagui, R., Rosa, R., Piquemal, D., Bachère, E., 2011. Whole Transcriptome Profiling of Successful Immune Response to Vibrio Infections in the Oyster Crassostrea gigas by Digital Gene Expression Analysis. PLoS ONE 6, e23142.

Love, M., Huber, W., Anders, S., 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology 15, 550.

Mazon-Moya, M., Willis, A., Torraca, V., Boucontet, L., Shenoy, A., Colucci-Guyon, E., Mostowy, S., 2017. Septins restrict inflammation and protect zebrafish larvae from Shigella infection. PLOS Pathogens 13, e1006467.

Mende, Petoukhova, Koulitchkova, Schaub, Lange, Kaufmann, Nowak, 1999. Dipetalogastin, a potent thrombin inhibitor from the blood-sucking insect. Dipetalogaster maximus cDNA cloning, expression and characterization. European J Biochem Febs 266, 583–90.

McCormack, R., Podack, E., 2015. Perforin-2/Mpeg1 and other pore-forming proteins throughout evolution. Journal of Leukocyte Biology 98, 761–768.

McDowell, I.C., Nikapitiya, C., Aguiar, D., Lane, C.E., Istrail, S., Gomez-Chiarri, M., 2014. Transcriptome of American oysters, Crassostrea virginica, in response to bacterial challenge: insights into potential mechanisms of disease resistance. PLoS ONE 9, e105097.

Mostowy, S. & Cossart, P. (2011). Septins as key regulators of actin based processes in bacterial infection. Biological Chemistry, 392(8-9), pp. 831-835.
Mostowy, S., Shenoy, A.R., 2015. The cytoskeleton in cell-autonomous immunity: structural determinants of host defence. Nat. Rev. Immunol. 15, 559–73.

Nadal, E., Real, F., Posas, F., Nadal, E., Real, F., Posas, F., 2007. Mucins, osmosensors in eukaryotic cells? Trends in Cell Biology.

Newell RI, 2004 Ecosystem influences of natural and cultivated populations of suspension-feeding bivalve molluscs: a review. Journal of Shellfish Research, 23:51–62.

Nikapitiya, C., Dorrington, T., Gomez-Chiarri, M., 2013. The role of histones in the immune responses of aquatic invertebrates. Invertebrate Survival Journal 10, 94–101.

Nikapitiya, C., McDowell, I.C., Villamil, L., Muñoz, P., Sohn, S., Gomez-Chiarri, M., 2014. Identification of potential general markers of disease resistance in American oysters, Crassostrea virginica through gene expression studies. Fish Shellfish Immunol. 41, 27–36.

Nitta T, Takahama Y 2007 The lymphocyte guard-IANs: regulation of lymphocyte survival by IAN/GIMAP family proteins. Trends Immunol 28:58–65.

Pagliuso, A., Tham, T., Stevens, J., Lagache, T., Persson, R., Salles, A., Olivo- Marin, J., Oddos, S., Spang, A., Cossart, P., Stavru, F., 2016. A role for septin 2 in Drp1-mediated mitochondrial fission. EMBO reports 858–873.

Pérez- Sánchez, T., Ruiz- Zarzuela, I., Blas, I., Balcázar, J., 2014. Probiotics in aquaculture: a current assessment. Reviews in Aquaculture 6, 133–146.

Pertea, M., Kim, D., Pertea, G., Leek, J., Salzberg, S., 2016. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nature Protocols 11, 1650–1667.

Peyre, J., Xue, Q.-G., Itoh, N., Li, Y., Cooper, R., 2010. Serine protease inhibitor cvSI-1 potential role in the eastern oyster host defense against the protozoan parasite Perkinsus marinus. Developmental & Comparative Immunology 34, 84–92.

Poirier, A., Schmitt, P., Rosa, R., Vanhove, A., Kieffer-Jaquinod, S., Rubio, T., Charrière, G., Destoumieux-Garzón, D., 2014. Antimicrobial Histones and DNA Traps in Invertebrate Immunity EVIDENCES IN CRASSOSTREA GIGAS. J Biol Chem 289, 24821–24831.

Qin, J., Huang, Z., Chen, J., Zou, Q., You, W., Ke, C., 2012. Sequencing and de novo Analysis of Crassostrea angulata (Fujian Oyster) from 8 Different Developing Phases Using 454 GSFlx. PloS one 7, e43653.
Ranasinghe, S., McManus, D., 2013. Structure and function of invertebrate Kunitz serine protease inhibitors. Dev Comp Immunol 39, 219–227.

Richards, G., Kingham, B., Shevchenko, O., Watson, M., Needleman, D., 2018. Complete Genome Sequence of Vibrio coralliilyticus RE22, a Marine Bacterium Pathogenic toward Larval Shellfish. Microbiol Resour Announc 7, e01332–18.

Saitoh, T., Fujita, N., Hayashi, T., Takahara, K., Satoh, T., Lee, H., Matsunaga, K., Kageyama, S., Omori, H., Noda, T., Yamamoto, N., Kawai, T., Ishii, K., Takeuchi, O., Yoshimori, T., Akira, S., 2009. Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. Proc National Acad Sci 106, 20842–20846.

Silva, A.J., Pham, K., Benitez, J.A., 2003. Haemagglutinin/protease expression and mucin gel penetration in El Tor biotype Vibrio cholerae. Microbiology 149, 1883–1891.

Sirianni, A., Krokowski, S., Lobato- Márquez, D., Buranyi, S., Pfanzelter, J., Galea, D., Willis, A., Culley, S., Henriques, R., Larrouy- Maumus, G., Hollinshead, M., Sancho- Shimizu, V., Way, M., Mostowy, S., Sirianni, A., Krokowski, S., Lobato-Márquez, D., Buranyi, S., Pfanzelter, J., Galea, D., Willis, A., Culley, S., Henriques, R., Larrouy- Maumus, G., Hollinshead, M., Sancho- Shimizu, V., Way, M., Mostowy, S., 2016. Mitochondria mediate septin cage assembly to promote autophagy of Shigella. EMBO reports.

Sohn, S., Lundgren, K., Tammi, K., Karim, M., Smolowitz, R., Nelson, D., Rowley, D., Gómez-Chiarri, M., 2016. Probiotic Strains for Disease Management in Hatchery Larviculture of the Eastern Oyster Crassostrea virginica. Journal of Shellfish Research 35, 307–317.

Spiliotis, E., Dolat, L., Spiliotis, E., Dolat, L., 2016. Priming for destruction: septins at the crossroads of mitochondrial fission and bacterial autophagy. EMBO reports.

Supek, F., Bošnjak, M., Škunca, N., Šmuc, T., Supek, F., Bošnjak, M., Škunca, N., Šmuc, T., 2011. REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms. PLoS ONE.

Tao, J., Zhou, X., Jiang, Z., 2016. cGAS- cGAMP- STING: The three musketeers of cytosolic DNA sensing and signaling. IUBMB Life 68, 858–870.

The UniProt Consortium., 2017 UniProt: the universal protein knowledgebase. Nucleic Acids Res. 45: D158-D169

Thomas, C., Versalovic, J., 2010. Probiotics-host communication: Modulation of signaling pathways in the intestine. Gut Microbes 1, 148–63.
Torraca, V., Mostowy, S., 2016. Septins and Bacterial Infection. Frontiers in Cell and Developmental Biology 4, 127.

Tuomola, E., Ouwehand, A., Salminen, S., 1999. The effect of probiotic bacteria on the adhesion of pathogens to human intestinal mucus. Fems Immunol Medical Microbiol 26, 137–142.

Verma, S., Dixit, R., Pandey, K., 2016. Cysteine Proteases: Modes of Activation and Future Prospects as Pharmacological Targets. Front Pharmacol 7, 107.

Vidal-Dupiol, J., Ladrière, O., Meistertzheim, A.-L., Fouré, L., Adjeroud, M., Mitta, G., 2011b. Physiological responses of the scleractinian coral Pocillopora damicornis to bacterial stress from Vibrio coralliilyticus. J Exp Biol 214, 1533–1545.

Vicente-Manzanares, M., and Sánchez-Madrid, F. 2004. Role of the cytoskeleton during leukocyte responses. Nature Reviews Immunology 4, 110–122.

Wang, L., Song, X., Song, L., 2018. The oyster immunity. Developmental & Comparative Immunology 80, 99–118.

Wilson, B., Muirhead, A., Bazanella, M., Huete-Stauffer, C., Vezzulli, L., Bourne, D., 2013. An Improved Detection and Quantification Method for the Coral Pathogen Vibrio coralliilyticus. Plos One 8, e81800.

Wei, X., Yang, J., Yang, J., Liu, X., Liu, M., Yang, D., Xu, J., Hu, X., 2012. A four-domain Kunitz-type proteinase inhibitor from Solen grandis is implicated in immune response. Fish Shellfish Immun 33, 1276–1284.

Wiens, M., Korzhev, M., Krasko, A., Thakur, N.L., Perović-Ottstadt, S., Breter, H.J., Ushijima, H., Diehl-Seifert, B., Müller, I.M., Müller, W.E., 2005. Innate immune defense of the sponge Suberites domuncula against bacteria involves a MyD88-dependent signaling pathway. Induction of a perforin-like molecule. J. Biol. Chem. 280, 27949–59.

Xiao, T., DeCamp, D.L., Sprang, S.R., 2000. Structure of a rat α₁ -macroglobulin receptor-binding domain dimer. Protein Sci. 9, 1889–97.

Yan, L., Su, J., Wang, Z., Yan, X., Yu, R., Ma, P., Li, Y., Du, J., 2017. Transcriptomic analysis of Crassostrea sikamea × Crassostrea angulata hybrids in response to low salinity stress. Plos One 12, e0171483.

Yu, H., He, Y., Wang, X., Zhang, Q., Bao, Z., Guo, X., 2011. Polymorphism in a serine protease inhibitor gene and its association with disease resistance in the eastern oyster (Crassostrea virginica Gmelin). Fish & Shellfish Immunology 30, 757–762.
Zhao, W., Dao, C., Karim, M., Gomez-Chiarri, M., Rowley, D., Nelson, D., 2016. Contributions of tropodithietic acid and biofilm formation to the probiotic activity of Phaeobacter inhibens. BMC Microbiol 16, 1.
CHAPTER 5

DISSERTATION SUMMARY: USE OF PROBIOTICS *Bacillus pumilus* RI06-95 AND *Phaeobacter inhibens* S4 IN LARVICULTURE OF *Crassostrea virginica* TO STIMULATE HOST IMMUNITY AND LIMIT IMPACT OF *Vibrio coralliilyticus* RE22
This dissertation research confirms the benefits of use of probiotics *B. pumilus* RI06-95 and *P. inhibens* S4 as a natural and environmentally safe solution in disease management of *C. virginica* larviculture (Karim et al., 2013, Zhao et al., 2016, Sohn et al., 2016).

Use of suitably formulated probiotics can aid vibriosis management in hatchery larviculture of *Crassostrea virginica* preventing sudden and massive larval mortalities. This research demonstrates the successful formulation of a candidate probiotic strain, *Bacillus pumilus* RI06-95, that facilitates stable long-term storage and easy delivery in a hatchery setting. Daily treatment of oyster larvae with the spray dried formulation in pilot-scale hatchery trials provided significant protection against laboratory challenge with *Vibrio coralliilyticus* RE22 (RPS 43 ± 4 %). The results demonstrated that a sprayed-dried formulation for probiotic RI06-95 is a commercially viable product that can be safely and effectively used to limit negative impacts of vibriosis in shellfish hatcheries. Understanding host-microbe interactions between *C. virginica* larvae and pathogen or between larvae and probiotics would immensely help in designing protocols of probiotic use commercially.

This research showed the swift progression of disease both in terms of rapidly increasing mortality post 14h of exposure as well as impact on host immune system. Immunological responses of *C. virginica* larvae to pathogen *V. coralliilyticus* RE22, as measured through transcriptome analysis, suggest the ability of vibrio exposure to suppress immune-related pathway activation and immune effector production. The research also highlights the need and suitability of preventative measures like probiotics rather than treatment options to protect larvae from effects of *V. coralliilyticus* RE22.
This dissertation research on the immunological responses of *C. virginica* larvae to both probiotics *B. pumilus* RI06-95 and *P. inhibens* S4 shows that the immunosuppression by RE22 may be counteracted by probiotics ‘priming’ of the larval immune response. This research demonstrates the ability of both probiotics to activate pathogen recognition receptors (PRRs) that could aid in pathogen detection, activation of immune signaling pathways and production of immune effectors that could potentially aid in inactivation of RE22 and its virulence factors.

A hypothesized model based on the findings of this dissertation research and previously published work is proposed here (Fig 1). When *C. virginica* larvae are pretreated with probiotics, RI and S4 for 6 to 24 h, most larvae are protected from RE22 challenge (Fig 1-1). A more prolonged 24 h pretreatment (versus 6 h) allows for more consistent elicitation of immune responses, and therefore more consistent levels of protection against RE22. Immune responses include activation of PRRs, immune signaling pathways and production of immune effectors like mucins, serine protease inhibitors and perform-2 (Fig 1-2). Oysters have a high basal rate of apoptosis that regulate hemocyte number (Sokolova 2009). Transcriptomic data suggests treatment with probiotics may inhibit hemocyte apoptosis, leading to increase in the number of hemocytes (Fig 1-3). This immunostimulation likely contributes to clearing probiotics from the system (Karim et al., 2013), but also may contribute to counteracting RE22 virulence. When probiotic pretreated (and hence immunostimulated larvae) are challenged with RE22, a series of changes brought about by the probiotics in the host may assist the larvae in blocking RE22 (Fig 1-4). Increased mucin production may enhance the epithelial barrier blocking penetration and prevent adhesion of pathogen.
Increased production of serine protease inhibitors may help to counter the effect of serine proteases potentially produced by RE22. This immunomodulation would complement other mechanisms of action of probiotics. Probiotic biofilm established during the pretreatment period may reduce colonization sites for RE22 competitively excluding them from colonizing the gut. Biofilm formation and competition assays between S4 and RE22 showed pretreatment with S4 excludes RE22 (Zhao et al., 2016). The draft genome of RI suggested its ability to form biofilms (Hamblin et al., 2015) but there is no experimental data to support it yet. Antibiotic tropodithietic acid (TDA) produced by S4 also aids in eliminating RE22 (Karim et al., 2013). S4 also secretes N-acyl homoserine lactones (AHLs) that quorum quench RE22 metalloprotease gene expression that are a crucial part of its virulence (Zhao et al., 2018). Increased production of perforin-2 due to probiotic pretreatment may also aid in neutralizing pathogens both intracellularly and extracellularly within oyster tissues. Increased number of hemocytes owing to apoptosis inhibition post probiotic treatment may increase phagocytic pressure on RE22 as well as buffer cytotoxic effects of hemolysins secreted by RE22 (Fig1-5) that diminish hemocyte survival (Gomez-Leon et al., 2008). All these effects probably work in concert to allow more probiotic pretreated C. virginica larvae to survive post RE22 challenge than those without probiotic pretreatment, by effectively reducing the infective dose of RE22 (Fig1-4) and providing larvae with mechanisms to further neutralize and kill RE22 within the oyster tissues (Fig1-5), leading to increased survival (Fig1-6). Due to effective clearing of probiotics within oysters due to the larval immune response, however, their protective effect
diminishes over time as also seen in experimental evidence (Karim et al., 2013) unless probiotics are applied repeatedly.

Immune effectors produced in response to probiotics, specifically highlighted in this study are highly suitable in blocking virulence factors and pathogenesis of RE22. However, application of probiotics and their overall immunostimulatory effect may likely help in protecting larvae from other bacterial and viral infections. Thus, this research advocates use of probiotic formulations in commercial shellfish aquaculture for their beneficial effects. In addition, it provides new insights in oyster immunity in response to non-pathogenic bacteria and the crosstalk between host and probiotics.
Figure 1: Hypothesized model showing in a series of steps (1-6) how effects of probiotic pretreatment on host immunity may complement other mechanisms of action of probiotics in providing protection from *V. coralliilyticus* RE22 challenge. QQ: quorum quenching, SPI: serine protease inhibitor, TDA: tropodithietic acid.
References

Gómez-León, J., Villamill, L., Salger, S., Sallum, R., Remacha-Triviño, A., Leavitt, D., Gómez-Chiarri, M., 2008. Survival of eastern oysters Crassostrea virginica from three lines following experimental challenge with bacterial pathogens. Dis Aquat Organ 79, 95–105.

Hamblin, M., Spinard, E., Gomez-Chiarri, M., Nelson, D., Rowley, D., 2015. Draft Genome Sequence of the Shellfish Larval Probiotic Bacillus pumilus RI06-95. Genome Announcements 3, e00858–15.

Karim, M., Zhao, W., Rowley, D., Nelson, D., Gomez-Chiarri, M., 2013. Probiotic Strains for Shellfish Aquaculture: Protection of Eastern Oyster, Crassostrea virginica, Larvae and Juveniles Against Bacterial Challenge. Journal of Shellfish Research 33, 401–408.

Sohn, S., Lundgren, K., Tammi, K., Karim, M., Smolowitz, R., Nelson, D., Rowley, D., Gómez-Chiarri, M., 2016. Probiotic Strains for Disease Management in Hatchery Larviculture of the Eastern Oyster Crassostrea virginica. Journal of Shellfish Research 35, 307–317.

Sokolova, 2009. Apoptosis in molluscan immune defense. ISJ 6, 49–58.

Zhao, W., Dao, C., Karim, M., Gomez-Chiarri, M., Rowley, D., Nelson, D., 2016. Contributions of tropodithietic acid and biofilm formation to the probiotic activity of Phaeobacter inhibens. Bmc Microbiol 16, 1.

Zhao, W., Yuan, T., Piva, C., Spinard, E.J., Schuttert, C., Rowley, D.C., Nelson, D.R., 2018. The probiotic bacterium, Phaeobacter inhibens, down-regulates virulence factor transcription in the shellfish pathogen, Vibrio coralliilyticus, by N-acyl homoserine lactone production. Appl. Environ. Microbiol.
### Table 1. Two-way ANOVA for the levels of *Vibrios* in water, tank surface, and oyster on each trial with RI formulations.

| ANOVA table | SS    | DF | MS   | F (DFn, DFd) | P value |
|-------------|-------|----|------|--------------|---------|
| **Trial I: oyster** |       |    |      |              |         |
| Interaction | 9.009 | 2  | 4.505| F (2, 10) = 2.278 | P = 0.1530 |
| Time        | 1.689 | 2  | 0.8446| F (2, 10) = 0.4271 | P = 0.6638 |
| Treatment   | 0.03975 | 1 | 0.03975 | F (1, 5) = 0.07956 | P = 0.7892 |
| Subjects (matching) | 2.498 | 5  | 0.4996| F (5, 10) = 0.2526 | P = 0.9289 |
| Residual    | 19.78 | 10 | 1.978 |       |         |
| **Trial I: water** |       |    |      |              |         |
| Interaction | 2.834 | 2  | 1.417| F (2, 10) = 2.879 | P = 0.1029 |
| Time        | 4.138 | 2  | 2.069| F (2, 10) = 4.204 | P = 0.0473 |
| Treatment   | 0.05357 | 1 | 0.05357 | F (1, 5) = 0.03503 | P = 0.8589 |
| Subjects (matching) | 7.647 | 5  | 1.529| F (5, 10) = 3.107 | P = 0.0599 |
| Residual    | 4.922 | 10 | 0.4922|       |         |
| **Trial II: oyster** |       |    |      |              |         |
| Interaction | 4.051 | 6  | 0.6752| F (6, 16) = 1.467 | P = 0.2512 |
| Time        | 46.39 | 2  | 23.19| F (2, 16) = 50.39 | P < 0.0001 |
| Treatment   | 8.178 | 3  | 2.726| F (3, 8) = 4.766 | P = 0.0344 |
| Subjects (matching) | 4.576 | 8  | 0.572| F (8, 16) = 1.243 | P = 0.3372 |
| Residual    | 7.364 | 16 | 0.4603|       |         |
| **Trial II: tank surface** |       |    |      |              |         |
| Interaction | 5.513 | 6  | 0.9188| F (6, 16) = 0.4252 | P = 0.8515 |
| Time        | 58.79 | 2  | 29.39| F (2, 16) = 13.60 | P = 0.0004 |
| Treatment   | 20.56 | 3  | 6.854| F (3, 8) = 4.529 | P = 0.0389 |
| Subjects (matching) | 12.11 | 8  | 1.513| F (8, 16) = 0.7004 | P = 0.6872 |
| Residual    | 34.57 | 16 | 2.161 |       |         |
Table 2: Differentially expressed genes with log fold change for probiotic or pathogen treatments when compared to control (Con 0 h) in laboratory transcriptomes (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h; RE22_6h: Larvae exposed to RE22 for 6h.

| Log2FoldChange | Hit_def                                              | Treatment |
|---------------|------------------------------------------------------|-----------|
| **Recognition** |                                                      |           |
| **TLRs**      |                                                      |           |
| 23.05478838   | toll-like receptor 13 [Crassostrea virginica]        | S4_6h     |
| -22.74173118  | toll-like receptor 13 [Crassostrea virginica]        | S4_24h    |
| 20.83600237   | toll-like receptor 13 [Crassostrea virginica]        | S4_24h    |
| 21.32340853   | toll-like receptor 13 [Crassostrea virginica]        | RI_24h    |
| 22.15592205   | toll-like receptor 13 [Crassostrea virginica]        | RE22_6h   |
| 21.51071325   | toll-like receptor 13 isoform X1 [Crassostrea virginica] | S4_24h    |
| Value     | Description                                                                 | Time  |
|-----------|------------------------------------------------------------------------------|-------|
| 22.42155892 | toll-like receptor 13 isoform X1 [Crassostrea virginica]                      | S4_24h|
| 17.30506755 | toll-like receptor 13 isoform X1 [Crassostrea virginica]                      | RI_24h|
| 21.06459929 | toll-like receptor 3 isoform X1 [Crassostrea virginica]                      | S4_24h|
| 22.49716465 | toll-like receptor 3 isoform X1 [Crassostrea virginica]                      | RI_24h|
| -22.48957053 | toll-like receptor 4 [Crassostrea virginica]                                 | S4_6h |
| -23.60095447 | toll-like receptor 4 [Crassostrea virginica]                                 | RI_24h|
| 21.86007267  | toll-like receptor 4 [Crassostrea virginica]                                 | S4_6h |
| 20.06293431  | toll-like receptor 4 [Crassostrea virginica]                                 | S4_24h|
| 18.52915288  | toll-like receptor 4 [Crassostrea virginica]                                 | RI_6h |
| 20.85337828  | toll-like receptor 4 [Crassostrea virginica]                                 | RE22_6h|
| -27.08359576 | toll-like receptor 4 isoform X1 [Crassostrea virginica]                      | S4_6h |
| -23.23844181 | toll-like receptor 4 isoform X1 [Crassostrea virginica]                      | S4_24h|
| -22.60452533 | toll-like receptor 4 isoform X1 [Crassostrea virginica]                      | S4_24h|
| -21.22164677 | toll-like receptor 4 isoform X1 [Crassostrea virginica]                      | S4_24h|
| Value           | Description                                                                 | Time  |
|-----------------|-----------------------------------------------------------------------------|-------|
| -3.670100715    | toll-like receptor 4 isoform X1 [Crassostrea virginica]                      | S4_24h|
| -21.77985815    | toll-like receptor 4 isoform X1 [Crassostrea virginica]                      | RI_6h |
| -25.3837144     | toll-like receptor 4 isoform X1 [Crassostrea virginica]                      | RE22_6h|
| -20.33473167    | toll-like receptor 4 isoform X1 [Crassostrea virginica]                      | RE22_6h|
| -23.85245048    | toll-like receptor 6 isoform X1 [Crassostrea virginica]                      | S4_6h |
| -24.52152638    | toll-like receptor 6 isoform X1 [Crassostrea virginica]                      | RI_6h |
| 6.948335986     | toll-like receptor Tollo isoform X2 [Crassostrea virginica]                  | RI_24h|
| 6.751339206     | toll-like receptor Tollo isoform X2 [Crassostrea virginica]                  | RE22_6h|
| -18.59470318    | toll-interacting protein-like isoform X3 [Crassostrea virginica]             | RE22_6h|
| **Lectins**     |                                                                             |       |
| 20.59470698     | lectin BRA-3-like [Crassostrea virginica]                                   | S4_24h|
| -21.67159       | lectin BRA-3-like [Crassostrea virginica]                                   | RI_6h |
| 15.5998376      | lectin BRA-3-like [Crassostrea virginica]                                   | RI_24h|
| -21.98669883    | hepatic lectin-like [Crassostrea virginica]                                 | S4_6h |
| Log2 Fold Change | Description                                                                 | Time Point |
|-----------------|-----------------------------------------------------------------------------|------------|
| -28.16031439    | complement C1q tumor necrosis factor-related protein 4-like isoform X3 [Crassostrea virginica] | RI_6h      |
| -2.942969529    | complement C1q-like protein 2 [Crassostrea virginica]                        | S4_6h      |
| -2.720935883    | complement C1q-like protein 2 [Crassostrea virginica]                        | RE22_6h    |
| -4.990716982    | complement C1q-like protein 4 [Crassostrea virginica]                        | RE22_6h    |
| 5.323119114     | fucolectin-like [Crassostrea virginica]                                      | S4_6h      |
| 5.500587362     | fucolectin-like [Crassostrea virginica]                                      | RI_6h      |
| 6.563854383     | fucolectin-like [Crassostrea virginica]                                      | RE22_6h    |
| -21.98669883    | hepatic lectin-like [Crassostrea virginica]                                  | S4_6h      |

**Scavenger receptors**

| Log2 Fold Change | Description                                                                 | Time Point |
|-----------------|-----------------------------------------------------------------------------|------------|
| -24.64487832    | scavenger receptor class B member 1 isoform B [Alligator mississippiensis]   | RI_6h      |
| -25.10222908    | scavenger receptor class B member 1 isoform B [Alligator mississippiensis]   | RE22_6h    |
| -5.982694265    | scavenger receptor class F member 2-like [Crassostrea virginica]            | S4_6h      |

**PGRP**
| Log2 FC  | Description                                                                 | Time  |
|---------|-----------------------------------------------------------------------------|-------|
| -5.7983 | peptidoglycan-recognition protein SC2-like \[Crassostrea virginica\]         | S4_6h |
| LRRs    |                                                                             |       |
| -5.1474 | leucine-rich repeat and fibronectin type III domain-containing protein 1-like protein \[Crassostrea virginica\] | S4_24h|
| -6.2123 | leucine-rich repeat and fibronectin type III domain-containing protein 1-like protein \[Crassostrea virginica\] | RI_24h|
| -21.9244| leucine-rich repeat and fibronectin type-III domain-containing protein 5-like isoform X1 \[Crassostrea virginica\] | RI_24h|
| 9.8448  | leucine-rich repeat transmembrane neuronal protein 3-like isoform X1 \[Crassostrea virginica\] | RI_6h |
| 20.9719 | leucine-rich repeat transmembrane neuronal protein 3-like isoform X1 \[Crassostrea virginica\] | RI_6h |
| 20.9608 | leucine-rich repeat transmembrane neuronal protein 3-like isoform X1 \[Crassostrea virginica\] | RE22_6h|
|                | Description                                                                 | Time  |
|----------------|------------------------------------------------------------------------------|-------|
| -23.84553133   | leucine-rich repeat transmembrane protein FLRT1-like [Crassostrea virginica] | S4_6h |
| -23.84658918   | leucine-rich repeat transmembrane protein FLRT1-like [Crassostrea virginica] | S4_24h |
| -23.04060289   | leucine-rich repeat-containing protein 24-like [Crassostrea virginica]       | S4_24h |
| -15.08871621   | leucine-rich repeat-containing protein 24-like [Crassostrea virginica]       | S4_24h |
| -8.156979152   | leucine-rich repeat-containing protein 24-like [Crassostrea virginica]       | S4_24h |
| 20.08727174    | leucine-rich repeat-containing protein 28-like isoform X3 [Crassostrea virginica] | S4_24h |
| 6.821818096    | leucine-rich repeat-containing protein 34-like isoform X2 [Crassostrea virginica] | S4_6h |
| -23.06503275   | leucine-rich repeat-containing protein 45-like [Crassostrea virginica]       | S4_24h |
| -23.72912188   | leucine-rich repeat-containing protein 45-like [Crassostrea virginica]       | RI_24h |
| 22.71972652    | leucine-rich repeat-containing protein 4C-like isoform X1 [Crassostrea virginica] | S4_6h |
| 20.7202629     | leucine-rich repeat-containing protein 4C-like isoform X1 [Crassostrea virginica] | RI_6h |
| 22.88621537    | leucine-rich repeat-containing protein 4C-like isoform X1 [Crassostrea virginica] | RI_24h |
| -24.40103127   | leucine-rich repeat-containing protein 70-like [Crassostrea virginica]       | S4_24h |
| -25.58565569   | leucine-rich repeat-containing protein 71-like isoform X21 [Crassostrea virginica] | S4_24h |
|     |                                                   |                        |
|-----|---------------------------------------------------|------------------------|
| -11.00397714 | leucine-rich repeat-containing protein 74A-like isoform X2 [Crassostrea virginica] | S4_6h                  |
| -11.92749456 | leucine-rich repeat-containing protein 74A-like isoform X2 [Crassostrea virginica] | S4_6h                  |
| -22.72669381 | leucine-rich repeat-containing protein 74B-like [Crassostrea virginica] | S4_24h                 |
| -23.52071418 | leucine-rich repeat-containing protein 74B-like [Crassostrea virginica] | RI_24h                 |
| 5.554434603  | leucine-rich repeat-containing protein 74B-like isoform X6 [Crassostrea virginica] | S4_6h                  |
| 7.401747777  | leucine-rich repeat-containing protein 74B-like isoform X6 [Crassostrea virginica] | S4_24h                 |
| -23.01756736 | leucine-rich repeat-containing protein 9-like isoform X2 [Crassostrea virginica] | RI_6h                  |
| -5.5609716   | leucine-rich repeat-containing protein 9-like isoform X2 [Crassostrea virginica] | RI_6h                  |
| -5.297693704 | leucine-rich repeat-containing protein 9-like isoform X2 [Crassostrea virginica] | RE22_6h                |

**Fibronectin type III domain**

|     |                                                   |                        |
|-----|---------------------------------------------------|------------------------|
| -4.785308683 | fibronectin type III domain-containing protein 1-like [Crassostrea virginica] | S4_24h                  |
| -23.90865588 | fibronectin type III domain-containing protein 2-like isoform X3 [Crassostrea virginica] | RI_24h                 |
| -22.69764157 | fibronectin type III domain-containing protein 2-like isoform X3 [Crassostrea virginica] | RI_24h                 |
| -24.13260348 | fibronectin type III domain-containing protein 2-like isoform X3 [Crassostrea virginica] | RE22_6h                |
| **C1q proteins** |                                     |         |
|------------------|-------------------------------------|---------|
| -28.16031439     | complement C1q tumor necrosis factor-related protein 4-like isoform X3 [Crassostrea virginica] | RI_6h   |
| -2.942969529     | complement C1q-like protein 2 [Crassostrea virginica] | S4_6h   |
| -2.720935883     | complement C1q-like protein 2 [Crassostrea virginica] | RE22_6h |
| -4.990716982     | complement C1q-like protein 4 [Crassostrea virginica] | RE22_6h |
| -27.07147054     | alpha-1-macroglobulin-like [Crassostrea virginica] | S4_6h   |
| -27.09597681     | alpha-1-macroglobulin-like [Crassostrea virginica] | S4_24h  |
| -4.827641592     | alpha-1-macroglobulin-like [Crassostrea virginica] | S4_24h  |
| -16.82943987     | Macrophage mannose receptor 1 [Crassostrea gigas] | S4_24h  |
| -23.67745527     | macrophage mannose receptor 1-like isoform X1 [Crassostrea virginica] | RI_24h  |

**Metabolic Enzymes with New Role of Carbohydrate Binding**

|                     |                                     |         |
|---------------------|-------------------------------------|---------|
| -3.019898078        | Phosphoenolpyruvate carboxykinase   | S4_24h  |
| 20.50362782         | hexokinase-2-like isoform X2 [Crassostrea virginica] | S4_6h   |
| Log2 Fold Change | Description                                                                 | Time  |
|------------------|------------------------------------------------------------------------------|-------|
| -27.8856754      | hexokinase-2-like isoform X2 [Crassostrea virginica]                         | RI_6h |
| -24.29212676     | hexokinase-2-like isoform X2 [Crassostrea virginica]                         | RI_6h |
| 10.04796022      | hexokinase-2-like isoform X2 [Crassostrea virginica]                         | RI_6h |
| 20.45474609      | hexokinase-2-like isoform X2 [Crassostrea virginica]                         | RI_6h |
| -27.93663561     | hexokinase-2-like isoform X2 [Crassostrea virginica]                         | RI_24h|
| -28.20643409     | hexokinase-2-like isoform X2 [Crassostrea virginica]                         | RE22_6h|
| -24.71581303     | hexokinase-2-like isoform X2 [Crassostrea virginica]                         | RE22_6h|
| 11.04164794      | hexokinase-2-like isoform X2 [Crassostrea virginica]                         | RE22_6h|
| 21.25153221      | hexokinase-2-like isoform X2 [Crassostrea virginica]                         | RE22_6h|
| **Cholinergic immunomodulation** |                                                                              |       |
| 2.908686031      | glutamate receptor 2-like [Crassostrea virginica]                            | RI_6h |
| -23.53192783     | glutamate receptor ionotopic                                                 | S4_24h|
| -8.851813981     | glutamate receptor ionotopic                                                 | S4_24h|
| -26.48442583     | glutamate receptor ionotopic                                                 | RI_6h |
| Value         | Description                                                                 | Time  |
|--------------|------------------------------------------------------------------------------|-------|
| -22.26041911 | glutamate receptor ionotropic                                                 | RE22_6h |
| 20.55673148  | glutamate receptor-interacting protein 1-like isoform X4 [Crassostrea virginica] | RI_24h |
| 7.766510402  | muscarinic acetylcholine receptor M3-like [Crassostrea virginica]              | RE22_6h |
| -23.96329241 | neuronal acetylcholine receptor subunit alpha-2-like [Crassostrea virginica]  | RE22_6h |
| 10.39346971  | neuronal acetylcholine receptor subunit alpha-5-like isoform X1 [Crassostrea virginica] | RE22_6h |
| 21.77501036  | neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica]  | S4_24h |
| 21.26581499  | neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica]  | RI_24h |
| -23.03542166 | neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica]  | S4_24h |
| -4.5426089   | neuropeptide SIFamide receptor-like [Crassostrea virginica]                   | S4_6h |
| -23.60128855 | neuropeptide Y receptor type 2-like [Crassostrea virginica]                   | RE22_6h |

**Signaling pathways in Immune response**

| Value         | Description                                                                 | Time  |
|--------------|------------------------------------------------------------------------------|-------|
| -11.1762089  | TNF receptor-associated factor 3-like isoform X3 [Crassostrea virginica]     | S4_6h |
| -9.894522176 | TNF receptor-associated factor 4-like isoform X5 [Crassostrea virginica]     | RE22_6h |
| 24.64790366  | LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica] | S4_6h |
| Value            | Description                                                                 | Time  |
|------------------|-----------------------------------------------------------------------------|-------|
| -23.39582662     | LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica] | S4_24h|
| -4.478976796     | LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica] | S4_24h|
| -21.85010489     | LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica] | RI_6h |
| 25.29177394      | LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica] | RI_24h|
| 24.11940272      | LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica] | RE22_6h|
| -7.662488479     | signal transducer and activator of transcription 3-like isoform X6 [Crassostrea virginica] | RI_24h|
| -26.82508167     | LOW QUALITY PROTEIN: son of sevenless homolog 2-like [Crassostrea virginica] | RE22_6h|
| -20.08059767     | LOW QUALITY PROTEIN: son of sevenless homolog 2-like [Crassostrea virginica] | S4_24h|
| -20.7042899      | LOW QUALITY PROTEIN: son of sevenless homolog 2-like [Crassostrea virginica] | RI_24h|
| -21.98909234     | epidermal growth factor receptor-like [Crassostrea virginica]               | S4_24h|
| -21.85708608     | epidermal growth factor receptor-like isoform X2 [Crassostrea virginica]    | S4_6h |
| -22.21636099     | epidermal growth factor receptor-like isoform X2 [Crassostrea virginica]    | RI_24h|
| 3.582236878      | epidermal growth factor receptor-like isoform X2 [Crassostrea virginica]    | S4_6h |
| -26.61502073     | epidermal growth factor receptor-like isoform X4 [Crassostrea virginica]    | S4_24h|
| ID       | Description                                                                 | Time  |
|----------|-----------------------------------------------------------------------------|-------|
| 4.440719006 | epidermal growth factor receptor-like isoform X4 [Crassostrea virginica] | S4_24h |
| 4.780146091 | PREDICTED: tyrosine-protein phosphatase non-receptor type 11 isoform X3 [Crassostrea gigas] | S4_6h |
| -24.59389772 | tyrosine-protein phosphatase non-receptor type 13-like isoform X3 [Crassostrea virginica] | S4_6h |
| -21.79438105 | tyrosine-protein phosphatase non-receptor type 13-like isoform X3 [Crassostrea virginica] | S4_6h |
| -21.90808833 | tyrosine-protein phosphatase non-receptor type 13-like isoform X3 [Crassostrea virginica] | S4_24h |
| -23.41598784 | tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea virginica] | S4_6h |
| 20.99622685 | tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea virginica] | S4_6h |
| Value          | Description                                                                 | Time  |
|---------------|------------------------------------------------------------------------------|-------|
| 20.32249114   | tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea virginica] | S4_24h |
| 21.72359644   | tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea virginica] | RI_6h  |
| 22.3115501    | tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea virginica] | RI_24h |
| 20.18049393   | tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea virginica] | RE22_6h |
| 19.62125156   | tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea virginica] | S4_6h  |
| 21.66755905   | tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea virginica] | S4_24h |
| 23.55240592   | tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea virginica] | RI_6h  |
| Value           | Description                                                                 | Time  |
|----------------|------------------------------------------------------------------------------|-------|
| 22.38124103    | tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea virginica] | RI_24h |
| 23.05607193    | tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea virginica] | RE22_6h |
| -10.65160003   | tyrosine-protein phosphatase non-receptor type 4-like isoform X6 [Crassostrea virginica] | S4_6h |
| -10.6365949    | tyrosine-protein phosphatase non-receptor type 4-like isoform X6 [Crassostrea virginica] | S4_24h |
| -8.931960108   | tyrosine-protein phosphatase non-receptor type 4-like isoform X6 [Crassostrea virginica] | RE22_6h |
| -24.13233234   | tyrosine-protein phosphatase non-receptor type 9-like isoform X2 [Crassostrea virginica] | RI_24h |
| -23.73611409   | NF-kappa-B inhibitor alpha-like isoform X1 [Crassostrea virginica]            | S4_6h |
| -9.500032383   | NF-kappa-B inhibitor alpha-like isoform X1 [Crassostrea virginica]            | RI_6h |
| Value         | Protein Description                                                                 | Time  |
|--------------|-------------------------------------------------------------------------------------|-------|
| -9.657932705 | NF-kappa-B inhibitor alpha-like isoform X1 [Crassostrea virginica]                   | RE22_6h |
| -24.81953437 | NF-kappa-B-activating protein-like [Crassostrea virginica]                          | S4_6h |
| -24.69597209 | NF-kappa-B-activating protein-like [Crassostrea virginica]                          | S4_24h |
| -24.42843374 | NF-kappa-B-activating protein-like [Crassostrea virginica]                          | S4_24h |
| -23.65126954 | NF-kappa-B-activating protein-like [Crassostrea virginica]                          | S4_24h |
| -24.77085054 | NF-kappa-B-activating protein-like [Crassostrea virginica]                          | RI_6h |
| -25.40980564 | NF-kappa-B-activating protein-like [Crassostrea virginica]                          | RI_24h |
| -24.86565855 | NF-kappa-B-activating protein-like [Crassostrea virginica]                          | RI_24h |
| -25.18633897 | NF-kappa-B-activating protein-like [Crassostrea virginica]                          | RE22_6h |
| -21.62114724 | smad nuclear interacting protein 1-like [Crassostrea virginica]                     | S4_6h |
| -22.01002997 | smad nuclear interacting protein 1-like [Crassostrea virginica]                     | RI_6h |
| 22.23806571  | TNFAIP3-interacting protein 1-like [Crassostrea virginica]                          | RI_6h |
| 23.32946941  | TNFAIP3-interacting protein 1-like [Crassostrea virginica]                          | RE22_6h |
| 3.669180885  | PREDICTED: B-cell lymphoma/leukemia 10-like [Crassostrea gigas]                     | S4_6h |
| Gene Name                                                                 | Description                                                                 | Timepoint |
|--------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------|
| 5.125890801                                                             | PREDICTED: B-cell lymphoma/leukemia 10-like [Crassostrea gigas]              | S4_24h    |
| -24.48845992                                                             | ELKS/Rab6-interacting/CAST family member 1-like isoform X3 [Crassostrea virginica] | RI_6h     |
| -24.52498266                                                             | ELKS/Rab6-interacting/CAST family member 1-like isoform X3 [Crassostrea virginica] | RI_24h    |
| 22.90392037                                                              | ELKS/Rab6-interacting/CAST family member 1-like isoform X5 [Crassostrea virginica] | S4_24h    |
| 21.99071309                                                              | ELKS/Rab6-interacting/CAST family member 1-like isoform X5 [Crassostrea virginica] | RI_24h    |
| 21.29621653                                                              | adapter protein CIKS-like [Crassostrea virginica]                            | S4_6h     |
| 21.89981234                                                              | adapter protein CIKS-like [Crassostrea virginica]                            | S4_24h    |
| 19.10179883                                                              | adapter protein CIKS-like [Crassostrea virginica]                            | RI_6h     |
| 21.9145228                                                               | adapter protein CIKS-like [Crassostrea virginica]                            | RI_24h    |
| 21.96174137                                                              | adapter protein CIKS-like [Crassostrea virginica]                            | RE22_6h   |
| -21.68449844                                                             | adapter protein CIKS-like isoform X4 [Crassostrea virginica]                 | RI_24h    |
| -5.87337841                                                              | PREDICTED: dual specificity mitogen-activated protein kinase kinase 1-like isoform X1 [Crassostrea gigas] | RI_24h    |
| -25.72060852                                                             | MAP kinase-activated protein kinase 2-like isoform X2 [Crassostrea virginica] | RI_24h    |
| Value                | Description                                                                 | Time   |
|----------------------|-----------------------------------------------------------------------------|--------|
| -2.470755161         | mitogen-activated protein kinase kinase kinase 13-like isoform X2 [Crassostrea virginica] | S4_24h |
| -24.25502986         | mitogen-activated protein kinase kinase kinase 13-like isoform X2 [Crassostrea virginica] | RI_24h |
| -7.716909755         | Mitogen-activated protein kinase kinase kinase 7 [Crassostrea gigas]         | RI_6h  |
| -21.70047837         | mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] | S4_6h  |
| -2.753446313         | mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] | S4_6h  |
| 22.14143778          | mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] | S4_6h  |
| -21.62740093         | mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] | S4_24h |
| 21.84933712          | mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] | RI_6h  |
| -3.340398882         | mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] | RI_24h |
| -22.1261532          | mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] | RE22_6h |
| 20.30696981          | dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea virginica] | S4_6h  |
| Value       | Description                                                                  | Time  |
|------------|------------------------------------------------------------------------------|-------|
| 21.95392224 | dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea virginica] | S4_24h |
| 21.12567936 | dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea virginica] | RI_6h |
| -18.51291804 | dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea virginica] | RI_24h |
| 22.55409809 | dual specificity mitogen-activated protein kinase kinase kinase 7-like isoform X1 [Crassostrea virginica] | RE22_6h |
| -10.42721287 | LOW QUALITY PROTEIN: mitogen-activated protein kinase 14A-like [Crassostrea virginica] | RI_6h |
| -22.51874945 | LOW QUALITY PROTEIN: mitogen-activated protein kinase kinase kinase kinase 3-like [Crassostrea virginica] | S4_24h |
| -23.17120745 | LOW QUALITY PROTEIN: mitogen-activated protein kinase kinase kinase kinase 3-like [Crassostrea virginica] | RI_24h |
| Value | Description                                                                 | Time   |
|-------|------------------------------------------------------------------------------|--------|
| 7.88002894 | transforming growth factor-beta, partial [Crassostrea ariakensis]             | RI_24h |
| 6.414756431 | transforming growth factor-beta, partial [Crassostrea ariakensis]             | S4_24h |
| -24.5406632 | LOW QUALITY PROTEIN: C-Jun-amino-terminal kinase-interacting protein 4-like  | S4_24h |
|          | [Crassostrea virginica]                                                        |        |
| -23.28637433 | LOW QUALITY PROTEIN: C-Jun-amino-terminal kinase-interacting protein 4-like  | S4_24h |
|          | [Crassostrea virginica]                                                        |        |
| 8.201025972 | extracellular signal-regulated kinase 2-like isoform X4 [Crassostrea virginica] | RI_24h |
| -22.50186319 | stimulator of interferon genes protein-like [Crassostrea virginica]          | S4_6h  |
| 20.17836595  | stimulator of interferon genes protein-like [Crassostrea virginica]          | S4_6h  |
| -16.95226096 | stimulator of interferon genes protein-like [Crassostrea virginica]          | S4_24h |
| -7.478972473 | stimulator of interferon genes protein-like [Crassostrea virginica]          | RI_6h  |
| 17.42282629  | stimulator of interferon genes protein-like [Crassostrea virginica]          | RI_6h  |
| 20.17813132  | stimulator of interferon genes protein-like [Crassostrea virginica]          | RI_24h |
| 20.42313211  | stimulator of interferon genes protein-like [Crassostrea virginica]          | RE22_6h|
| Z-score | Description                                                                 | Time  |
|---------|------------------------------------------------------------------------------|-------|
| -6.713339842 | death domain-containing protein 1-like [Crassostrea virginica]               | S4_6h |
| -6.937781661  | death domain-containing protein 1-like [Crassostrea virginica]               | S4_24h|
| -4.130539001  | death domain-containing protein 1-like [Crassostrea virginica]               | RI_6h |
| -6.57016357   | death domain-containing protein 1-like [Crassostrea virginica]               | RE22_6h|
| 21.29117555   | death domain-containing protein CRADD-like [Crassostrea virginica]           | S4_6h |
| 19.33282647   | death domain-containing protein CRADD-like [Crassostrea virginica]           | RI_6h |
| 21.07018009   | death domain-containing protein CRADD-like [Crassostrea virginica]           | RE22_6h|
| 19.40341779   | integrin alpha-4-like isoform X1 [Crassostrea virginica]                    | S4_24h|
| 20.6821385    | integrin alpha-4-like isoform X1 [Crassostrea virginica]                    | RI_24h|
| -2.282127264  | integrin beta-3-like [Crassostrea virginica]                                | S4_24h|
| 11.0047672    | ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis]     | S4_6h |
| 21.44939539   | ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis]     | S4_24h|
| 11.5782336    | ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis]     | RI_6h |
| 21.74942278   | ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis]     | RI_24h|
| ID          | Description                                                                 | Time  |
|------------|-----------------------------------------------------------------------------|-------|
| 11.12138173 | ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis]     | RE22_6h |
| -24.21434106 | ubiquitin carboxyl-terminal hydrolase 20-like isoform X2 [Crassostrea virginica] | S4_24h |
| 22.53788386 | ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica] | S4_6h |
| 19.53896908 | ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica] | S4_24h |
| 21.61706409 | ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica] | RI_6h |
| 21.55529349 | ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica] | RI_24h |
| 22.99322029 | ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica] | RE22_6h |
| -7.636639706 | serine protease 44-like [Crassostrea virginica]                        | S4_24h |
| 21.50670849 | serine protease inhibitor Cvsi-2-like [Crassostrea virginica]    | S4_6h |
| 12.83482328 | serine protease inhibitor Cvsi-2-like [Crassostrea virginica]    | S4_24h |
| 21.11968406 | serine protease inhibitor Cvsi-2-like [Crassostrea virginica]    | RI_6h |
| 20.26304644 | serine protease inhibitor Cvsi-2-like [Crassostrea virginica]    | RI_24h |
| 28.4447526  | serine protease inhibitor dipetalogastin-like [Crassostrea virginica] | S4_6h |

**Effectors**
| Expression   | Description                                                                 | Time  |
|--------------|------------------------------------------------------------------------------|-------|
| 22.3104239   | serine protease inhibitor dipetalogastin-like [Crassostrea virginica]        | RI_24h|
| 15.3518296   | serine protease inhibitor dipetalogastin-like [Crassostrea virginica]        | S4_24h|
| -22.79409461 | kunitz-type protease inhibitor 1-like [Crassostrea virginica]                | S4_6h |
| 20.0825116   | LOW QUALITY PROTEIN: digestive cysteine proteinase 2-like [Crassostrea virginica] | S4_6h |
| 20.26000192  | LOW QUALITY PROTEIN: digestive cysteine proteinase 2-like [Crassostrea virginica] | S4_24h|
| 21.99420619  | LOW QUALITY PROTEIN: digestive cysteine proteinase 2-like [Crassostrea virginica] | RI_6h |
| 19.1215388   | LOW QUALITY PROTEIN: digestive cysteine proteinase 2-like [Crassostrea virginica] | RI_24h|
| -23.58012026 | Signaling mucin HKR1 [Mizuhopecten yessoensis]                              | S4_6h |
| -23.80421719 | Signaling mucin HKR1 [Mizuhopecten yessoensis]                              | S4_24h|
| -9.356963695 | Signaling mucin HKR1 [Mizuhopecten yessoensis]                              | S4_24h|
| -24.38357841 | Signaling mucin HKR1 [Mizuhopecten yessoensis]                              | RI_6h |
| -21.90572271 | Signaling mucin HKR1 [Mizuhopecten yessoensis]                              | RI_6h |
| -16.19910691 | Signaling mucin HKR1 [Mizuhopecten yessoensis]                              | RI_24h|
| -24.51441136 | Signaling mucin HKR1 [Mizuhopecten yessoensis]                              | RE22_6h|
| Value          | Description                                                                 | Time                  |
|---------------|-----------------------------------------------------------------------------|-----------------------|
| -2.369460824  | integumentary mucin C.1-like [Crassostrea virginica]                         | S4_24h               |
| 3.541415795   | integumentary mucin C.1-like [Crassostrea virginica]                         | RI_24h               |
| 21.31111159   | integumentary mucin C.1-like isoform X1 [Crassostrea virginica]             | S4_24h               |
| -15.40397187  | integumentary mucin C.1-like isoform X1 [Crassostrea virginica]             | RI_24h               |
| -23.4017782   | integumentary mucin C.1-like isoform X3 [Crassostrea virginica]             | S4_24h               |
| -24.11558579  | integumentary mucin C.1-like isoform X3 [Crassostrea virginica]             | RI_6h                |
| 15.84736053   | LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica]                  | S4_6h                |
| 19.8605114    | LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica]                  | S4_24h               |
| 21.24020302   | LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica]                  | RI_6h                |
| 20.3172585    | LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica]                  | RI_24h               |
| 20.50006596   | LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica]                  | RE22_6h              |
| -25.58549501  | mucin-17-like isoform X2 [Crassostrea virginica]                            | S4_6h                |
| -22.60499384  | mucin-17-like isoform X2 [Crassostrea virginica]                            | S4_24h               |
| -23.3302576   | mucin-17-like isoform X2 [Crassostrea virginica]                            | RI_24h               |
| Value         | Description                                      | Time   |
|---------------|--------------------------------------------------|--------|
| -12.40357314  | mucin-2-like [Crassostrea virginica]              | RE22_6h|
| 3.74775207    | mucin-3B-like isoform X4 [Crassostrea virginica] | S4_6h  |
| 4.020665081   | mucin-3B-like isoform X4 [Crassostrea virginica] | S4_6h  |
| -22.20357216  | mucin-3B-like isoform X4 [Crassostrea virginica] | S4_24h |
| 3.986726111   | mucin-3B-like isoform X4 [Crassostrea virginica] | RI_6h  |
| 4.460044136   | mucin-3B-like isoform X4 [Crassostrea virginica] | RI_24h |
| -10.73484035  | mucin-3B-like isoform X4 [Crassostrea virginica] | S4_24h |
| -23.44462362  | mucin-4-like isoform X7 [Crassostrea virginica]  | S4_24h |
| -6.728200181  | mucin-4-like isoform X8 [Crassostrea virginica]  | RI_6h  |
| 19.8087086    | mucin-5AC-like [Crassostrea virginica]           | S4_24h |
| 24.20835013   | mucin-5AC-like [Crassostrea virginica]           | RI_24h |
| -23.63449535  | mucin-5AC-like isoform X2 [Crassostrea virginica] | S4_24h |
| -25.71724187  | mucin-5AC-like isoform X5 [Crassostrea virginica] | S4_24h |
| -25.5565658   | mucin-5AC-like isoform X5 [Crassostrea virginica] | S4_24h |
| Expression Level | Gene Description                                               | Timepoint |
|------------------|----------------------------------------------------------------|-----------|
| -25.02710707     | mucin-5AC-like isoform X5 [Crassostrea virginica]               | S4_24h   |
| -24.9869002      | mucin-5AC-like isoform X5 [Crassostrea virginica]               | S4_24h   |
| -24.55559512     | mucin-5AC-like isoform X5 [Crassostrea virginica]               | S4_24h   |
| 20.15216503      | macrophage-expressed gene 1 protein-like [Crassostrea virginica] | S4_6h    |
| -23.12210565     | macrophage-expressed gene 1 protein-like [Crassostrea virginica] | S4_24h   |
| 21.2588995       | macrophage-expressed gene 1 protein-like [Crassostrea virginica] | S4_24h   |
| 21.13829677      | macrophage-expressed gene 1 protein-like [Crassostrea virginica] | RI_6h    |
| 19.19639966      | macrophage-expressed gene 1 protein-like [Crassostrea virginica] | RI_24h   |
| -25.14528973     | antistasin-like [Crassostrea virginica]                        | RI_6h    |
| -25.22546326     | antistasin-like [Crassostrea virginica]                        | RI_24h   |
| -8.191296146     | cystatin-A-like [Crassostrea virginica]                        | RI_24h   |
| **Apoptosis**    |                                                                |           |
| -6.21042132      | caspase-1-like [Crassostrea virginica]                          | S4_24h   |
| 20.95052586      | caspase-1-like [Crassostrea virginica]                          | S4_6h    |
| Value         | Description                                      | Time  |
|--------------|--------------------------------------------------|-------|
| 20.96735265  | caspase-1-like [Crassostrea virginica]            | S4_24h|
| 21.36960577  | caspase-1-like [Crassostrea virginica]            | RI_6h |
| 21.94629746  | caspase-1-like [Crassostrea virginica]            | RI_24h|
| 20.13240973  | caspase-1-like [Crassostrea virginica]            | RE22_6h|
| 8.059692737  | caspase-3-like isoform X2 [Crassostrea virginica]| S4_6h |
| -22.07884074 | caspase-3-like isoform X2 [Crassostrea virginica]| S4_24h|
| 19.83057052  | caspase-3-like isoform X2 [Crassostrea virginica]| S4_24h|
| -8.724115052 | caspase-3-like isoform X2 [Crassostrea virginica]| RI_24h|
| 18.89735984  | caspase-3-like isoform X2 [Crassostrea virginica]| RI_24h|
| 5.865260258  | caspase-6-like [Crassostrea virginica]            | RI_6h |
| 6.332228555  | caspase-6-like [Crassostrea virginica]            | RE22_6h|
| -11.6773146  | caspase-6-like isoform X2 [Crassostrea virginica]| S4_24h|
| -8.871803044 | caspase-6-like isoform X2 [Crassostrea virginica]| S4_24h|
| 3.340083172  | caspase-6-like isoform X2 [Crassostrea virginica]| S4_24h|
|                   |                                                                 |         |
|-------------------|------------------------------------------------------------------|---------|
| -12.17173082      | caspase-6-like isoform X2 [Crassostrea virginica]                | RI_24h  |
| -8.40424419       | caspase-6-like isoform X2 [Crassostrea virginica]                | RI_24h  |
| 3.27853441        | caspase-6-like isoform X2 [Crassostrea virginica]                | RI_24h  |
| 18.19169296       | caspase-7-like [Crassostrea virginica]                           | S4_6h   |
| 19.24463486       | caspase-7-like [Crassostrea virginica]                           | RI_6h   |
| 19.8989936        | caspase-7-like [Crassostrea virginica]                           | RE22_6h |
| -7.554426297      | caspase-7-like isoform X1 [Crassostrea virginica]                | S4_6h   |
| -6.02479199       | caspase-7-like isoform X1 [Crassostrea virginica]                | S4_24h  |
| -6.826149987      | caspase-7-like isoform X1 [Crassostrea virginica]                | RI_24h  |
| -6.880726858      | caspase-7-like isoform X1 [Crassostrea virginica]                | RE22_6h |
| -21.01107236      | caspase-7-like isoform X3 [Crassostrea virginica]                | RI_24h  |
| -21.23808674      | caspase-7-like isoform X3 [Crassostrea virginica]                | RE22_6h |
| -25.94532375      | baculoviral IAP repeat-containing protein 2-like [Crassostrea virginica] | S4_24h  |
| -26.32635634      | baculoviral IAP repeat-containing protein 2-like [Crassostrea virginica] | RE22_6h |
| Log2 Fold Change | Description                                                                 | Sample Time |
|-----------------|-----------------------------------------------------------------------------|-------------|
| -24.35012269    | baculoviral IAP repeat-containing protein 3-like [Crassostrea virginica]    | S4_24h      |
| 19.47455056     | baculoviral IAP repeat-containing protein 3-like isoform X1 [Crassostrea virginica] | S4_6h      |
| 19.10971772     | baculoviral IAP repeat-containing protein 3-like isoform X1 [Crassostrea virginica] | RI_6h      |
| 21.20706554     | baculoviral IAP repeat-containing protein 3-like isoform X1 [Crassostrea virginica] | RE22_6h   |
| -11.87771995    | baculoviral IAP repeat-containing protein 6-like isoform X5 [Crassostrea virginica] | S4_6h      |
| -6.7526098      | baculoviral IAP repeat-containing protein 6-like isoform X5 [Crassostrea virginica] | S4_6h      |
| -23.00355415    | baculoviral IAP repeat-containing protein 7-A-like isoform X2 [Crassostrea virginica] | RI_24h    |
| -23.45580618    | baculoviral IAP repeat-containing protein 7-A-like isoform X2 [Crassostrea virginica] | RI_24h    |
| 18.88003432     | putative inhibitor of apoptosis [Crassostrea virginica]                       | RE22_6h    |
| 20.38877928     | putative inhibitor of apoptosis [Crassostrea virginica]                       | RI_6h      |
| 20.544862       | putative inhibitor of apoptosis [Crassostrea virginica]                       | S4_6h      |
| 20.82027693     | putative inhibitor of apoptosis [Crassostrea virginica]                       | RI_24h    |
| 21.23594337     | putative inhibitor of apoptosis [Crassostrea virginica]                       | S4_24h      |
| -21.79877969    | bifunctional apoptosis regulator-like isoform X1 [Crassostrea virginica]    | S4_6h      |
| Value          | Description                                                                 | Time   |
|---------------|------------------------------------------------------------------------------|--------|
| -21.84056799  | bifunctional apoptosis regulator-like isoform X1 [Crassostrea virginica]     | S4_24h |
| -4.862913449  | apoptogenic protein 1                                                          | RI_6h  |
| -22.71920742  | cathepsin L-like isoform X2 [Crassostrea virginica]                           | S4_24h |
| -25.24123094  | cathepsin L-like isoform X2 [Crassostrea virginica]                           | RI_6h  |
| -22.92152325  | cathepsin O-like [Crassostrea virginica]                                      | S4_6h  |
| -24.09391392  | programmed cell death 6-interacting protein-like isoform X3 [Crassostrea virginica] | S4_24h |
| -7.976483879  | programmed cell death protein 6-like isoform X2 [Crassostrea virginica]      | S4_6h  |
| 23.29208898   | XK-related protein 6-like [Crassostrea virginica]                             | RI_6h  |
| 24.85645254   | XK-related protein 6, partial [Stegodyphus mimosarum]                         | RE22_6h|
| 8.288290515   | XK-related protein 6, partial [Stegodyphus mimosarum]                         | RI_6h  |
| 20.4704348    | XK-related protein 6, partial [Stegodyphus mimosarum]                         | S4_6h  |
| 24.25694523   | XK-related protein 6, partial [Stegodyphus mimosarum]                         | RI_24h |
| 23.1394026    | XK-related protein 6, partial [Stegodyphus mimosarum]                         | S4_24h |
| 19.26657006   | XK-related protein 8-like isoform X2 [Crassostrea virginica]                 | RE22_6h|
| Value         | Description                                                                 | Time   |
|--------------|-----------------------------------------------------------------------------|--------|
| 20.93957528  | XK-related protein 8-like isoform X2 [Crassostrea virginica]                 | RI_6h  |
| 19.66346021  | XK-related protein 8-like isoform X2 [Crassostrea virginica]                 | S4_6h  |
| 4.704739877  | cell death-inducing p53-target protein 1-like isoform X5 [Crassostrea virginica] | S4_6h  |
| 7.038385691  | cell death-inducing p53-target protein 1-like isoform X5 [Crassostrea virginica] | S4_24h |
| **Autophagy** |                                                                             |        |
| 19.68063935  | autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]         | S4_6h  |
| 22.23975139  | autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]         | S4_6h  |
| 19.00211451  | autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]         | S4_24h |
| 20.33463466  | autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]         | S4_24h |
| 20.2328524   | autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]         | RI_6h  |
| 22.04434718  | autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]         | RI_6h  |
| 17.69258697  | autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]         | RI_24h |
| 19.97079557  | autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]         | RI_24h |
| 17.464467    | autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]         | RE22_6h|
| ID          | Description                                                                 | Time  |
|-------------|-----------------------------------------------------------------------------|-------|
| 20.1113826  | autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]         | RE22_6h |
| -22.38835903| transcription factor SPT20 homolog isoform X1 [Crassostrea virginica]        | S4_6h |
| -22.81940536| transcription factor SPT20 homolog isoform X1 [Crassostrea virginica]        | RI_6h |
| -23.79270551| vacuole membrane protein 1-like [Crassostrea virginica]                      | S4_6h |
| -24.49304386| vacuole membrane protein 1-like [Crassostrea virginica]                      | RI_6h |
| -22.8200889 | PREDICTED: protein kinase C delta type [Crassostrea gigas]                   | S4_24h|
| -23.97489076| PREDICTED: protein kinase C delta type [Crassostrea gigas]                   | RI_24h|
| 20.26349909 | DNA damage-regulated autophagy modulator protein 1-like [Crassostrea virginica] | S4_6h |
| 20.91174474 | DNA damage-regulated autophagy modulator protein 1-like [Crassostrea virginica] | S4_24h|
| 20.84051785 | DNA damage-regulated autophagy modulator protein 1-like [Crassostrea virginica] | RE22_6h|
| -6.547974505| run domain Beclin-1-interacting and cysteine-rich domain-containing protein-like isoform X3 [Crassostrea virginica] | S4_24h|
| 20.7845565  | phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like isoform X1 [Crassostrea virginica] | S4_6h |
| Gene ID          | Description                                                                 | Time Point |
|-----------------|------------------------------------------------------------------------------|------------|
| 21.39532399     | phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like isoform X1 [Crassostrea virginica] | S4_24h     |
| 22.58624048     | phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like isoform X1 [Crassostrea virginica] | RI_6h      |
| 21.22674556     | phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like isoform X1 [Crassostrea virginica] | RI_24h     |
| 22.60384771     | phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like isoform X1 [Crassostrea virginica] | RE22_6h    |

**Phagosome**

| Gene ID          | Description                                                                 | Time Point |
|-----------------|------------------------------------------------------------------------------|------------|
| -11.04839433    | Actin, cytoplasmic [Crassostrea gigas]                                       | S4_6h      |
| -22.15040686    | actin-3-like isoform X1 [Crassostrea virginica]                             | S4_6h      |
| -23.28807439    | actin-3-like isoform X1 [Crassostrea virginica]                             | RI_6h      |
| -2.009714808    | actin-like [Crassostrea virginica]                                          | S4_24h     |
| -25.67615427    | cytoplasmic dynein 1 heavy chain 1-like isoform X1 [Crassostrea virginica] | S4_6h      |
| Value        | Description                                                                 | Time  |
|-------------|------------------------------------------------------------------------------|-------|
| -24.78846969 | cytoplasmic dynein 1 heavy chain 1-like isoform X1 [Crassostrea virginica]  | S4_24h |
| -18.35355926 | cytoplasmic dynein 1 light intermediate chain 2-like isoform X11 [Crassostrea virginica] | S4_6h |
| -23.99337051 | cytoplasmic dynein 1 light intermediate chain 2-like isoform X11 [Crassostrea virginica] | S4_24h |
| 20.46400243  | cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica] | S4_6h |
| 19.94858466  | cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica] | S4_24h |
| 19.68213706  | cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica] | RI_6h |
| 20.2666716   | cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica] | RI_24h |
| 19.56136995  | cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica] | RI_24h |
| 22.65257645  | cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica]  | RI_6h |
| 22.2320337   | cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica]  | RI_24h |
| 22.04398056  | cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica]  | S4_6h |
| -6.510608147 | cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica]  | RI_6h |
| 22.65257645  | cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica]  | RI_6h |
| Gene ID | Description                                                                 | Time Point |
|---------|------------------------------------------------------------------------------|------------|
| 21.24015816 | cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica]   | RE22_6h    |
| -26.35735397 | lysosomal-associated transmembrane protein 4A-like [Crassostrea virginica]  | S4_6h      |
| -27.83132813 | lysosomal-associated transmembrane protein 4A-like [Crassostrea virginica]  | RI_24h     |
| -5.595601397  | lysosomal acid lipase/cholesteryl ester hydrolase-like [Crassostrea virginica] | RI_6h      |

**Lysosome**

- **Endocytosis & Peroxisome**
  - 7.204505845 | AP-2 complex subunit mu-1 [Crassostrea gigas] | RI_24h |
  - 8.234098827 | probable peroxisomal membrane protein PEX13 [Crassostrea virginica] | S4_6h |
  - 7.151949067 | probable peroxisomal membrane protein PEX13 [Crassostrea virginica] | S4_24h |
  - -24.32891036 | peroxisomal acyl-coenzyme A oxidase 1-like [Crassostrea virginica] | RI_24h |
  - -23.1387346 | peroxisomal acyl-coenzyme A oxidase 1-like [Crassostrea virginica] | S4_24h |
  - -23.64616222 | peroxisomal acyl-coenzyme A oxidase 1-like [Crassostrea virginica] | RI_24h |
  - -6.184641444 | peroxisomal acyl-coenzyme A oxidase 1-like isoform X2 [Crassostrea virginica] | S4_24h |

**Antioxidant enzymes**
| Gene Name                                                                 | Description                                                                 | Time Point |
|--------------------------------------------------------------------------|------------------------------------------------------------------------------|------------|
| -3.86662093 glutathione peroxidase 7-like [Crassostrea virginica]        |                                                                              | S4_24h     |
| -21.14341297 glutathione S-transferase C-terminal domain-containing protein-like isoform X1 [Crassostrea virginica] |                                                                              | S4_24h     |
| 4.340577781 glutathione S-transferase kappa 1-like [Crassostrea virginica] |                                                                              | RI_6h      |
| -21.74743898 maleylacetoacetate isomerase-like [Crassostrea virginica]    |                                                                              | S4_6h      |
| -22.28036183 maleylacetoacetate isomerase-like [Crassostrea virginica]    |                                                                              | RI_24h     |
| -22.57607848 maleylacetoacetate isomerase-like [Crassostrea virginica]    |                                                                              | RE22_6h    |
| -9.092994732 Superoxide dismutase [Cu-Zn] [Crassostrea gigas]            |                                                                              | S4_24h     |
| 24.656834 thioredoxin domain-containing protein 15-like [Crassostrea virginica] |                                                                              | S4_6h      |
| 22.08653805 thioredoxin domain-containing protein 15-like [Crassostrea virginica] |                                                                              | RE22_6h    |
| -22.17861058 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] |                                                                              | S4_6h      |
| -5.275085802 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] |                                                                              | S4_6h      |
| -24.08250505 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] |                                                                              | S4_24h     |
| -22.68468309 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] |                                                                              | S4_24h     |
| Value       | Description                                                                 | Time  |
|-------------|-----------------------------------------------------------------------------|-------|
| -15.3248519 | thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] | S4_24h |
| 9.959973369 | thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] | S4_24h |
| 19.68049721 | thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] | S4_24h |
| -22.94170493 | thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] | RI_6h |
| -24.96201578 | thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] | RI_24h |
| -24.87983434 | thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] | RI_24h |
| -22.95218203 | thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] | RI_24h |
| 7.365024046  | thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] | RI_24h |
| 18.02755971  | thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] | RI_24h |
| 23.85507502  | thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] | RI_24h |
| -23.27838106 | thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] | RE22_6h |
| -2.096359322 | thioredoxin domain-containing protein 5-like [Crassostrea virginica] | S4_24h |
| -25.88062202 | thioredoxin-like [Crassostrea virginica] | S4_24h |
| -10.64240601 | thioredoxin-like [Crassostrea virginica] | RI_6h |
|                | Expression Level | Protein Name and Species                     | Timepoint   |
|----------------|------------------|---------------------------------------------|-------------|
| -26.51486203   | thioredoxin-like [Crassostrea virginica]    | RI_24h                                      |
| -3.729163339   | thioredoxin-like protein 1 [Crassostrea virginica] | RI_24h                                      |
| 3.293281563    | thioredoxin-related transmembrane protein 1-like isoform X1 [Crassostrea virginica] | RI_6h       |
| 3.156411653    | thioredoxin-related transmembrane protein 1-like isoform X1 [Crassostrea virginica] | RI_24h       |
| -24.70491532   | thioredoxin-related transmembrane protein 2 homolog [Crassostrea virginica] | RI_24h       |
| -24.9360089    | thioredoxin-related transmembrane protein 2 homolog [Crassostrea virginica] | RE22_6h     |

**Acute phase proteins**

|                | Expression Level | Protein Name and Species                     | Timepoint   |
|----------------|------------------|---------------------------------------------|-------------|
| -9.723127722   | Heat shock 70 kDa protein 12A [Crassostrea gigas] | S4_24h                                      |
| 5.535364462    | heat shock 70 kDa protein 12A-like [Crassostrea virginica] | S4_24h       |
| 5.686282343    | heat shock 70 kDa protein 12A-like [Crassostrea virginica] | RI_24h       |
| -22.26223254   | heat shock 70 kDa protein 12A-like [Crassostrea virginica] | RE22_6h     |
| -23.79702313   | heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica] | S4_6h       |
| 6.658680636    | heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica] | S4_6h       |
| 5.254504823    | heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica] | RI_6h       |
| log2 Fold Change | Gene Description                                      | Timepoint   |
|------------------|-------------------------------------------------------|-------------|
| 5.250678277      | heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica] | RE22_6h     |
| -4.162351016     | heat shock 70 kDa protein 12B-like [Crassostrea virginica]        | RE22_6h     |
| -23.06134796     | heat shock 70 kDa protein 12B-like [Crassostrea virginica]        | S4_24h      |
| 19.64075977      | heat shock 70 kDa protein 12B-like isoform X4 [Crassostrea virginica] | S4_6h       |
| 19.49655284      | heat shock 70 kDa protein 12B-like isoform X4 [Crassostrea virginica] | RI_6h       |
| 18.54456763      | heat shock 70 kDa protein 12B-like isoform X4 [Crassostrea virginica] | RE22_6h     |
| -22.43374437     | heat shock factor protein-like [Crassostrea virginica]            | RI_24h      |
| -18.35638131     | heat shock protein 30C-like [Crassostrea virginica]               | S4_24h      |
| 3.254119893      | heat shock protein HSP 90-beta-like [Crassostrea virginica]       | S4_6h       |

**Cytoskeletal organization**

| log2 Fold Change | Gene Description                                      | Timepoint   |
|------------------|-------------------------------------------------------|-------------|
| -24.67660059     | PREDICTED: dynamin-1 isoform X2 [Crassostrea gigas]   | S4_6h       |
| -11.01417755     | dynamin-1-like isoform X6 [Crassostrea virginica]     | S4_6h       |
| 23.58398582      | dynamin-1-like isoform X6 [Crassostrea virginica]     | S4_6h       |
| -21.25056055     | dynamin-1-like isoform X6 [Crassostrea virginica]     | S4_24h      |
| Value          | Description                                                                 | Time  |
|---------------|------------------------------------------------------------------------------|-------|
| -23.6794566   | dynamin-1-like isoform X6 [Crassostrea virginica]                            | RI_6h |
| 23.2104963    | dynamin-1-like isoform X6 [Crassostrea virginica]                            | RI_6h |
| -13.1405264   | dynamin-1-like isoform X6 [Crassostrea virginica]                            | RI_24h|
| 18.62495089   | dynamin-1-like isoform X6 [Crassostrea virginica]                            | RE22_6h|
| 9.249110026   | PREDICTED: septin-7 isoform X3 [Crassostrea gigas]                           | S4_6h |
| 9.161299284   | PREDICTED: septin-7 isoform X3 [Crassostrea gigas]                           | RI_6h |
| -21.6896377   | septin-11-like isoform X2 [Crassostrea virginica]                            | RE22_6h|
| -22.00129053  | septin-2-like isoform X1 [Crassostrea virginica]                             | S4_6h |
| 7.044855946   | septin-2-like isoform X1 [Crassostrea virginica]                             | S4_6h |
| -21.88584245  | septin-2-like isoform X1 [Crassostrea virginica]                             | S4_24h|
| -22.73608544  | septin-2-like isoform X1 [Crassostrea virginica]                             | RI_24h|
| -23.27740458  | septin-2-like isoform X1 [Crassostrea virginica]                             | S4_24h|
| -10.38732509  | septin-2-like isoform X8 [Crassostrea virginica]                             | RI_6h |
| -7.952386425  | septin-2-like isoform X8 [Crassostrea virginica]                             | RI_6h |
### Others

|     |                                                  |            |
|-----|--------------------------------------------------|------------|
| 21.7 | multidrug resistance protein 1-like isoform X1 [Crassostrea virginica] | S4_6h      |
| 21.7 | multidrug resistance protein 1-like isoform X6 [Crassostrea virginica] | S4_24h     |
| 21.7 | multidrug resistance protein 1-like isoform X6 [Crassostrea virginica] | RI_6h      |
| 21.7 | multidrug resistance protein 1-like isoform X6 [Crassostrea virginica] | RI_24h     |
| 21.7 | multidrug resistance protein 1-like isoform X6 [Crassostrea virginica] | RE22_6h    |
| 21.7 | multidrug resistance-associated protein 4-like [Crassostrea virginica] | S4_6h      |
| 21.7 | multidrug resistance-associated protein 4-like [Crassostrea virginica] | S4_24h     |
| 21.7 | multidrug resistance-associated protein 5-like isoform X2 [Crassostrea virginica] | S4_24h     |
| 21.7 | multidrug resistance-associated protein 7-like [Crassostrea virginica] | S4_24h     |
| 21.7 | laccase-3-like [Crassostrea virginica]             | RI_24h     |
| 21.7 | laccase-like [Crassostrea virginica]              | RI_6h      |
| 21.7 | Hemicentin-1, partial [Crassostrea gigas]         | S4_6h      |
| 21.7 | Hemicentin-1                                      | S4_6h      |
| Value          | Description                                                                 | Time  |
|---------------|------------------------------------------------------------------------------|-------|
| -8.779619013 | Hemicentin-1                                                                 | S4_6h |
| -26.12075367 | Hemicentin-1                                                                 | S4_24h|
| -22.82446184 | Hemicentin-1                                                                 | RE22_6h|
| 4.970041769  | hemicentin-1-like [Crassostrea virginica]                                    | S4_6h |
| -23.57120259 | hemicentin-1-like [Crassostrea virginica]                                    | S4_6h |
| 7.211995212  | hemicentin-1-like [Crassostrea virginica]                                    | S4_6h |
| -24.43651737 | hemicentin-1-like [Crassostrea virginica]                                    | RE22_6h|
| -22.74745907 | hemicentin-1-like isoform X2 [Crassostrea virginica]                         | S4_24h|
| -22.04213544 | hemicentin-1-like isoform X2 [Crassostrea virginica]                         | S4_24h|
| -23.91446285 | hemicentin-1-like isoform X2 [Crassostrea virginica]                         | RE22_6h|
| -6.483050928 | hemicentin-1-like isoform X2 [Crassostrea virginica]                         | RI_6h |
| -20.92100668 | hemicentin-1-like isoform X21 [Crassostrea virginica]                        | S4_6h |
| -21.90630905 | hemicentin-1-like isoform X21 [Crassostrea virginica]                        | RI_6h |
| -21.71429592 | hemicentin-1-like isoform X21 [Crassostrea virginica]                        | RI_24h|
| Value       | Description                                      | Time   |
|-------------|--------------------------------------------------|--------|
| -22.5262628 | hemicentin-1-like isoform X21 [Crassostrea virginica] | RE22_6h |
| -21.95606244| hemicentin-1-like isoform X21 [Crassostrea virginica] | RE22_6h |
| -25.24784795| hemicentin-1-like isoform X3 [Crassostrea virginica]    | S4_24h |
| 15.22210309 | hemicentin-1-like isoform X34 [Crassostrea virginica]    | S4_6h  |
| 19.54287658 | hemicentin-1-like isoform X34 [Crassostrea virginica]    | S4_24h |
| 19.38940516 | hemicentin-1-like isoform X34 [Crassostrea virginica]    | RI_6h  |
| 19.36636019 | hemicentin-1-like isoform X34 [Crassostrea virginica]    | RI_24h |
| 19.77553284 | hemicentin-1-like isoform X34 [Crassostrea virginica]    | RE22_6h |
| -21.26298714| hemicentin-1-like isoform X40 [Crassostrea virginica]    | S4_6h  |
| -22.32330998| hemicentin-1-like isoform X40 [Crassostrea virginica]    | S4_24h |
| 7.289148836 | hemicentin-1-like isoform X5 [Crassostrea virginica]      | S4_6h  |
| 17.82784086 | hemicentin-1-like isoform X5 [Crassostrea virginica]      | S4_24h |
| 20.84952352 | hemicentin-1-like isoform X5 [Crassostrea virginica]      | RI_24h |
| -24.07441428| hemicentin-1-like isoform X6 [Crassostrea virginica]      | S4_6h  |
| Log2 Fold Change | Gene Description                                                                 | Time Point |
|------------------|----------------------------------------------------------------------------------|------------|
| -22.70945451     | hemicentin-1-like isoform X9 [Crassostrea virginica]                             | S4_24h     |
| -25.40188462     | hemicentin-1-like isoform X9 [Crassostrea virginica]                             | RI_6h      |
| -29.99115794     | hemicentin-1-like isoform X9 [Crassostrea virginica]                             | RI_24h     |
| 9.38130971       | hemicentin-2-like isoform X2 [Crassostrea virginica]                             | S4_6h      |
| 20.95642279      | hemicentin-2-like isoform X2 [Crassostrea virginica]                             | S4_24h     |
| 9.373853638      | hemicentin-2-like isoform X2 [Crassostrea virginica]                             | RI_6h      |
| 20.55310454      | hemicentin-2-like isoform X2 [Crassostrea virginica]                             | RI_24h     |
| 9.777286784      | hemicentin-2-like isoform X2 [Crassostrea virginica]                             | RE22_6h    |
| -8.922154094     | histamine H2 receptor-like [Crassostrea virginica]                               | S4_24h     |
| -22.19114574     | histamine H2 receptor-like [Crassostrea virginica]                               | S4_24h     |
| -22.75801453     | histamine H2 receptor-like [Crassostrea virginica]                               | RI_24h     |
| -22.90867354     | histamine H2 receptor-like [Crassostrea virginica]                               | RE22_6h    |
| -5.471576144     | oxidative stress-induced growth inhibitor 2-like [Crassostrea virginica]         | S4_6h      |
| -9.718337318     | oxidative stress-induced growth inhibitor 2-like [Crassostrea virginica]         | RI_6h      |
|                | Description                                                                 | Time  |
|----------------|------------------------------------------------------------------------------|-------|
| -6.452016421   | oxidative stress-induced growth inhibitor 2-like [Crassostrea virginica]    | RE22_6h |
| -2.071397009   | cytochrome b [Crassostrea virginica]                                        | RI_6h |
| 20.23697806    | cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]           | S4_24h |
| 22.07024714    | cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]           | RI_6h |
| 17.91802039    | cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]           | RI_24h |
| 21.0441541     | cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]           | RE22_6h |
| -30            | cytochrome c oxidase subunit I [Crassostrea virginica]                      | S4_6h |
| -12.21152488   | cytochrome c oxidase subunit I [Crassostrea virginica]                      | S4_6h |
| 13.83136184    | cytochrome c oxidase subunit I [Crassostrea virginica]                      | S4_6h |
| -12.7345641    | cytochrome c oxidase subunit I [Crassostrea virginica]                      | S4_24h |
| 23.04305396    | cytochrome c oxidase subunit I [Crassostrea virginica]                      | S4_24h |
| 27.42296011    | cytochrome c oxidase subunit I [Crassostrea virginica]                      | S4_24h |
| 29.20729823    | cytochrome c oxidase subunit I [Crassostrea virginica]                      | S4_24h |
| -24.69050988   | cytochrome c oxidase subunit I [Crassostrea virginica]                      | RI_6h |
| Value          | Description                                           | Time  |
|---------------|-------------------------------------------------------|-------|
| -24.66864706  | cytochrome c oxidase subunit I [Crassostrea virginica] | RI_6h |
| 29.16889206   | cytochrome c oxidase subunit I [Crassostrea virginica] | RI_6h |
| -30           | cytochrome c oxidase subunit I [Crassostrea virginica] | RI_24h|
| -13.01827661  | cytochrome c oxidase subunit I [Crassostrea virginica] | RI_24h|
| 20.69401443   | cytochrome c oxidase subunit I [Crassostrea virginica] | RI_24h|
| 30            | cytochrome c oxidase subunit I [Crassostrea virginica] | RI_24h|
| -30           | cytochrome c oxidase subunit I [Crassostrea virginica] | RE22_6h|
| -11.365341    | cytochrome c oxidase subunit I [Crassostrea virginica] | RE22_6h|
| -10.31599264  | cytochrome c oxidase subunit I [Crassostrea virginica] | RE22_6h|
| 30            | cytochrome c oxidase subunit I [Crassostrea virginica] | RE22_6h|
| -12.33130181  | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] | S4_24h|
| -26.50197006  | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] | RI_6h |
| -17.04367675  | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] | RI_24h|
| 11.0050444    | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] | S4_6h |
| Value         | Description                                                                 | Time  |
|--------------|-----------------------------------------------------------------------------|-------|
| 15.84125515  | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | S4_6h |
| 26.82143733  | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | S4_6h |
| 28.26611263  | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | S4_6h |
| 10.86124348  | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | S4_24h|
| 11.67321719  | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | S4_24h|
| 30           | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | S4_24h|
| 30           | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | S4_24h|
| 12.78997263  | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | RI_6h |
| 30           | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | RI_6h |
| 30           | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | RI_6h |
| 14.9301273   | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | RI_24h|
| 25.83550682  | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | RI_24h|
| 27.94606978  | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | RI_24h|
| 15.68484216  | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | RE22_6h|
| Value       | Description                                                                 | Time  |
|------------|------------------------------------------------------------------------------|-------|
| 29.89148054| cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]     | RE22_6h |
| 7.51088163 | cytochrome P450 27C1-like [Crassostrea virginica]                           | S4_6h |
| 8.171393189| cytochrome P450 27C1-like [Crassostrea virginica]                           | S4_24h |
| -24.81197395| cytochrome P450 27C1-like [Crassostrea virginica]                           | RI_6h |
| 9.022848188| cytochrome P450 27C1-like [Crassostrea virginica]                           | RI_6h |
| 7.477144414| cytochrome P450 27C1-like [Crassostrea virginica]                           | RI_24h |
| 6.794994273| cytochrome P450 27C1-like [Crassostrea virginica]                           | RE22_6h |
| 21.27504686| cytochrome P450 2C28-like isoform X2 [Crassostrea virginica]                | S4_6h |
| 18.70986303| cytochrome P450 2C28-like isoform X2 [Crassostrea virginica]                | S4_24h |
| -22.33591302| cytochrome P450 2C28-like isoform X2 [Crassostrea virginica]              | RI_6h |
| 20.28813849| cytochrome P450 2C28-like isoform X2 [Crassostrea virginica]                | RI_24h |
| 20.46500703| cytochrome P450 2C28-like isoform X2 [Crassostrea virginica]                | RE22_6h |
| 6.238313253| Cytochrome P450 2D14 [Crassostrea gigas]                                   | RI_6h |
| -21.35382089| cytochrome P450 2F5-like [Crassostrea virginica]                          | S4_6h |
| Value       | Description                                                                 | Time     |
|------------|------------------------------------------------------------------------------|----------|
| -21.63670878 | cytochrome P450 2F5-like [Crassostrea virginica]                             | S4_24h   |
| -22.27759983 | cytochrome P450 2F5-like [Crassostrea virginica]                             | RI_24h   |
| -22.65584492 | cytochrome P450 2F5-like [Crassostrea virginica]                             | RE22_6h  |
| -21.3071929  | cytochrome P450 2J5-like isoform X2 [Crassostrea virginica]                  | S4_24h   |
| -22.51502577 | cytochrome P450 3A6-like [Crassostrea virginica]                             | S4_24h   |
| -9.01112453  | cytochrome P450 4A25-like [Crassostrea virginica]                            | S4_6h    |
| -10.01277913 | cytochrome P450 4V2-like isoform X1 [Crassostrea virginica]                  | S4_6h    |
| -20.02751343 | cytochrome P450 4V2-like isoform X1 [Crassostrea virginica]                  | RI_24h   |
| -8.791304071 | dual specificity protein phosphatase 1-A-like [Crassostrea virginica]        | RI_24h   |
| 4.381729845  | dual specificity protein phosphatase 14-like isoform X1 [Crassostrea virginica] | RI_24h   |
| -23.83873688 | dual specificity protein phosphatase 18-like [Crassostrea virginica]         | RI_24h   |
| -24.07000154 | dual specificity protein phosphatase 18-like [Crassostrea virginica]         | RE22_6h  |
| 9.288349328  | dual specificity protein phosphatase 19-like [Crassostrea virginica]         | S4_24h   |
| 8.034347824  | dual specificity protein phosphatase 19-like [Crassostrea virginica]         | RI_24h   |
| Value          | Description                                                                 | Time   |
|---------------|------------------------------------------------------------------------------|--------|
| -24.95777889  | dual specificity protein phosphatase 7-like [Crassostrea virginica]          | RI_6h  |
| 8.541240553   | dual specificity protein phosphatase 7-like [Crassostrea virginica]          | RI_24h |
| -25.38312764  | dual specificity protein phosphatase 7-like [Crassostrea virginica]          | RE22_6h|
| -8.245775085  | protein phosphatase 1 regulatory subunit 12A-like isoform X4 [Crassostrea virginica] | S4_24h |
| -24.53980697  | protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica] | S4_6h  |
| 10.20776883   | protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica] | S4_6h  |
| 9.22513492    | protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica] | S4_24h |
| 9.587762441   | protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica] | RI_6h  |
| 8.067829643   | protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica] | RI_24h |
| 8.666364977   | protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica] | RE22_6h|
| 8.659545152   | protein phosphatase 1 regulatory subunit 36-like isoform X1 [Crassostrea virginica] | RI_6h  |
| -7.364558291  | protein phosphatase 1 regulatory subunit 37-like [Crassostrea virginica]    | S4_6h  |
| -7.980896037  | protein phosphatase 1 regulatory subunit 37-like [Crassostrea virginica]    | RE22_6h|
| 7.015542075   | protein phosphatase 1 regulatory subunit 42-like isoform X1 [Crassostrea virginica] | RI_24h |
| Gene Description                                                                 | Sample Time  |
|--------------------------------------------------------------------------------|--------------|
| protein phosphatase 1 regulatory subunit 42-like isoform X5 [Crassostrea virginica] | S4_24h       |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | S4_6h        |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | S4_6h        |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | S4_24h       |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | S4_24h       |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | RI_6h        |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | RI_6h        |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | RI_6h        |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | RI_6h        |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | RI_6h        |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | RI_6h        |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | RE22_6h      |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | RE22_6h      |
| Tripartite motif-containing protein 2 [Crassostrea gigas]                         | S4_24h       |
| Value       | Description                                                                 | Time  |
|------------|-----------------------------------------------------------------------------|-------|
| -24.94189095 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | S4_6h |
| -21.21518109 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | S4_6h |
| -24.99785172 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | S4_24h|
| -22.97055523 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | S4_24h|
| -22.56316651 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | S4_24h|
| -21.63143212 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | S4_24h|
| -21.555795   | tripartite motif-containing protein 2-like [Crassostrea virginica]          | S4_24h|
| -21.48502657 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | S4_24h|
| 2.440722296  | tripartite motif-containing protein 2-like [Crassostrea virginica]          | S4_24h|
| -23.52232576 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | RI_24h|
| -22.27754888 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | RI_24h|
| -6.664288475 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | RI_24h|
| -23.67795281 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | RE22_6h|
| -22.94845541 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | RE22_6h|
| Value   | Description                                                                 | Time  |
|---------|-----------------------------------------------------------------------------|-------|
| 20.60131168 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | S4_6h |
| 20.75582702  | tripartite motif-containing protein 2-like [Crassostrea virginica]          | S4_24h|
| 20.51645227  | tripartite motif-containing protein 2-like [Crassostrea virginica]          | RI_6h |
| -23.97927626 | tripartite motif-containing protein 2-like [Crassostrea virginica]          | RI_24h|
| 20.6240354   | tripartite motif-containing protein 2-like [Crassostrea virginica]          | RI_24h|
| 20.61455877  | tripartite motif-containing protein 2-like [Crassostrea virginica]          | RE22_6h|
| -21.16657646 | tripartite motif-containing protein 2-like isoform X2 [Crassostrea virginica] | S4_6h |
| 9.572758843  | tripartite motif-containing protein 2-like isoform X2 [Crassostrea virginica] | S4_6h |
| -21.69698695 | tripartite motif-containing protein 2-like isoform X2 [Crassostrea virginica] | RI_6h |
| 7.793596061  | tripartite motif-containing protein 2-like isoform X2 [Crassostrea virginica] | RI_6h |
| 22.30459712  | tripartite motif-containing protein 2-like isoform X4 [Crassostrea virginica] | S4_6h |
| 21.31432232  | tripartite motif-containing protein 2-like isoform X4 [Crassostrea virginica] | RE22_6h|
| -24.62951513 | tripartite motif-containing protein 3-like [Crassostrea virginica]          | S4_24h|
| -25.52121202 | tripartite motif-containing protein 3-like [Crassostrea virginica]          | RI_24h|
| Log2 Fold Change | Description                                                                 | Time Point |
|------------------|------------------------------------------------------------------------------|------------|
| -25.70706555     | tripartite motif-containing protein 3-like [Crassostrea virginica]            | RE22_6h    |
| -6.05725712      | tripartite motif-containing protein 3-like [Crassostrea virginica]            | RE22_6h    |
| -24.1355023      | tripartite motif-containing protein 45-like [Crassostrea virginica]           | RE22_6h    |
| -21.78539178     | tripartite motif-containing protein 5-like isoform X2 [Crassostrea virginica]| RI_24h     |
| -21.98439629     | perlucin-like [Crassostrea virginica]                                         | S4_6h      |
| -23.38363804     | perlucin-like [Crassostrea virginica]                                         | S4_24h     |
| -21.96732063     | perlucin-like [Crassostrea virginica]                                         | S4_24h     |
| -8.094282488     | perlucin-like [Crassostrea virginica]                                         | S4_24h     |
| -23.03677587     | perlucin-like isoform X1 [Crassostrea virginica]                              | S4_24h     |
| -22.45971194     | perlucin-like isoform X1 [Crassostrea virginica]                              | RE22_6h    |
| 18.507209        | perlucin-like isoform X2 [Crassostrea virginica]                              | S4_24h     |
| 15.20165795      | perlucin-like isoform X2 [Crassostrea virginica]                              | RI_24h     |
| -23.43817576     | perlucin-like protein [Crassostrea virginica]                                 | S4_24h     |
| Log2FoldChange | Hit_def                          | Treatment   |
|---------------|---------------------------------|-------------|
| -6.765931252  | perlucin-like protein [Crassostrea virginica] | RI_24h      |
| 21.94929471   | perlucin-like protein isoform X1 [Crassostrea virginica] | S4_6h       |
| 21.68188164   | perlucin-like protein isoform X1 [Crassostrea virginica] | RE22_6h     |
| 25.09518802   | Chitin synthase 3 [Crassostrea gigas]              | RE22_6h     |
| 24.46274385   | Chitin synthase 3 [Crassostrea gigas]              | RI_6h       |
| 21.58959401   | Chitin synthase 3 [Crassostrea gigas]              | S4_6h       |
| -7.045235918  | Chitin synthase C [Crassostrea gigas]              | S4_24h      |

**Table 3:** Differentially expressed genes with log fold change for probiotic treatment when compared to control in hatchery transcriptomes (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). HT-RI: larvae treated daily with probiotic *Bacillus pumilus* RI0695 (RI) for 5, 12 or 16 days.
| Recognition        | TLRs |                                                                 |
|--------------------|------|-----------------------------------------------------------------|
|                    |      | **toll-like receptor 1** [Crassostrea virginica]                 |
|                    | **-6.333302299** | HT_RI                                                          |
|                    |      | **toll-like receptor 6** [Crassostrea virginica]                 |
|                    | **-5.117571098** | HT_RI                                                          |
|                    |      | **toll-like receptor 6** [Crassostrea virginica]                 |
|                    | **10.50152784**  | HT_RI                                                          |
|                    |      | **toll-like receptor 4 isoform X1** [Crassostrea virginica]     |
|                    | **-7.016997176** | HT_RI                                                          |
|                    |      | **toll-like receptor 4 isoform X1** [Crassostrea virginica]     |
|                    | **5.181661209**  | HT_RI                                                          |
|                    |      | **toll-like receptor 4 isoform X1** [Crassostrea virginica]     |
|                    | **-13.50652647** | HT_RI                                                          |
|                    |      | **toll-like receptor 4 isoform X1** [Crassostrea virginica]     |
|                    | **-28.195436**   | HT_RI                                                          |
|                    |      | **toll-like receptor 13** [Crassostrea virginica]               |
|                    | **-10.52830632** | HT_RI                                                          |
|                    |      | **C-type lectin domain family 4 member E-like** [Crassostrea   |
|                    | **-7.548517655** | HT_RI                                                          |
|                    |      | **C-type lectin domain family 3 member A-like** [Crassostrea   |
|                    | **-9.313083618** | HT_RI                                                          |
|                    |      | **Scavenger receptors**                                         |
|                    |      |                                                                 |
|                    |      |                                                                 |
| Score     | Description                                                                 | Accession |
|-----------|-----------------------------------------------------------------------------|-----------|
| -8.035179262 | scavenger receptor class B member 1-like isoform X1 [Crassostrea virginica] | HT_RI     |
| -8.089778373 | scavenger receptor class B member 1-like isoform X1 [Crassostrea virginica] | HT_RI     |
| -3.505324316 | scavenger receptor cysteine-rich type 1 protein M130-like isoform X1 [Crassostrea virginica] | HT_RI     |
| -5.113872743 | scavenger receptor cysteine-rich type 1 protein M130-like isoform X1 [Crassostrea virginica] | HT_RI     |
| **LRFN**  |                                                                               |           |
| -7.614151619 | leucine-rich repeat and fibronectin type III domain-containing protein 1-like protein [Crassostrea virginica] | HT_RI     |
| -10.54947853 | leucine-rich repeat and fibronectin type-III domain-containing protein 5-like [Crassostrea virginica] | HT_RI     |
| **LRRs**   |                                                                               |           |
| 7.538001578  | leucine-rich repeat and IQ domain-containing protein 1-like [Crassostrea virginica] | HT_RI     |
| Value        | Description                                                                 | Symbol |
|-------------|-----------------------------------------------------------------------------|--------|
| 7.603603801 | leucine-rich repeat neuronal protein 3-like [Crassostrea virginica]         | HT_RI  |
| -7.290369986| leucine-rich repeat neuronal protein 3-like [Crassostrea virginica]         | HT_RI  |
| -3.910728944| leucine-rich repeat transmembrane protein FLRT3-like [Crassostrea virginica]| HT_RI  |
| 8.884936086 | leucine-rich repeat-containing G-protein coupled receptor 4-like [Crassostrea virginica] | HT_RI  |
| -5.222764772| leucine-rich repeat-containing G-protein coupled receptor 4-like [Crassostrea virginica] | HT_RI  |
| 6.417892215 | leucine-rich repeat-containing protein 24-like [Crassostrea virginica]       | HT_RI  |
| -5.851688629| leucine-rich repeat-containing protein 24-like [Crassostrea virginica]       | HT_RI  |
| -6.888253251| leucine-rich repeat-containing protein 24-like [Crassostrea virginica]       | HT_RI  |
| -10.67681921| leucine-rich repeat-containing protein 71-like isoform X21 [Crassostrea virginica] | HT_RI  |
| 11.13843633 | leucine-rich repeat-containing protein 71-like isoform X22 [Crassostrea virginica] | HT_RI  |
| Z-score | Description                                                                                  | Species                          | Location |
|---------|---------------------------------------------------------------------------------------------|----------------------------------|----------|
| -12.73  | leucine-rich repeat-containing protein 74A-like isoform X2 [Crassostrea virginica]          |                                  | HT_RI    |
| -9.68   | leucine-rich repeat-containing protein 74B-like isoform X3 [Crassostrea virginica]          |                                  | HT_RI    |

**Fibronectin domain containing**

| Z-score | Description                                                                                  | Species                          | Location |
|---------|---------------------------------------------------------------------------------------------|----------------------------------|----------|
| 3.47    | fibronectin type-III domain-containing protein 3A-like isoform X4 [Crassostrea virginica]  |                                  | HT_RI    |
| -7.59   | fibronectin type-III domain-containing protein 3A-like isoform X4 [Crassostrea virginica]  |                                  | HT_RI    |

**C1q proteins**

| Z-score | Description                                                                                  | Species                          | Location |
|---------|---------------------------------------------------------------------------------------------|----------------------------------|----------|
| 7.07    | complement C1q tumor necrosis factor-related protein 2-like [Crassostrea virginica]        |                                  | HT_RI    |
| -8.69   | complement C1q tumor necrosis factor-related protein 4-like isoform X3 [Crassostrea virginica] |                                  | HT_RI    |
| Others               |                          |        |
|---------------------|--------------------------|--------|
| -5.683456288        | Macrophage mannose receptor 1 [Crassostrea gigas] | HT_RI  |
| -9.358422983        | Macrophage mannose receptor 1-like [Crassostrea virginica] | HT_RI  |
| 7.683007501         | Macrophage migration inhibitory factor-like [Crassostrea virginica] | HT_RI  |
| **Cholinergic immunomodulation** |                          |        |
| -6.155933795        | Muscarinic acetylcholine receptor M1-like [Crassostrea virginica] | HT_RI  |
| -10.64631968        | Muscarinic acetylcholine receptor M1-like [Crassostrea virginica] | HT_RI  |
| -10.62270936        | Glutamate receptor ionotropic | HT_RI  |
| -10.76881678        | Glutamate receptor ionotropic | HT_RI  |
| -9.746999757        | Neuronal acetylcholine receptor subunit alpha-10-like isoform X2 [Crassostrea virginica] | HT_RI  |
| -10.55585177        | Neuronal acetylcholine receptor subunit alpha-10-like isoform X2 [Crassostrea virginica] | HT_RI  |
| Value       | Description                                                                 | HT_RI |
|-------------|------------------------------------------------------------------------------|-------|
| -10.41167226 | neuronal acetylcholine receptor subunit alpha-10-like isoform X3 [Crassostrea virginica] |       |
| 2.6604451    | neuronal acetylcholine receptor subunit alpha-6-like [Crassostrea virginica]   |       |
| 11.8076763   | neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica]   |       |
| -7.276192743 | neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica]   |       |
| -12.41663085 | neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica]  |       |
| 10.57507598  | neuropeptide FF receptor 2-like [Crassostrea virginica]                       |       |
| 19.88309004  | neuropeptide Y receptor type 1-like [Crassostrea virginica]                   |       |
|             | **Signaling pathways**                                                        |       |
| -11.49570393 | TNF receptor-associated factor 3-like isoform X3 [Crassostrea virginica]      |       |
| 8.268728895  | tumor necrosis factor receptor superfamily member 1B-like isoform X1 [Crassostrea virginica] |       |
| 4.135043574  | NF-kappa-B inhibitor-interacting Ras-like protein 1 isoform X8 [Crassostrea virginica] |       |
|            |                                                                                           |     |
|------------|------------------------------------------------------------------------------------------|-----|
| 3.572468448 | NF-kappa-B inhibitor-interacting Ras-like protein 1 isoform X8 [Crassostrea virginica]   | HT_RI |
| -6.180435424 | nuclear factor NF-kappa-B p105 subunit-like isoform X2 [Crassostrea virginica]            | HT_RI |
| 6.794484856  | C-Jun-amino-terminal kinase-interacting protein 4-like [Crassostrea virginica]           | HT_RI |
| 11.83894875  | stress-activated protein kinase JNK-like isoform X1 [Crassostrea virginica]              | HT_RI |
| 11.81769312  | stress-activated protein kinase JNK-like isoform X1 [Crassostrea virginica]              | HT_RI |
| 5.027413466  | stress-activated protein kinase JNK-like isoform X1 [Crassostrea virginica]              | HT_RI |
| -7.126718787 | mitogen-activated protein kinase 11-like [Crassostrea virginica]                          | HT_RI |
| -9.730631672 | mitogen-activated protein kinase 11-like [Crassostrea virginica]                          | HT_RI |
| -13.9275785  | mitogen-activated protein kinase 11-like [Crassostrea virginica]                          | HT_RI |
| -10.23892565 | mitogen-activated protein kinase 7-like isoform X2 [Crassostrea virginica]              | HT_RI |
| -11.91394746 | interferon regulatory factor 2-binding protein-like [Crassostrea virginica]             | HT_RI |
| -10.43886642 | integrin alpha-2-like isoform X10 [Crassostrea virginica]                               | HT_RI |
| 11.26277301  | integrin alpha-2-like isoform X5 [Crassostrea virginica]                                | HT_RI |
| ID            | Description                                                                 | Reference          |
|---------------|-----------------------------------------------------------------------------|--------------------|
| 12.22522579   | integrin beta-like protein C isoform X1 [Crassostrea virginica]              | HT_RI              |
| 9.093480693   | nuclear factor of activated T-cells 5-like isoform X2 [Crassostrea virginica] | HT_RI              |
| 3.339268822   | nuclear factor of activated T-cells 5-like isoform X2 [Crassostrea virginica] | HT_RI              |
| **Effectors** |                                                                             |                    |
| 5.805191913   | serine protease inhibitor Cvsi-2-like [Crassostrea virginica]                | HT_RI              |
| -2.31732885   | kunitz-type serine protease inhibitor conotoxin Cal9.1b-like [Crassostrea virginica] | HT_RI              |
| -11.91394746  | interferon regulatory factor 2-binding protein-like [Crassostrea virginica]  | HT_RI              |
| 10.23389419   | interferon-induced protein 44-like isoform X2 [Crassostrea virginica]        | HT_RI              |
| 4.93870882    | interferon-induced protein 44-like isoform X2 [Crassostrea virginica]        | HT_RI              |
| 10.86738137   | Signaling mucin HKR1 [Mizuhopecten yessoensis]                               | HT_RI              |
| -9.926277007  | Signaling mucin HKR1 [Mizuhopecten yessoensis]                               | HT_RI              |
| -11.19554614  | Signaling mucin HKR1 [Mizuhopecten yessoensis]                               | HT_RI              |
| -7.627259354  | integumentary mucin C.1-like isoform X3 [Crassostrea virginica]              | HT_RI              |
| Expression   | Description                                                                 | HT_RI   |
|--------------|------------------------------------------------------------------------------|---------|
| 5.366202536  | mucin-17-like isoform X2 [Crassostrea virginica]                              |         |
| -5.772730703 | mucin-17-like isoform X2 [Crassostrea virginica]                              | HT_RI   |
| -13.12905042 | mucin-2-like [Crassostrea virginica]                                          | HT_RI   |
| -5.905452651 | mucin-5AC-like [Crassostrea virginica]                                        | HT_RI   |
| -8.77598416  | mucin-5AC-like isoform X5 [Crassostrea virginica]                             | HT_RI   |
| Apoptosis    |                                                                              |         |
| -7.924485961 | caspase-1-like [Crassostrea virginica]                                        | HT_RI   |
| -9.46806142  | caspase-1-like [Crassostrea virginica]                                        | HT_RI   |
| 10.97406116  | caspase-14-like isoform X2 [Crassostrea virginica]                            | HT_RI   |
| -3.233698531 | caspase-7-like [Crassostrea virginica]                                        | HT_RI   |
| -10.00654536 | caspase-7-like [Crassostrea virginica]                                        | HT_RI   |
| -3.686137851 | caspase recruitment domain-containing protein 14-like isoform X5 [Crassostrea virginica] | HT_RI   |
| Score | Description                                                                 |
|-------|-----------------------------------------------------------------------------|
| 6.27972333 | baculoviral IAP repeat-containing protein 2-like isoform X1 [Crassostrea virginica] |
| 10.35840243 | baculoviral IAP repeat-containing protein 2-like isoform X2 [Crassostrea virginica] |
| -9.552992158 | baculoviral IAP repeat-containing protein 3-like [Crassostrea virginica] |
| -10.01313701 | baculoviral IAP repeat-containing protein 3-like [Crassostrea virginica] |
| -7.12622932 | baculoviral IAP repeat-containing protein 7-like isoform X3 [Crassostrea virginica] |
| 11.86479373 | Apoptosis inhibitor IAP [Crassostrea gigas] |
| 5.960093895 | LOW QUALITY PROTEIN: apoptosis-inducing factor 3-like [Crassostrea virginica] |
| 2.788401176 | protein kinase C iota type-like isoform X4 [Crassostrea virginica] |
| 20.80442465 | multiple epidermal growth factor-like domains protein 10 [Crassostrea virginica] |
| -6.43860015 | multiple epidermal growth factor-like domains protein 10 [Crassostrea virginica] |
| Value       | Description                                                                 | HT_RI      |
|-------------|------------------------------------------------------------------------------|------------|
| -7.224748576 | multiple epidermal growth factor-like domains protein 10 [Crassostrea virginica] | HT_RI      |
| 10.58406136  | multiple epidermal growth factor-like domains protein 10 isoform X2 [Crassostrea virginica] | HT_RI      |
| 7.215833061  | multiple epidermal growth factor-like domains protein 10 isoform X2 [Crassostrea virginica] | HT_RI      |
| 5.064940886  | multiple epidermal growth factor-like domains protein 10 isoform X2 [Crassostrea virginica] | HT_RI      |
| 2.789935488  | multiple epidermal growth factor-like domains protein 10 isoform X2 [Crassostrea virginica] | HT_RI      |
| 8.594189834  | multiple epidermal growth factor-like domains protein 6 [Crassostrea virginica] | HT_RI      |
| -10.50534165 | multiple epidermal growth factor-like domains protein 6 [Crassostrea virginica] | HT_RI      |
| 10.20740385  | multiple epidermal growth factor-like domains protein 6 isoform X1 [Crassostrea virginica] | HT_RI      |
| Score       | Protein Name                                                                 | Species                     | Ratio  |
|------------|------------------------------------------------------------------------------|-----------------------------|--------|
| 10.20312945| multiple epidermal growth factor-like domains protein 6 isoform X1 [Crassostrea virginica] | Crassostrea virginica      | HT_RI  |
| 7.471679862| multiple epidermal growth factor-like domains protein 6 isoform X1 [Crassostrea virginica] | Crassostrea virginica      | HT_RI  |
| 8.053324948| programmed cell death protein 2-like isoform X1 [Crassostrea virginica]       | Crassostrea virginica      | HT_RI  |
| 11.33719413| cell death abnormality protein 1-like [Crassostrea virginica]                  | Crassostrea virginica      | HT_RI  |
| 11.40372414| GTPase IMAP family member 7-like isoform X1 [Crassostrea virginica]           | Crassostrea virginica      | HT_RI  |
| -10.0861395| DNA damage-regulated autophagy modulator protein 2-like [Crassostrea virginica] | Crassostrea virginica      | HT_RI  |

**Cytoskeletal reorganization**

| Score       | Protein Name                                                                 | Species                     | Ratio  |
|------------|------------------------------------------------------------------------------|-----------------------------|--------|
| 9.029226712| LOW QUALITY PROTEIN: septin-2-like [Crassostrea virginica]                   | Crassostrea virginica      | HT_RI  |
| 5.82670463 | LOW QUALITY PROTEIN: septin-2-like [Crassostrea virginica]                   | Crassostrea virginica      | HT_RI  |
| 4.705387778| LOW QUALITY PROTEIN: septin-2-like [Crassostrea virginica]                   | Crassostrea virginica      | HT_RI  |

**Others**
| PseudogeneID     | Gene Name                                                                 | Abbreviation  |
|------------------|---------------------------------------------------------------------------|---------------|
| -9.657810466    | lysosomal acid lipase/cholesteryl ester hydrolase-like [Crassostrea virginica] | HT_RI         |
| 14.2444413      | lysosomal alpha-glucosidase-like isoform X1 [Crassostrea virginica]        | HT_RI         |
| -10.73769432    | lysosomal-trafficking regulator-like isoform X4 [Crassostrea virginica]    | HT_RI         |
| 10.97945875     | glutathione S-transferase C-terminal domain-containing protein-like isoform X1 [Crassostrea virginica] | HT_RI         |
| -6.354844406    | glutathione-independent glyoxalase HSP31-like [Crassostrea virginica]      | HT_RI         |
| 4.264547363     | maleylacetoacetate isomerase-like [Crassostrea virginica]                  | HT_RI         |
| 11.70064297     | Heat shock 70 kDa protein 12A [Crassostrea gigas]                         | HT_RI         |
| -6.944842925    | Heat shock 70 kDa protein 12A [Crassostrea gigas]                         | HT_RI         |
| -6.695090302    | heat shock 70 kDa protein 12A-like [Crassostrea virginica]                | HT_RI         |
| -10.35513436    | heat shock 70 kDa protein 12A-like [Crassostrea virginica]                | HT_RI         |
| -10.53471861    | heat shock 70 kDa protein 12A-like [Crassostrea virginica]                | HT_RI         |
| -10.66480031    | heat shock 70 kDa protein 12A-like [Crassostrea virginica]                | HT_RI         |
| 10.32935057     | heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica]     | HT_RI         |
| Value            | Description                                                                 | Reference       |
|------------------|------------------------------------------------------------------------------|-----------------|
| 5.822952857      | heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica]       | HT_RI           |
| 3.278219628      | actin                                                                        | HT_RI           |
| 11.26723475      | actin-3-like isoform X1 [Crassostrea virginica]                              | HT_RI           |
| -3.288605929     | tripartite motif-containing protein 2-like [Crassostrea virginica]           | HT_RI           |
| -28.23091398     | tripartite motif-containing protein 2-like [Crassostrea virginica]           | HT_RI           |
| 11.97821512      | tripartite motif-containing protein 2-like isoform X1 [Crassostrea virginica] | HT_RI           |
| 6.138377301      | tripartite motif-containing protein 3-like [Crassostrea virginica]           | HT_RI           |
| 4.616161652      | tripartite motif-containing protein 3-like [Crassostrea virginica]           | HT_RI           |
| -5.355761746     | tripartite motif-containing protein 3-like [Crassostrea virginica]           | HT_RI           |
| 20.95857011      | tripartite motif-containing protein 3-like isoform X1 [Crassostrea virginica] | HT_RI           |
| -6.051600924     | tripartite motif-containing protein 55-like [Crassostrea virginica]          | HT_RI           |
| -12.53777229     | protein phosphatase 1 regulatory subunit 11-like [Crassostrea virginica]     | HT_RI           |
| 7.873357051      | protein phosphatase 1 regulatory subunit 12B-like isoform X13 [Crassostrea virginica] | HT_RI           |
| Value          | Description                                                                 | HT_RI   |
|---------------|-----------------------------------------------------------------------------|---------|
| 7.282656314   | protein phosphatase 1 regulatory subunit 12B-like isoform X13 [Crassostrea virginica] |         |
| -12.67858882  | protein phosphatase 1 regulatory subunit 12B-like isoform X13 [Crassostrea virginica] |         |
| 14.50001928   | protein phosphatase 1 regulatory subunit 37-like [Crassostrea virginica]      |         |
| -3.004388061  | protein phosphatase 1 regulatory subunit 37-like [Crassostrea virginica]      |         |
| -6.650729756  | protein phosphatase 1 regulatory subunit 42-like isoform X5 [Crassostrea virginica] |         |
| 6.602761261   | multidrug resistance-associated protein 5-like isoform X2 [Crassostrea virginica] |         |
| -10.91470969  | multidrug resistance-associated protein 5-like isoform X2 [Crassostrea virginica] |         |
| -13.24809012  | multidrug resistance-associated protein 5-like isoform X2 [Crassostrea virginica] |         |
| 9.2023305     | cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]             |         |
| 16.35993502   | cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]       |         |
| -12.35764438  | cytochrome P450 27C1-like [Crassostrea virginica]                             |         |
| Score   | Description                                                                 | Localization  |
|---------|------------------------------------------------------------------------------|---------------|
| -10.85697882 | cytochrome P450 2C42-like [Crassostrea virginica]                           | HT_RI         |
| 2.675102652  | Cytochrome P450 3A11 [Crassostrea gigas]                                    | HT_RI         |
| -4.440107252 | cytochrome P450 3A29-like [Crassostrea virginica]                           | HT_RI         |
| -7.518489118 | cytochrome P450 4V2-like isoform X1 [Crassostrea virginica]                 | HT_RI         |
| -12.02720282 | Ig-like and fibronectin type-III domain-containing protein 2 [Crassostrea virginica] | HT_RI         |
| 7.683007501  | macrophage migration inhibitory factor-like [Crassostrea virginica]         | HT_RI         |
| 2.309585304  | histone H2B-like [Crassostrea virginica]                                     | HT_RI         |
| -9.231433964 | perlucin-like isoform X2 [Crassostrea virginica]                            | HT_RI         |
| 9.231041006  | perlucin-like protein [Crassostrea virginica]                                | HT_RI         |
| 9.062890569  | perlucin-like protein [Crassostrea virginica]                                | HT_RI         |
| -4.500074021 | perlucin-like protein [Crassostrea virginica]                                | HT_RI         |
| -6.333143999 | Chitin synthase C [Crassostrea gigas]                                       | HT_RI         |